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Abstract: 
Administration of recombinant human erythropoietin (rHuEpo) improves endurance 
performance. Hence rHuEpo is, allegedly, frequently subject to abuse by athletes, although 
rHuEpo is prohibited by the World Anti-Doping Agency. A transcriptomic-based longitudinal 
screening approach has the potential to improve further the performance of current detection 
methods. AIM: To assess the effects of rHuEpo on blood gene expression profiles in order to 
identify a “molecular signature” of rHuEpo doping. METHODS: 19 Caucasian trained males at 
sea-level (Scotland – SCO) and 20 Kenyan endurance runners at moderate altitude (~2,150 m, 
Kenya – KEN) received rHuEpo injections of 50 IU∙kg-1 body mass every two days for 4 weeks. 
Blood was obtained 2 weeks before, during and 4 weeks after administration. 3,000 m time trial 
performance was measured pre, post administration and at the end of the study. RNA was 
extracted from blood stabilized in Tempus RNA tubes, amplified, labelled and hybridized to 
Illumina HumanHT-12v4 Expression BeadChips. Expression data was analyzed using Rank 
Products with a 5% false discovery rate and an additional 1.5 fold-change threshold. A subset of 
target and housekeeping genes was further validated using QuantiGene Plex assay. RESULTS: 
Despite markedly different baseline values between SCO and KEN, as exemplified by the 
haematocrit (41.9 ± 1.8% vs. 45.3 ± 2.6, p < 0.001), key blood parameters significantly increased 
during rHuEpo in both groups (p < 0.001) to reach similar levels at the end of administration 
(49.2 ± 2.0% vs. 49.6 ± 2.6, p = 0.638). The relative improvements in running performance post 
rHuEpo (~5%) and 4 weeks post administration (~3%) compared to baseline were of similar 
magnitude in both groups (p > 0.188). These results confirmed that the perturbation involving 
rHuEpo worked effectively. Relative to baseline, the expression of hundreds of genes were found 
to be altered by rHuEpo. In particular, 30 transcripts were already differentially expressed two 
days after the first injection while 15 transcripts were profoundly up-regulated during and 
subsequently down-regulated up to 4 weeks post administration in both groups. Importantly, the 
same pattern was observed in all subjects. The functions of the discovered genes were mainly 
related to either the functional or structural properties of the erythrocyte or to the cell cycle and 
its regulation. CONCLUSION: This research successfully identified the blood “molecular 
signature” of rHuEpo administration and provides the strongest evidence to date that gene 
biomarkers have the potential to substantially improve the performance of current anti-doping 
methods such as the Athlete Biological Passport for rHuEpo detection.  
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“Case presentation: 
 
A 40-year-old man has undergone chronic 
hemodialysis for 7 years. He had nephrotic 
syndrome from age 2 to 5 years but was 
apparently well until age 18, when proteinuria 
was detected again. At age 28, hypertension was 
noted. Hematocrit was 36%. (...) At age 32, his 
blood pressure was 145/90 mm Hg. The 
hematocrit was 20.5%. (...) At age 33, uremic 
symptoms were evident. The hematocrit was 
14%. Two units of red blood cells were 
transfused and hemodialysis was begun. 
 
He improved and returned to his home in Alaska 
to continue chronic hemodialysis. Because his 
hematocrit fell repeatedly to levels of 12%—
l4%, he returned to Seattle every 2 to 3 weeks to 
receive packed red cell transfusions. Five 
months after starting dialysis, his blood pressure 
was 152/100mm Hg. (...) Transfusion 
requirements did not diminish. 
 
At age 34 (15 months after the patient started 
hemodialysis), he received a cadaveric renal 
transplant. The hematocrit rose within one 
month to 27%. (...) Three months following 
transplantation, the aliograft was rejected, and 
treatment with chronic hemodialysis was 
resumed. The hematocrit fell to 11%, and 
frequent packed red-cell transfusions again were 
required to stabilize the level at about 19%. (...). 
Although he worked 7 days a week running his 
country store, his energy and "wind" would 
"give out" by early afternoon and he would rest 
the remainder of the day. He could no longer 
unload the supplies delivered to his store. 
 
By age 39, he had received a total of 313 units of 
red blood cells. 
 
At that time, recombinant human erythropoietin 
(rHuEpo) was given in an initial dose of 300 
units/kg intravenously and was continued three 
times per week. Within 8 weeks after initiation of 
rHuEpo therapy, his hematocrit was 38%; no 
transfusions had been administered over this 
time 
 
Clinical improvement was dramatic; he was 
able to play handball and to meet all the 
physical demands of running his country store. 
This included working a full day without 
becoming exhausted, and now being able to 
unload the heavy boxes of supplies delivered to 
his store. After one year of rHuEpo therapy (75 
units/kg, 3 times/week, intravenously), the 
hematocrit was 36%. (...) 
 
He continues to enjoy an active life.” 
(Eschbach 1989) 
Following this personal and clinical triumph … 
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1.1 Erythropoietin and its therapeutic use: 
Erythropoietin is a glycoprotein hormone produced primarily in the kidney that regulates red 
blood cell mass by stimulating the survival, proliferation and differentiation of erythrocytic 
progenitors (Figure 1.2) (Jelkmann 1992, 2011). Anaemia is a common complication of chronic 
kidney disease caused principally by a deficiency in the synthesis of endogenous erythropoietin 
(Eschbach et al. 2002). Recombinant human erythropoietin (rHuEpo) was first produced in the 
1980s (Jacobs et al. 1985; Lin et al. 1985). In 1989 a 40 year-old patient with chronic kidney 
disease associated anaemia, who had undergone chronic haemodialysis for 7 years, unsuccessful 
kidney transplantation and received 313 units of red blood cells, was the first patient to receive 
rHuEpo treatment (Eschbach 1989; Eschbach et al. 1989)
1
. Within 8 weeks of rHuEpo therapy, 
his haematocrit increased from 15% to 38%, red blood cells transfusions were no longer 
required, he was able to play handball and resumed his physically demanding work (Eschbach 
1989; Eschbach et al. 1989). Since this success of almost biblical proportions, many clinical 
trials have demonstrated the efficacy and short-term safety of rHuEpo for increasing and 
maintaining haemoglobin concentration, for reducing the need for red blood cell transfusion and 
improving the quality of life of patients with anaemia (Glaspy et al. 2010). However, the fact 
that rHuEpo has improved the quality of life of more than a million anaemic patients (Brines and 
Cerami 2005) has to be balanced against the concerns regarding an increased risk of venous-
thromboembolic events and possible unknown adverse long-term effects in patients (Glaspy et 
al. 2010; Jelkmann 2010). rHuEpo is currently widely and mainly used to treat symptomatic 
anaemia caused by chronic kidney disease and anaemia with related symptoms in some cancer 
patients receiving chemotherapy, as well as to increase the amount of blood that can be taken 
from people donating their own blood before surgery. 
 
 
                                                          
1
 See Preface. 
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Figure 1.1: Simplified schematic diagram of the regulation of erythropoiesis. 
Oxygen regulates the rate at which hypoxia-inducible factor 1α (HIF-1α) protein is degraded in the kidney. 1) Under normoxic 
conditions (normoxia), the von Hippel-Lindau (VHL) protein binds HIF-1α via the oxygen-dependent hydroxylation of proline 
residues (P402 and P564) by the enzymes prolyl hydroxylase-domain protein 1-3 (PHD1-3), resulting in the ubiquitylation of HIF-1α, 
its degradation and the inhibition of HIF-1α-mediated gene transcription. 2) Under hypoxic conditions (hypoxia), VHL cannot bind 
HIF-1α, resulting in a decreased rate of HIF-1α degradation, which, in turn, allows the transcriptional activation of HIF-1α target 
genes such as erythropoietin (EPO). 3) In the bone marrow, EPO binds to the erythropoietin receptor (EpoR) and activates the Jak2-
STAT5 signalling cascade which then stimulates the survival, proliferation and differentiation (red arrow) of erythrocytic progenitors 
(proerythroblast, erythroblast and eventually reticulocyte) without affecting the leukocytes production.  
Figure adapted from (Semenza 2003, 2004) and (Jelkmann 2011). 
Images adapted from http://upload.wikimedia.org/wikipedia/commons/6/69/Hematopoiesis_(human)_diagram.png and http://www.netterimages.com/images/vtn/000/000/008/8732-150x150.jpg.  
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1.2 The emergence of blood doping and the misuse of erythropoietin: 
During the Olympic Games in Mexico City in 1968, held at moderate altitude (2250 m a.s.l), the 
premise that blood adaptations, such as an increase in haemoglobin concentration, helped those 
athletes living at altitude to win most of the endurance races defined the new research focus in 
the field of sport physiology (Eichner 2007). “We’ve just started to scratch the surface in athletic 
research” reported Dr Faulkner, an exercise physiologist, in a newspaper article published in The 
Windsor Start on 6
th
 December 1968, entitled “Altitude improved Olympic effort” (Herbert 
1968). A few years later, the pioneering work of Ekblom et al. demonstrated that elevation in 
haemoglobin concentration increased maximal oxygen uptake (  O2max) and improved 
performance (Ekblom et al. 1972). Interestingly enough, soon after came the first accounts of 
blood manipulation in sports as well as the term “blood doping” in the media (Cazzola 2000; 
Leigh-Smith 2004; Lundby et al. 2012b). The newspapers Star-News and Pittsburgh Post-
Gazette reported in an article published on 1
st
 August 1976 entitled “Blood doping and other 
things” that “The scientific scandal of the Olympics was as quiet as the flow of blood until Lasse 
Viren of Finland added the 5,000-meter gold medal to his 10,000-meter gold medal. ‘He has got 
that extra blood in him,’ said Ron Dixon of New Zealand. Lasse Viren and other European 
distance runners are suspected of being strengthened by what is known as ‘blood doping’ – the 
removal of a pint of the runner’s blood, then the return of that same blood perhaps two weeks 
later. In that time his body has compensated for its absence. The runner now has an extra pint of 
blood in his system” (Reporter unknown 1976). Indeed, there is evidence that blood transfusions 
were used with a certain success in the 1970s and 1980s by, among others, cyclists, marathoners 
and cross-country skiers (Eichner 2007; Lundby et al. 2012b). 
 
Doping in sport seems to adapt rapidly to the new technology available. The appearance of 
rHuEpo, which was shown to successfully increase haemoglobin concentration in patients, 
radically transformed blood doping practices. Following the “transfusion era”, rHuEpo doping 
took over in the 1990s, as was highlighted by the numerous doping cases during the Tour de 
France bicycle race and especially the Festina affair in 1998 (Lundby et al. 2012b). In 2000 
Birkeland et al. scientifically demonstrated in his laboratory that rHuEpo administration for 4 
weeks in 20 male athletes increased haematocrit (43% to 51%),   O2max by 7% as well as time to 
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exhaustion by 9% (Birkeland et al. 2000). In the last decade, the practice of red cell transfusions 
has made a strong comeback in response to the development of anti-doping tests (see next 
paragraph). Based on testimonies from athletes who have been detected, it is now known that 
athletes are using rHuEpo in combination with blood transfusions (Lundby et al. 2012b).  
 
1.3 Erythropoietin and anti-doping: 
In 1990, erythropoietin was included on the list of prohibited substances by the International 
Olympic Committee because misuse by athletes was suspected, although no approved test 
existed at that time (Reichel 2011b). During these years, there were rumours that cheats used 
huge amount of rHuEpo which induced very high values of blood parameters. For instance, 
Bjarne Riis, the 1996 Tour de France winner (who admitted doping in 2007), acquired the 
nickname of “Mr 60%” which referred to his haematocrit level (Shermer 2008). Because rHuEpo 
was directly undetectable at the time, and as well as to protect the health of athletes, the 50% 
haematocrit rule was introduced in 1997 by the International Cycling Union (Sottas et al. 2010). 
Briefly, any racing cyclist who had a haematocrit above 50%
2
 was declared ineligible and was 
excluded from the race. Despite this rule, the Festina scandal at the Tour de France in 1998 
provided the proof of organized and widespread doping in professional cycling and highlighted 
the need for the creation of an independent international agency, which would set “unified 
standards for anti-doping work and coordinate the efforts of sports organizations and public 
authorities” (World Anti-Doping Agency 2010). The World Anti-Doping Agency (WADA) was 
consequently established in 1999.  
 
Although the detection of rHuEpo doping is difficult because rHuEpo is structurally very similar 
to endogenous erythropoietin, a direct urinary test based on the presence of different isoforms in 
isoelectric profiles was developed and published by Lasne et al. in 2000 (Lasne and de Ceaurriz 
2000; Lasne et al. 2002). This test became the first WADA approved detection method for 
rHuEpo doping. However, while the effects of rHuEpo administration can last for weeks, the test 
has a rather limited detection window, i.e. a few hours up to a few days depending on the dose 
used (Ashenden et al. 2006; Breidbach et al. 2003; Lundby et al. 2008a). At the same time as the 
                                                          
2
 50% for male athletes and 47% for female athletes. 
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development of the direct test, potential indirect detection of rHuEpo using blood markers of 
altered erythropoiesis was being investigated (Cazzola 2000; Parisotto et al. 2000). Notably, 
Parisotto et al. (2000) developed statistical models using indirect markers of altered 
erythropoiesis in order to detect rHuEpo doping during current (ON-model) and after repeated 
recent (OFF-model) administration, respectively. The OFF-model based on haemoglobin 
concentration and reticulocyte levels
3
 identified at 12-21 days after the last rHuEpo injection 
approximately two-thirds of the subjects who had previously been administered with rHuEpo for 
4 weeks without any false positives (Parisotto et al. 2000). However, despite these promising 
laboratory-based results, both direct and indirect detection methods have been shown to lead to 
unidentified doping due to inadequate detection (Ashenden et al. 2011; Borno et al. 2010; 
Lundby et al. 2008a) as well as unacceptable cases of false positives (Beullens et al. 2006; 
Parisotto et al. 2000; Schumacher et al. 2000). For instance, it is known that terrestrial or 
simulated altitude exposure can increase the risk of false positives by influencing the indices of 
rHuEpo doping (Ashenden 2004; Ashenden et al. 2003; Ashenden et al. 2001). There is 
therefore an urgent need for these methods to be revised in the hope of removing any possibility 
of athletes being incorrectly banned from competition or, conversely, avoiding sanctions due to 
broad definitions of legal reference limits. 
 
1.4 Athlete Biological Passport: 
The Athlete Biological Passport (ABP) was recently introduced as a new tool to indirectly detect 
erythropoiesis-stimulating agents, such as rHuEpo, and which can lead to a doping sanction 
imposed by a sports organization or its tribunal at the same time as intelligently targeting athletes 
for additional testing (Schumacher and d'Onofrio 2012; Schumacher et al. 2012; Zorzoli and 
Rossi 2012). The ABP approach relies on identifying intra-individual abnormal variability over 
time of selected haematological parameters (Figure 1.2) (Callaway 2011; Sottas et al. 2010). As 
nicely demonstrated by Zorzoli and Rossi, the behaviour of the athletes related to blood doping 
has changed since the introduction of the ABP (Zorzoli and Rossi 2010). Extreme reticulocyte 
values (i.e. <0.4% or >2.0%) have drastically decreased and, in that sense, the implementation of 
the ABP has undeniably been a step forward in the anti-doping field (Zorzoli and Rossi 2010). 
                                                          
3
 OFFscore = haemoglobin concentration (g∙L-1) – 60√reticulocyte (%). 
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However, although this approach can potentially be suitable to identify abnormal enhanced 
erythropoiesis regardless of the method used, the sensitivity of the ABP has been questioned 
(Lippi and Plebani 2011). In order to minimise the risk of being caught via the ABP, it is well 
recognized that athletes are now using the so-called "micro doses" of rHuEpo which allegedly 
range from 10 to a maximum of 40 IU∙kg-1 body mass (Ashenden et al. 2011; Ashenden et al. 
2006; Morkeberg et al. 2013). These micro doses aim to increase haemoglobin mass (Hbmass) 
while avoiding a large fluctuation in the ABP blood markers as well as minimising the detection 
window for conventional direct methods (Ashenden et al. 2011). Indeed, Ashenden et al. have 
demonstrated that the ABP did not reveal any suspicious doping activities when rHuEpo 
microdosing strategy was used (Ashenden et al. 2011). In addition, physiological variations of 
the haematological parameters of the ABP due to factors such as training or hypoxia exposure 
can conflict with the interpretation of the ABP results (Sanchis-Gomar et al. 2011). There is 
therefore a need for the ABP approach to be improved. 
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Figure 1.2: Examples of the Athlete Biological Passport (ABP) including haemoglobin 
concentration (HGB) and reticulocyte percentage (RET%). 
Blue lines: actual tests results. Red lines: individual “normal” limits calculated by the ABP 
software. Athlete A presented normal variations. Conversely, athlete B presented abnormal 
variations, and was consequently suspected of doping. Figure adapted from Sottas et al. (2011).  
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1.5 Omics technologies – a transcriptomic approach: 
A genome is defined as the entire collection of genetic information encoded by a particular 
organism (Snyder and Gerstein 2003). By semantic association, the words transcriptome, 
proteome and metabolome refer to the entirety of all transcripts, proteins and metabolites 
expressed by a genome at a specific time, respectively. The science related to these terms was 
named accordingly genomics, transcriptomics, proteomics and metabolomics and form the so-
called “omics-cascade” (Reichel 2011a) (Figure 1.3). Using microarray technology, a 
characteristic gene expression signature of a particular stimulus can be revealed by assessing the 
transcriptional state of the cells of the experimental samples (Bilitewski 2009; Kurella et al. 
2001). Therefore, if the gene expression profile following rHuEpo administration yields to a 
specific signature, new methods based on gene-expression profiles with potentially improved 
discriminatory power relative to current detection protocols can be developed. Data have 
emerged in support of this hypothesis (Varlet-Marie et al. 2009). Using the serial analysis of 
gene expression (SAGE) method, Varlet-Marie et al. identified 95 genes whose differential 
expression was subsequently tested by quantitative real-time polymerase chain reaction in two 
athletes (Varlet-Marie et al. 2009). These athletes were treated first with high doses of rHuEpo 
and then with micro doses. During the high dose regime, 33 marker genes for rHuEpo 
administration were identified and 5 remained differentially expressed during the micro dose 
regime. Moreover, this transcriptomic approach is not only confined to rHuEpo abuse, but can 
also be applied to other doping methods and substances used by the athletes. For instance, 
potential characteristic gene expression profiles have also been shown in 6 subjects after 
autologous blood transfusion (Pottgiesser et al. 2009; Pottgiesser et al. 2007). These recent 
preliminary results, although from only a limited number of subjects, provide the first 
confirmatory data to support the hypothesis that gene expression profiles may provide a sensitive 
method for the detection of rHuEpo and blood doping.  
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Figure 1.3: The “omics” cascade. 
The cascade depicts the flow of information from the gene to the metabolism. 
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1.6 Current anti-doping policy and criticisms: 
Following its creation, WADA drafted and implemented the World Anti-Doping Code which has 
been effective since 2004. The Code was revised in 2009, but its purposes remained unchanged, 
i.e. “to protect the athlete’s fundamental right to participate in doping-free sport and thus 
promote health, fairness and equality for athletes worldwide”, as well as “to ensure harmonized, 
coordinated and effective anti-doping programs at the international and national level with 
regards to detection, deterrence and prevention of doping”. The World Anti-Doping Code 
defined doping as the occurrence of one or more of the anti-doping rule violations, in brief: the 
presence of a prohibited substance or its metabolites or markers in an athlete’s sample; the use or 
attempted use of a prohibited substance or method; refusing or failing to submit to sample 
collection; possession of prohibited substances or methods (World Anti-Doping Agency 2009). 
A substance or method is considered for inclusion on the Prohibited List if WADA determines 
that the substance or method meets any two of the following three criteria: in brief, the substance 
or method 1) has the potential to enhance sport performance, 2) represents a health risk to the 
athlete, 3) violates the spirit of sport (World Anti-Doping Agency 2009).  
 
While discussion of the WADA policy is beyond the scope of this thesis, it should be noted that 
criticisms have been addressed to the anti-doping policy (Kayser and Broers 2012; Kayser et al. 
2007; Kayser and Smith 2008; Smith and Stewart 2008). For instance, Kayser and Broers argued 
that. although at first glance the current anti-doping policy appears reasonable and simple, it 
seems not to be able to attain its objectives using a zero-tolerance approach and possibly leads to 
more harm to society than it can prevent (Kayser and Broers 2012). Their possible alternative 
would be a pragmatic model based on regulation and harm reduction inspired by the experience 
gained with alternative drug policies (Kayser and Broers 2012; Smith and Stewart 2008). 
Another alternative (not necessarily incompatible with the latter) to the current anti-doping 
policy suggested by Lippi et al. would be to focus the effort on education and prevention as well 
as on biochemical or haematological identification and monitoring of “pathological” deviations 
rather than on all-out repression (Lippi et al. 2008). Although this debate on anti-doping policy 
(which is much broader than implied by the previous examples) is beyond the scope of this 
thesis, it is important to note that the knowledge gained from the longitudinal investigations of 
the effect of rHuEpo administration carried out during this doctoral research is valuable 
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regardless of the policy adopted. For instance, in addition to providing insights into the 
mechanism of the action of rHuEpo, the results of this research can be used not only for anti-
doping repression but also for health screening. 
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1.7 Aims and objective of the research: 
The overall aim of this doctoral research was to assess the effects of rHuEpo on blood gene 
expression profiles in endurance trained volunteers in order to identify a molecular signature of 
rHuEpo doping and hence provide a basis for the development of novel and robust testing 
models to detect blood doping. Using both phenotypic and molecular methods, this research was 
carried out firstly at sea-level in Glasgow (Scotland, UK) with Caucasian endurance trained 
males and then at moderate-altitude (~2,150 m) in Eldoret (Kenya) with Kenyan endurance 
runners who abstained from official sporting competition for the entire duration of the study. To 
achieve the overall aim of determining the blood molecular signature of rHuEpo doping, this 
research addressed the following objectives: 
 
 To determine and compare the effects of rHuEpo administration on blood parameters and 
exercise performance in endurance trained males living and training at or near sea-level 
with another cohort living and training at moderate-altitude (~2,150 m) in Kenya. 
(Chapter 2 and 4). 
 
 To establish adequate molecular methods and molecular workflow to enable valid and 
optimal assessment of blood gene expression (Chapter 3). 
 
 To assess the effects of rHuEpo on blood gene expression profiles in endurance trained 
volunteers living and training at or near sea-level (Chapter 3). 
 
 To replicate and compare the effects of rHuEpo administration on blood gene expression 
profiles in another cohort living and training at moderate-altitude (~2,150 m) in Kenya. 
(Chapter 5). 
 
 To validate the gene microarray based findings using another specific and sensitive 
quantitative gene expression technology (Chapter 6). 
 
 To evaluate and discuss the potential direct applications of the findings in the anti-doping 
field to detect rHuEpo doping (Chapter 7).   
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Chapter 2 : Haemoglobin Mass and Running Performance 
after Recombinant Human Erythropoietin Administration in 
Trained Men 
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2.1 Introduction and aim: 
In healthy subjects, administration of rHuEpo increases haemoglobin concentration not only by 
the well known increase in red blood cell mass but also by a decrease in plasma volume (Lundby 
et al. 2007; Olsen et al. 2011). Theoretically, normal human red blood cells can persist in the 
circulation for approximately 17 weeks (Franco 2009). However, neocytolysis, the selective 
haemolysis of young circulating red blood cells, which contributes to the regulation of red cell 
mass, seems to appear during specific conditions that cause a rapid decrease in erythropoietin 
levels such as spaceflight, high altitude exposure or blood doping (Alfrey et al. 1997; Chang et 
al. 2009; Franco 2009; Rice and Alfrey 2005; Rice et al. 2001; Risso et al. 2007). Little is known 
about the time course of these mechanisms post rHuEpo administrations. In this study, Hbmass 
and related blood volumes were repeatedly determined using the optimized carbon monoxide 
(CO) rebreathing method (Durussel et al. 2013b; Schmidt and Prommer 2005) pre, during and 
post rHuEpo administration in healthy trained men. 
 
Most studies investigating the effects of erythropoietin on exercise performance have used 
  O2max tests. However,   O2max tests alone may probably be of little help in predicting exercise 
performance among athletes of similar ability (Conley and Krahenbuhl 1980; Costill et al. 1973; 
Faria et al. 2005; Noakes 2008b; Shephard 2009). One study assessed submaximal performance 
in healthy male subjects and reported improvements of more than 50% in time to exhaustion on a 
cycle ergometer at a given 80% of   O2max whereas the increase in   O2max was approximately 
12% (Thomsen et al. 2007). Despite being a very interesting finding which questions the 
mechanisms by which rHuEpo improves submaximal exercise performance (Noakes 2008a), the 
validity of the time to exhaustion test in assessing human exercise performance has been 
questioned (Jeukendrup and Currell 2005). In addition to being more variable than time trial tests 
(Laursen et al. 2007), time to exhaustion tests are less likely to mimic the exercise performance 
environment (Jeukendrup and Currell 2005; Laursen et al. 2007). There are indeed only minimal 
occasions where an athlete is required to maintain a constant intensity until volitional exhaustion 
compared with self-paced exercise (Jeukendrup and Currell 2005; Laursen et al. 2007). 
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The main purpose of the present study was to investigate the time course of Hbmass and related 
blood parameters as well as changes in running 3,000 m time trial performance following 4 
weeks of rHuEpo administration in healthy trained men in order to determine whether the 
augmented   O2max observed in laboratory-based experiments would translate into actual 
improvements in running performance in the field. 
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2.2 Methods: 
Twenty healthy non-smoking physically active men (mean ± SD, age: 26.5 ± 5.0 yr, body mass: 
74.8 ± 7.7, height: 179.5 ± 5.4 cm) participated in this study. All subjects underwent a medical 
assessment and provided written informed consent to participate. The subjects were regularly 
engaged in predominantly endurance-based activities such as running, cycling, swimming, 
triathlon and team sports. Subjects were requested to maintain their normal training but abstain 
from official sporting competition for the duration of the research protocol (Howman 2013; 
Wagner 2013). One subject dropped out of the study because he wished to participate in the 
London marathon, which was scheduled during the last week of the research protocol and 
although three rHuEpo injections had been given, seven weeks of washout were deemed 
sufficient to return to competition at this event (his performance in this marathon was 2h 57min 
26s; his best performance is 2h 48min 23s). The subjects were divided into two groups for 
exercise performance analysis. The first group included subjects who had a history of running (n 
= 10) and the second group included the remaining subjects who were involved in other sporting 
activities (n = 9). This study was approved by University of Glasgow Ethics Committee and 
conformed to the Declaration of Helsinki. One of the subjects in the running group suffered from 
nasal obstruction and coughing during the study and could not perform the exercise tests post 
rHuEpo administration. The running performance data of this subject was excluded from the 
analyses. 
 
2.2.1 Experimental design: 
Each subject subcutaneously self-injected 50 IU∙kg-1 body mass of rHuEpo (NeoRecormon, 
Roche, Welwyn Garden City, UK) every second day for 4 weeks. Daily oral iron 
supplementation (~ 100 mg of elemental iron, Ferrous Sulphate Tablets, Almus, Barnstaple, UK) 
was given during the 4 weeks of rHuEpo administration. None of the subjects reached the 
predetermined safety haematocrit limit of 55% and all subjects tolerated the rHuEpo 
administration well with no signs of hypertension (see Results and Discussion sections of this 
chapter). Venous blood samples from an antecubital vein were obtained in triplicate at baseline 
(over 2 weeks prior to the first rHuEpo administration), during rHuEpo administration (on days 
2, 4, 8, 10, 14, 16, 20, 22, 26, 28) and for 4 weeks after rHuEpo administration (on days 30, 35, 
41, 43, 48, 50, 57) (Figure 2.1 and Figure 2.2). All blood samples were taken after 10 minutes of 
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rest in the supine position (Ahlgrim et al. 2010) (Figure 2.3). Blood samples were homogenized 
using a roller mixer and then analysed in triplicate using a Sysmex XT-2000i (Sysmex UK, 
Milton Keynes, UK). Blood-count variables such as haemoglobin concentration, haematocrit and 
reticulocyte percentage were measured by the fluorescence method and flow cytometry of the 
Sysmex. The mean value of the triplicate was reported. Resting blood pressure and heart rate 
were recorded three times on both arms in the supine position before blood sampling using an 
automated cuff oscillometric device (Boso-Medicus, Bosch & Sohn GmbH, Jungingen, 
Germany). 
 
2.2.2 Measurements of haemoglobin mass and related blood volumes: 
Hbmass was determined in triplicate prior to the first rHuEpo injection and then weekly up to 4 
weeks post rHuEpo administration (Figure 2.1) using the optimized CO-rebreathing method as 
previously described (Durussel et al. 2013b; Schmidt and Prommer 2005) (Figure 2.4). Briefly, a 
bolus of chemically pure CO dose of 1.0 mL∙kg-1 body mass was administered with the first 
breath through a spirometer and rebreathed for 2 min with 4 L of oxygen. Change in 
carboxyhaemoglobin percentage in venous blood samples from baseline to 8 min after CO 
administration was measured using a blood gas analyzer (ABL 725, Radiometer, Copenhagen, 
Denmark). CO concentration was measured using the Pac 7000 Draeger CO-analyzer (Draeger 
Safety, Northumberland, UK) and an estimated alveolar ventilation of 7.5 l∙min-1 was used for 
calculations. Hbmass as well as blood, red cell and plasma volume were calculated as previously 
described elsewhere (Durussel et al. 2013b). Blood volume was derived by dividing Hbmass by 
the haemoglobin concentration. Red cell volume was obtained by multiplying blood volume by 
the haematocrit and plasma volume was then calculated by subtracting red cell volume from 
blood volume. The typical error of measurement for Hbmass calculated from the two first baseline 
measurements was 1.5% (95% confidence interval (CI) 1.1 to 2.2%). The typical error of 
measurement for blood, red cell and plasma volume between the two weeks prior to the first 
rHuEpo administration were 2.4%, 1.6% and 3.6% (CI 1.8 to 3.5, 1.2 to 2.4 and 2.7 to 5.3), 
respectively. 
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Figure 2.1: Experimental design. 
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Figure 2.2: Example of the subject’s schedule.  
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Figure 2.3: Standardised samples collection protocol. 
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Figure 2.4: Picture of the carbon monoxide rebreathing procedure. 
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2.2.3 Running performance assessment: 
Two 3,000 m time trials separated by at least one day of rest were performed on a 200 m indoor 
athletic track (Kelvin Hall, Glasgow, UK) pre, post rHuEpo administration and at the end of the 
study (Figure 2.1). Verbal encouragement was given with feedback provided for the split time 
and remaining laps. The best performance on each occasion was used for analysis. The typical 
error of measurement for time trial performance calculated from the two tests on each phase was 
1.3% (CI 1.1 to 1.7). Borg’s rating of perceived exertion (RPE) was recorded at the completion 
of the time trial (Borg 1970). Temperature and humidity were recorded using a hygrometer. In 
addition to the time trial,   O2max was determined pre, post rHuEpo administration and at the end 
of the study using an incremental test to exhaustion on a motorised treadmill. Both continuous or 
discontinuous protocols were used because of other purposes of the study (the speed was 
increased by 1 km∙h-1∙min-1 or by 2 km∙h-1 every 3 min with 3 min of active recovery at a 
walking pace between each bout, respectively). Following a 30 min recovery,   O2max was 
verified using a square-wave protocol to exhaustion at a speed equivalent to the end speed 
attained during the incremental test minus 1 km∙h-1 (Kirkeberg et al. 2011; Pettitt et al. 2013). 
Gas exchange was measured breath by breath using an automated metabolic gas analysis system 
(Cosmed Quark b2, Cosmed, Rome, Italy). 
 
2.2.4 Statistical analysis: 
Individual mean value was calculated when more than one blood sample was collected per week 
before further analysis. Changes over time in Hbmass, blood, red cell and plasma volume were 
assessed using t-test to determine whether the slope of these parameters was significantly 
different from zero; the slope coefficient for each individual came from a linear regression of his 
measurements, using time as the predictor. Time trial performance,   O2max and blood parameters 
data for the key stages of the study were analyzed using repeated measures ANOVA. 
Relationships between time trial performance,   O2max and Hbmass were assessed using Pearson’s 
product moment correlation coefficients. Analyses were performed using Statistical Package for 
Social Sciences (SPSS, version 19). In the results section, data are described as mean ± SD and p 
values are from the repeated measures ANOVA analysis, unless mentioned otherwise.  
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2.3 Results: 
2.3.1 Running performance (Table 2.1): 
Running performance data of both groups combined (n=18, see Table 4.3) are presented in this 
paragraph (Table 2.1 for separate groups). Irrespective of running history, time trial performance 
significantly improved by ~6% post administration (10:30 ± 1:07 min:sec vs. 11:08 ± 1:15 
min:sec, p < 0.001) and remained significantly enhanced by ~3% 4 weeks after rHuEpo 
compared to baseline (10:46 ± 1:13 min:sec vs. 11:08 ± 1:15 min:sec, p < 0.001). RPE did not 
significantly differ between the time trials pre, post rHuEpo administration and 4 weeks after 
rHuEpo (p > 0.111). Temperature (19.4 ± 2.8 °C) and humidity (46.6 ± 9.0%) remained 
relatively constant (p > 0.441). Relative to baseline,   O2max significantly increased post 
administration (60.7 ± 5.8 mL∙min-1∙kg-1 vs. 56.0 ± 6.2 mL∙min-1∙kg-1, p < 0.001) and remained 
significantly increased 4 weeks after rHuEpo (58.0 ± 5.6 mL∙min-1∙kg-1 vs. 56.0 ± 6.2 mL∙min-
1∙kg-1, p = 0.021).   O2max was at least moderately correlated with Hbmass as well as time trial 
performance throughout the study (range, r = 0.48 to r = 0.88, p < 0.045). However, a significant 
correlation in individual responses compared to baseline between these three parameters was 
only observed for Hbmass and time trial performance at the end of the study (r = -0.68, p = 0.002). 
 
2.3.2 Haematological parameters and resting blood pressure and heart rate (Table 2.2, Table 
2.3 and Figure 2.5): 
Table 2.2 illustrates the changes in the main haematological parameters for five key stages of the 
study. Relative to baseline values, both haematocrit and haemoglobin concentration gradually 
increased throughout the rHuEpo administration to reach a maximum approximately one week 
after the last injection (p < 0.001) and remained significantly elevated 4 weeks post rHuEpo 
administration (p < 0.001) (Figure 2.5A and Figure 2.5B). Reticulocyte percentage increased 
rapidly after the first two weeks of injections (p < 0.001) (Figure 2.5C). Nadir with a very low 
inter-subject variation was reached approximately two weeks after injections ceased, which was 
significantly lower compared with baseline values (p < 0.001) (Figure 2.5C). Body mass did not 
change during the study (p = 1.000). rHuEpo administration did not induce any significant 
changes in resting systolic (p > 0.441) and diastolic (p = 1.000) blood pressure as well as in 
resting heart rate (p = 1.000) throughout the study. 
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2.3.3 Haemoglobin mass and blood volumes (Table 2.2, Table 2.4 and Figure 2.6): 
Relative to baseline, Hbmass and plasma volume were significantly increased (p < 0.001) and 
decreased (p = 0.004) at the end of the rHuEpo administration, respectively. Hbmass and red cell 
volume gradually increased by approximately 40 g∙wk-1 (t-test, p < 0.001) and 135 mL∙wk-1 (t-
test, p < 0.001), respectively (Figure 2.6A and Figure 2.6B). Plasma volume decreased 
significantly by approximately 100 mL∙wk-1 (t-test, p < 0.001) (Figure 2.6C) while blood volume 
remained relatively unchanged (t-test, p = 0.318) (Figure 2.6D). From week 1 to week 4 post 
rHuEpo administration, the rate of decrease in Hbmass and red cell volume toward baseline values 
was similar to that of the increase during administration (t-test, p = 0.888 and p = 0.928, 
respectively) (Figure 2.6A and Figure 2.6B) but both Hbmass and red cell volume were still 
significantly elevated 4 weeks post administration compared to baseline (p < 0.001). Plasma 
volume was restored to pre-injection levels 4 weeks post administration (p = 0.108) (Figure 
2.6C). 
 
2.3.4 Carboxyhaemoglobin (Table 2.2 and Figure 2.7): 
Relative to baseline values, basal percentage of carboxyhaemoglobin prior to the CO-rebreathing 
procedure was significantly elevated at the end of the rHuEpo administration (p < 0.001). 
Percentage of carboxyhaemoglobin returned to pre-injection values 4 weeks post rHuEpo 
administration (p = 0.851). 
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Figure 2.5: Individual changes in haematocrit (A), haemoglobin concentration (B) and 
reticulocytes (C). 
Each line corresponds to one subject (n = 19) and each symbol corresponds to the same subject 
in all figures. Individual mean value was calculated when more than one blood sample was 
collected per week. The bar graphs represent the mean values of the 19 subjects. The grey bars 
represent the 4 weeks of rHuEpo administration.  
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Figure 2.6: Individual changes in Hbmass (A), red cell (B), plasma (C) and blood (D) volume. 
Each line corresponds to one subject (n = 19) and each symbol corresponds to the same subject 
in all figures. Individual mean value was calculated when more than one blood sample was 
collected per week. The bar graphs represent the mean values of the 19 subjects. The grey bars 
represent the 4 weeks of rHuEpo administration. 
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Figure 2.7: Individual changes in carboxyhaemoglobin. 
Each line corresponds to one (n = 19) subject. Individual mean value was calculated when more 
than one blood sample was collected per week. The bar graphs represent the mean values of the 
19 subjects. The grey bars represent the 4 weeks of rHuEpo administration.  
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Table 2.1. Running 3,000 m time trial performance and maximal oxygen uptake 
 
 
Group 1 Group 2 
  Baseline 
End of 
rHuEpo 
End of 
the study 
Baseline 
End of 
rHuEpo 
End of 
the study 
3,000 m total time (min:sec) 
10:12 ± 
0:42
 
9:40 ± 
0:37
** 
9:53 ± 
0:43
*
 
12:05 ± 
0:55 
11:19 ±  
0:53
*** 
11:39 ± 
0:58
**
 
1
st
 1,000 m split (min:sec) 
3:16 ± 
0:13 
3:10 ± 
0:12
*
 
3:13 ± 
0:13 
3:53 ±  
0:27
 
3:36 ±  
0:14
*
 
3:41 ±  
0:20 
2
nd
 1,000 m split (min:sec) 
3:26 ± 
0:16
††
 
3:15 ± 
0:14
**†
 
3:20 ± 
0:14
††
 
4:05 ±  
0:17
 
3:54 ±  
0:26
†
 
3:59 ±  
0:20
††
 
3
rd
 1,000 m split (min:sec) 
3:29 ± 
0:15
†
 
3:15 ± 
0:13
**
 
3:20 ± 
0:16
**
 
4:07 ±  
0:16  
3:49 ±  
0:15
**††
 
3:59 ±  
0:19
††
 
RPE scale (6-20) 
18.0 ±  
1.7 
18.4 ±  
0.9 
19.0 ±  
1.2 
17.7 ±  
2.2  
18.4 ±  
1.6  
18.6 ±  
1.4 
  O2max (mL∙min
-1∙kg-1) 
60.3 ± 
5.0 
64.4 ± 
3.9
*
 
61.8 
± 3.4 
51.6 ± 
3.5 
57.0 ±  
5.1
***
 
54.2 ±  
4.7
**
 
 
Group 1 included subjects who had a history of running (n = 9) and group 2 included the other 
subjects who were involved in other activities (n = 9). Values are means ± SD. Data were analyzed 
using repeated measures ANOVA (SPSS, version 19). Significant differences compared to baseline 
values are indicated by * p < 0.05, ** p < 0.01 and *** p < 0.001. Significant differences compared to 
the first 1,000 m split time within the same time trial are indicated by † p < 0.05, †† p < 0.01 and ††† 
p < 0.001.   O2max: Maximal oxygen uptake. 
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Table 2.2. Haematocrit, haemoglobin concentration, reticulocytes, haemoglobin mass, blood 
volumes, carboxyhaemoglobin and body mass before, during and 4 weeks post rHuEpo 
administration 
  Baseline 
Week 2 of 
rHuEpo 
End of rHuEpo 
Week 2 post 
rHuEpo 
Week 4 post 
rHuEpo 
Haematocrit (%) 41.9 ± 1.8 44.7 ± 2.0
***
 49.2 ± 2.0
***
 47.7 ± 2.2
***
 45.1 ± 1.7
***
 
Haemoglobin (g∙dl-1) 14.4 ± 0.7 15.2 ± 0.7*** 16.7 ± 0.9*** 16.1 ± 0.9*** 15.6 ± 0.7*** 
Reticulocytes( %) 1.07 ± 0.31 2.57 ± 0.44
***
 1.46 ± 0.41
**
 0.44 ± 0.13
***
 0.55 ± 0.15
***
 
Hbmass (g∙kg
-1
) 12.7 ± 1.2 13.4 ± 1.3
***
 15.2 ± 1.5
***
 15.1 ± 1.4
***
 13.7 ± 1.1
***
 
Hbmass (g) 947 ± 109 1001 ± 127
***
 1131 ± 131
***
 1126 ± 136
***
 1023 ± 132
***
 
Blood volume (L) 6.6 ± 0.9 6.6 ± 1.0 6.8 ± 0.8 6.7 ± 0.9 6.6 ± 0.8 
Red cell volume (L) 2.8 ± 0.3 2.9 ± 0.3
***
 3.3 ± 0.4
***
 3.3 ± 0.4
***
 3.0 ± 0.4
***
 
Plasma volume (L) 3.8 ± 0.6 3.7 ± 0.7 3.5 ± 0.4
**
 3.4 ± 0.6
***
 3.6 ± 0.5 
Carboxyhaemoglobin (%) 0.73 ± 0.15 0.77 ± 0.16 1.04 ± 0.19
***
 1.01 ± 0.20
***
 0.65 ± 0.15 
Body mass (kg) 75.1 ± 8.4 74.7 ± 7.8 75.0 ± 7.9 74.6 ± 7.6 74.6 ± 7.5 
 
N = 19. Values are means ± SD. Data were analyzed using repeated measures ANOVA (SPSS, version 
19). Significant differences compared to baseline values are indicated by * p < 0.05, ** p < 0.01 and *** 
p < 0.001. Hbmass: Haemoglobin mass. 
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Table 2.3. Resting blood pressure and heart rate before, during and 4 weeks post rHuEpo 
administration 
  Baseline 
Week 2 of 
rHuEpo 
End of 
rHuEpo 
Week 2 post 
rHuEpo 
Week 4 post 
rHuEpo 
Systolic blood pressure (mmHg) 128 ± 9 126 ± 7 126 ± 6 126 ± 7 124 ± 7 
Diastolic blood pressure (mmHg) 70 ± 8 69 ± 8 69 ± 7 70 ± 7 69 ± 8 
Heart rate (beats∙min-1) 62 ± 8 60 ± 7 60 ± 7 59 ± 7 61 ± 8 
 
N = 19. Values are means ± SD. Data were analyzed using repeated measures ANOVA (SPSS, 
version 19). No significant differences compared to baseline values were observed. 
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Table 2.4. Changes in haemoglobin mass, blood, red cell and plasma volume during and for 4 
weeks post rHuEpo administration 
  rHuEpo Post rHuEpo  
Haemoglobin mass (g∙kg-1∙wk-1) 0.54 (0.46 to 0.63)*** -0.53 (-0.68 to -0.38)*** 
Blood volume (mL∙kg-1∙wk-1) 0.34 (-0.36 to 1.05) -0.60 (-1.20 to 0.00) 
Red cell volume (mL∙kg-1∙wk-1) 1.80 (1.50 to 2.10)*** -1.77 (-2.22 to -1.33)*** 
Plasma volume (mL∙kg-1∙wk-1) -1.30 (-1.94 to -0.66)*** 0.50 (0.10 to 0.90)* 
 
N = 19. Values are means (95% confidence interval). Changes over time were assessed using t-test to 
determine whether the slope of Hbmass, blood, red cell and plasma volume was significantly different 
from zero; the slope coefficient for each individual came from a linear regression of his 
measurements, using time as the predictor. Significant changes are indicated by * p < 0.05, ** p < 
0.01 and *** p < 0.001. 
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2.4 Discussion: 
The aim of this study was to investigate the time course of Hbmass and related blood parameters as well 
as changes in running 3,000 m time trial performance following 4 weeks of rHuEpo administration in 
order to determine whether the augmented   O2max would translate into actual improvements in running 
performance in the field. The main findings of this study are that, relative to baseline, running 
performance was significantly improved following 4 weeks of rHuEpo administration and remained 
significantly elevated 4 weeks post administration and that these performance effects coincided with 
significantly rHuEpo-induced elevated   O2max and Hbmass. 
 
2.4.1 Running performance: 
The effects of rHuEpo on exercise performance have principally been investigated using   O2max tests. 
Despite slight differences in the frequency of injections and in the dosage used, rHuEpo administration 
for 4 to 6 weeks in healthy subjects has previously been shown to increase   O2max by approximately 8% 
(Audran et al. 1999; Berglund and Ekblom 1991; Birkeland et al. 2000; Connes et al. 2003; Parisotto et 
al. 2000; Russell et al. 2002; Wilkerson et al. 2005), which was confirmed by our observations. 
However,   O2max varies considerably among professional athletes (Lucia et al. 2002; Mujika and Padilla 
2001) and   O2max tests alone may probably be of little help in determining and ranking exercise 
performance when athletes of similar endurance ability are compared (Conley and Krahenbuhl 1980; 
Costill et al. 1973; Faria et al. 2005; Noakes 2008b; Shephard 2009). Time trial performance more 
closely reproduces competition conditions and more importantly allows the subjects to choose their own 
pace. It has previously been observed that blood doping via one unit of autologous blood transfusion, 
which increased the haematocrit by 5%, improved 10,000 m running performance by approximately one 
minute in 6 highly trained male distance runners, which corresponded to a ~3% improvement (Brien and 
Simon 1987). However, to our knowledge, no study has measured running time trial performance in 
order to determine whether the augmented   O2max after rHuEpo administration would translate into 
actual improvements in performance in the field. 
 
Relative to baseline, running performance improved post rHuEpo administration and remained enhanced 
4 weeks after administration by approximately 6% and 3%, respectively. Following rHuEpo 
administration, subjects were able to maintain a faster pace throughout the 3,000 m time trial compared 
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to baseline. While the augmented oxygen transport capacity illustrated by the increase in Hbmass can 
explain the increase in   O2max post rHuEpo administration, it cannot really explain the significant 
improvement in running performance. Indeed, as oxygen supply and demand are adequately matched 
during submaximal exercise in healthy men, the rHuEpo-induced augmented oxygen transport capacity 
cannot be the reason for the improvement in time trial running performance observed in our study 
(Noakes 2008a, b). In addition, failure to observe a strong correlation between individual changes in 
  O2max, Hbmass and running performance may imply that rHuEpo administration improves submaximal 
exercise performance by other mechanisms, although it could also be partly explained by the limited 
sensitivity of the methods of measurement and by the limitations of the study (see next paragraph). 
Other mechanisms than the increase in oxygen transport capacity have been proposed to explain the 
effects of rHuEpo on exercise performance (Boning et al. 2008, 2011). For instance, it has been 
demonstrated that self-reported mood, cognitive function and perceived physical condition were 
improved following rHuEpo administration (Miskowiak et al. 2008; Ninot et al. 2006). rHuEpo may 
indeed exert effects in nonhematopoietic tissues including the brain (Breidbach et al. 2003; Charrier et 
al. 2003; Jelkmann et al. 2009). Admittedly, two different studies conducted by the same research group 
did not reveal any measurable nonhematopoietic ergogenic effect of rHuEpo on exercise performance 
and the authors therefore concluded that the increased oxygen carrying capacity is the main if not the 
only reason why rHuEpo enhances exercise performance in healthy men (Chapman et al. 2011; Lundby 
et al. 2008b). On the other hand, the central governor model can give an alternative view (Noakes 
2008b). As the perception of effort of the subjects did not change and because the subjects were not 
limited by an inadequate oxygen supply either before or after administration as they ran at submaximal 
levels, the central governor model would argue that the subjects ran faster after rHuEpo administration 
because of greater recruitment of motor units allowed for by a control mechanism of feed-forward and 
feedback to the brain (Noakes 2008b; especially Fig. 2 of that paper). 
 
This study was part of a larger research project funded by WADA (see following chapters) and was 
designed primarily for other purposes. The present study was not blinded, did not include a control 
group and the subjects, whilst all were involved in endurance activities, were not all runners. As such, 
we were unable to adequately assess changes in the training load during the study due to the absence of 
a placebo group and the heterogeneity of sporting/training activity of the subjects. It is not impossible 
that the performance enhancements observed may, therefore, be partly due to placebo effect, to an 
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increase in the training load and to an improvement in pacing strategy, especially for the non-runners. It 
was, however, reassuring that the typical error of measurement for the two time trials conducted during 
each phase was low and that the amplitude of the improvement observed was well above the 95% 
confidence interval for the two attempts during each phase. 
 
2.4.2 Haemoglobin mass and haematological parameters: 
The level of Hbmass prior to the intervention reflected the regular participation in endurance activities of 
the subjects (Heinicke et al. 2001). Following the first week of rHuEpo administration, Hbmass gradually 
increased and reached its maximum one week after the last injection. The weekly increase of 
approximately 40 g is equivalent to the haemoglobin contained in one bag of 450 mL stored blood 
(Morkeberg et al. 2009). The delay of approximately one week between rHuEpo injections and the 
observed responses in Hbmass and red cell volume is explained by the reticulocyte maturation time of 1-4 
days (Banfi 2008). While normal human red blood cells can theoretically persist in the circulation for 
approximately 17 weeks (Franco 2009), Hbmass and red cell volume started to decrease toward baseline 
values from approximately the second week post rHuEpo administration with a similar rate to that of the 
increase during administration. This decrease in Hbmass and red cell volume post rHuEpo administration 
entailed the haemolysis of circulating red blood cells and therefore the release of haem from 
haemoglobin (Belcher et al. 2010). The haem degradation is catalyzed by haem oxygenase and generates 
one molecule of CO per molecule of haem oxidized (Ryter and Otterbein 2004). The CO produced by 
haem metabolism represents more than 85% of the endogenous CO production in healthy non-smoking 
subjects (Ryter and Otterbein 2004). Although measurement of blood carboxyhaemoglobin is influenced 
by environmental factors such as air pollution (Franco 2009), carboxyhaemoglobin can be used as an 
index of haemolysis (Engel et al. 1971). Indeed, basal carboxyhaemoglobin levels increased at the end 
of the rHuEpo administration and remained elevated for 2 weeks post administration, reflecting 
accelerated haemolysis. Despite being only an indirect marker, these results are in agreement with the 
negative regulation of red cell mass by neocytolysis when supraphysiologic red cell mass and 
endogenous Epo suppression occur (induced by rHuEpo administration, for instance) (Chang et al. 
2009; Rice and Alfrey 2005). In addition, this study confirmed that 4 weeks of rHuEpo administration 
sufficient to induce a significant increase in haematocrit did not increase resting blood pressure in 
healthy subjects when blood pressure was assessed by standard techniques compared to intra-arterial 
pressure transducers (Berglund and Ekblom 1991; Lundby and Olsen 2011; Lundby et al. 2008b; 
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Wilkerson et al. 2005). This study also demonstrates that the optimized CO-rebreathing method 
performed weekly for ten weeks is safe and well tolerated by healthy subjects. 
 
2.4.3 Plasma volume: 
Apart from confirming previous observations that rHuEpo administration increases haemoglobin 
concentration by increasing Hbmass and by decreasing plasma volume (Lundby et al. 2007; Olsen et al. 
2011), the present study showed that plasma volume returned to pre-injection values only approximately 
4 weeks post rHuEpo administration. Previous studies have concluded that plasma volume returned 
rather rapidly toward baseline value thus restoring pre-administration haemoglobin concentration values 
without affecting red cell volume (Lundby and Olsen 2011; Olsen et al. 2011). Olsen et al. (2011) used 
injections of 5,000 IU rHuEpo administered every second day for 2 weeks and thereafter only once a 
week for the 2 consecutive weeks to demonstrate that rHuEpo down-regulates the renin-angiotensin-
aldosterone system as well as the rate of proximal renal tubular reabsorption and glomerular filtration. 
The longer and more contrasted rHuEpo administration regimen used in the present study with a more 
abrupt erythropoiesis stimulation termination may have induced a more profound down-regulation of the 
renin-angiotensin-aldosterone system and therefore, may explain why plasma volume had not been 
restored until 4 weeks after rHuEpo administration. In agreement with previous findings which used a 
similar rHuEpo regimen than the present study, pre-injection haemoglobin concentration values were 
not restored 4 weeks post administration (Parisotto et al. 2000). 
 
2.4.5 Conclusion: 
In conclusion, relative to baseline, running performance was significantly improved following 4 weeks 
of rHuEpo administration in trained men and remained significantly elevated 4 weeks after 
administration by approximately 6% and 3%, respectively. These performance effects coincided with 
significantly rHuEpo-induced elevated   O2max and Hbmass.  
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3.1 Introduction and aim: 
Administration of rHuEpo improves endurance performance (Durussel et al. 2013a; Thomsen et 
al. 2007). Hence rHuEpo is frequently subject to abuse by athletes as revealed by the 
declarations of confessed dopers such as Lance Armstrong (Walsh 2012) and Tyler Hamilton 
(Hamilton and Coyle 2012), although the use of rHuEpo is prohibited by WADA. The ABP was 
recently introduced as a new tool to indirectly detect erythropoiesis-stimulating agents, such as 
rHuEpo, which can lead to a doping sanction imposed by a sports organization or its tribunal at 
the same time as intelligently targeting athletes for direct testing (Schumacher and d'Onofrio 
2012; Schumacher et al. 2012; Zorzoli and Rossi 2012). The ABP approach relies on identifying 
intra-individual abnormal variability over time of selected haematological parameters (Callaway 
2011; Sottas et al. 2010). Although this approach appears to be suitable to identify abnormal 
enhanced erythropoiesis regardless of the method used, the sensitivity of the ABP has been 
questioned (Lippi and Plebani 2011). In order to induce only minor fluctuations in the ABP 
blood markers and/or to "normalize" these markers after blood manipulations such as autologous 
blood transfusion, athletes are now using the so-called "micro doses" of rHuEpo which allegedly 
range from 10 to a maximum of 40 IU∙kg-1 body mass (Ashenden et al. 2011; Ashenden et al. 
2006; Morkeberg et al. 2013). Indeed, Ashenden et al. have demonstrated that the ABP did not 
reveal any suspicious doping activities when a rHuEpo microdosing strategy was used 
(Ashenden et al. 2011). In addition, physiological variations of the haematological parameters of 
the ABP due to factors such as training or hypoxia exposure can conflict with the interpretation 
of the ABP results (Sanchis-Gomar et al. 2011). There is therefore a need for the ABP approach 
to be improved. Using omics technologies, a specific molecular signature of a particular stimulus 
(rHuEpo doping for instance) can be revealed. Molecular markers, such as gene markers, 
characteristic of rHuEpo doping have the potential to improve further the ABP (Reichel 2011a). 
The aim of the current study was to assess the effects of rHuEpo on blood gene expression 
profiles in order to identify a “molecular signature” of rHuEpo doping and hence provide a basis 
for the development of novel testing models to detect rHuEpo doping.  
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3.2 Methods: 
3.2.1 Experimental design: 
Nineteen healthy trained men (mean ± SD, age: 26.0 ± 4.5 yr, body mass: 74.8 ± 7.9 kg, height: 
179.8 ± 5.4 cm) participated and completed the study. All subjects underwent a medical 
assessment and provided written informed consent to participate. The subjects were regularly 
engaged in predominantly endurance-based activities such as running, cycling, swimming, 
triathlon and team sports. Subjects were requested to maintain their normal training but abstain 
from official sporting competition for the duration of the research protocol (Howman 2013; 
Wagner 2013). This study was approved by University of Glasgow Ethics Committee and 
conformed to the Declaration of Helsinki. Each subject subcutaneously self-injected 50 IU∙kg-1 
body mass of rHuEpo (NeoRecormon, Roche, Welwyn Garden City, UK) every second day for 4 
weeks. Daily oral iron supplementation (~ 100 mg of elemental iron, Ferrous Sulphate Tablets, 
Almus, Barnstaple, UK) was given during the 4 weeks of rHuEpo administration. As the sample 
capacity on Illumina HumanHT-12 v4.0 Expression BeadChips meant that the sample sizes 
should be a multiple of 3, the subject who suffered from nasal obstruction and coughing during 
the study and could not perform the time trials post rHuEpo administration was not included in 
the microarray experiment. 
 
3.2.2 Blood sampling, RNA extraction and processing for microarray analysis (Figure 3.1): 
After 10 min of rest in the supine position, 3 milliliters of whole blood were collected into 
Tempus Blood RNA tubes (Applied Biosystems, Foster City, USA) from an antecubital vein in 
triplicate at baseline, during rHuEpo administration and for 4 weeks after rHuEpo administration. 
The Tempus tubes were vigorously mixed immediately after collection, incubated at room 
temperature for 3 hours, and stored at -20˚C before RNA extraction. Eight time points per 
subjects were selected for gene expression analysis, i.e. two baseline samples, then one sample 
each at 2 days, 2 weeks and 4 weeks after the first rHuEpo injection and 1 week, 2 weeks and 4 
weeks after rHuEpo administration (Figure 2.1). RNA was extracted using the MagMAX for 
stabilized blood tubes RNA isolation kit (Ambion, Austin, USA). RNA yield was determined 
using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, USA) and the 
RNA integrity number (RIN) was assessed using an Agilent 2100 Bioanalyzer (Agilent 
technologies, Santa Clara, USA). The RIN is a value between 1 (totally degraded) and 10 (intact) 
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which describes the quality of the RNA sample. Samples with RIN below 7 are more likely to 
generate poor-quality arrays with low percentage of present calls (Kiewe et al. 2009). RNA was 
stored at -80°C until further analysis. The labelled cRNA was then produced using the Illumina 
TotalPrep RNA Amplification Kit (Ambion, Austin, USA). The procedure consists in 
synthesizing cRNA by in vitro transcription from the cDNA produced by reverse transcription 
from 500 ng of RNA. For the Illumina microarray, 750 ng of the purified labeled cRNA samples 
were randomly hybridized to the Illumina HumanHT-12 v4.0 Expression BeadChip Kits 
following the manufacturers’ recommended procedures (Illumina, San Diego, Canada). The 
Bead arrays were scanned on the Illumina BeadArray Reader and raw intensity values were 
saved in Illumina GenomeStudio software. 
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Figure 3.1: Molecular workflow.  
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3.2.3 Microarray data analysis: 
Data were log2 transformed after adding a small constant of 51 to avoid negative values as well 
as to reduce the influence of probes with low signal intensities close to the background noise. 
The constant’s value was chosen after inspection of scatter plots of the two baseline samples 
from each individual. To remove the array effect a linear model was fitted to the each gene’s data 
using array as the predictor, and the coefficients for each array were removed from each value 
(Figure 3.2 and Figure 3.3). Rank Products analysis (Breitling et al. 2004) with a 5% false 
discovery rate (Benjamini and Hochberg 1995) was used to identify the differentially expressed 
transcripts during and post rHuEpo administration. An additional 1.5 fold-change threshold was 
applied for a more stringent analysis. Ingenuity Pathway Analysis was used to further analyze 
the data by incorporating biologically valid relationships (in a similar manner to Gene 
Ontologies). 
 
3.2.4 Housekeeping genes: 
In order to determine suitable housekeeping genes, transcripts were ranked according to three 
criteria: 1) high relative expression level, 2) low maximum fold change across the samples and 3) 
low variation over time using the Z score of generalized linear model. Rank products were used 
to determine the best housekeeping genes. 
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Figure 3.2: Principal component analysis (PCA) of the data before removing the array effect. 
A) Each point is represented by the phase, time point and subject 
number (n = 18). The colours (dark green, green, orange, red, dark 
red, light blue, dark blue and blue) represent the 8 time points, 
respectively: two baseline (Base.1 and Base.2); three during 
rHuEpo administration, 2 days (EPO.3), 2 weeks (EPO.4) and 4 weeks (EPO.5) after the 
first rHuEpo injection; and three after rHuEpo administration, 1 week (Post.6), 2 weeks 
(Post.7) and 4 weeks (Post.8).  
A. 
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Figure 3.2 (continued): 
B) Each point is represented by the array ID number and the array lane (n = 18 subjects x 8 
time points). The 12 different colours represent the different arrays (n = 12). An array 
effect can be observed. 
  
B. 
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Figure 3.3: Principal component analysis (PCA) of the data after removing the array effect. 
A) Each point is represented by the phase, time point and subject 
number (n = 18). The colours (dark green, green, orange, red, dark 
red, light blue, dark blue and blue) represent the 8 time points, 
respectively: two baseline (Base.1 and Base.2); three during 
rHuEpo administration, 2 days (EPO.3), 2 weeks (EPO.4) and 4 weeks (EPO.5) after the 
first rHuEpo injection; and three after rHuEpo administration, 1 week (Post.6), 2 weeks 
(Post.7) and 4 weeks (Post.8).  
A. 
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Figure 3.3 (continued): 
A) Each point is represented by the array ID number and the array lane (n = 18 subjects x 8 
time points). The 12 different colours represent the different arrays (n = 12). The array 
effect has been removed. 
  
B. 
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3.3 Results: 
3.3.1 RNA yield and cRNA: 
Relative to baseline (9.2 ± 2.9 μg), the RNA yield significantly increased during the last 2 weeks 
of rHuEpo administration (18.1 ± 7.0 μg, p < 0.001) and significantly decreased 2 and 4 weeks 
post rHuEpo administration (6.2 ± 2.2 μg and 7.0 ± 1.9 μg, p = 0.003 and p = 0.034), 
respectively (Figure 3.4). There was a good agreement between RNA yield and reticulocyte 
percentage (Figure 3.5 and Figure 2.5). The average RIN was 8.3 ± 1.1 (Figure 3.6). The quality 
of the cRNA samples was assessed by electrophoresis (Agilent 2100 Bioanalyzer, Agilent 
technologies, Santa Clara, USA) and as expected for RNA isolated from whole blood, the 
labelled cRNA profile showed a typical high concentration of globin mRNA (Figure 3.6). As a 
qualitative observation, the peak of globin mRNA was usually more prominent in samples 
collected during rHuEpo administration while it was less prominent post rHuEpo administration 
(see Appendix D). 
 
3.3.2 Transcripts altered by rHuEpo administration: 
Using the additional 1.5 fold-change threshold, 392 (389 up- and 3 down-regulated) transcripts 
were found to be differentially expressed during the last 2 weeks of rHuEpo administration 
compared to baseline (Figure 3.7). It is worth noting that 41 of these transcripts were found to be 
already up-regulated 2 days after only one single rHuEpo injection and remained so throughout 
administration (Figure 3.7). 135 (down-regulated) transcripts were differentially expressed at 
both 2 weeks and 4 weeks after the last rHuEpo injection (Figure 3.8). 133 transcripts were 
found to be differentially expressed in the same way during (up-regulated) and subsequently post 
(down-regulated) rHuEpo administration (Figure 3.9 and Figure 3.10). Using Ingenuity Pathway 
Analysis, the discovered genes were found to be mainly related to either the functional or 
structural properties of the erythrocyte or to the cell cycle and its regulation (see Appendix C for 
the list of these genes). 
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Figure 3.4: Changes in total RNA yield extracted from 3 ml of whole blood stabilized in 
Tempus tubes (n = 18 subjects x 8 time points). 
Values are means ± SD. Time point 0 represents the first rHuEpo injection. The grey zone 
represents the 4 weeks rHuEpo administration. 
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Figure 3.5: Relationship between reticulocyte percentage and RNA. 
Each point represents one sample (n = 144) collected from 18 subjects at the 8 different time 
points which are represented by the different colours. The curve was fitted using polynomial 
regression. 
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Figure 3.6: Quality assessment of total RNA and cRNA. 
A representative electropherogram (Agilent 2100 Bioanalyzer, Agilent technologies, Santa Clara, 
USA) of total RNA (A) and cRNA (B). 
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Figure 3.7: Venn diagram of transcripts differentially expressed during rHuEpo compared to 
baseline (n = 18 subjects). 
The Venn diagram depicts the transcripts differentially expressed (5% false discovery rate and 
1.5 fold-change threshold) 2 days (yellow, solid line circle), 2 weeks (red, dotted line circle) and 
4 weeks (brown, dashed line circle) after the first rHuEpo injection compared to baseline, 
respectively. Values in brackets are number of transcripts up- (↑) and down-regulated (↓) 
compared to baseline. 
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Figure 3.8: Venn diagram of transcripts differentially expressed post rHuEpo compared to 
baseline (n = 18 subjects). 
The Venn diagram depicts the transcripts differentially expressed (5% false discovery rate and 
1.5 fold-change threshold) 2 weeks (purple, solid line circle) and 4 weeks (green, dashed line 
circle) post rHuEpo administration compared to baseline, respectively. Values in brackets are 
number of transcripts up- (↑) and down-regulated (↓) compared to baseline. 
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Figure 3.9: Venn diagram of transcripts differentially expressed during and post rHuEpo 
compared to baseline (n = 18 subjects). 
The Venn diagram depicts the transcripts differentially expressed (5% false discovery rate and 
1.5 fold-change threshold) during the last 2 weeks of rHuEpo (dark red, dashed and dotted line 
circle) as well as 2 weeks (purple, solid line circle) and 4 weeks (green, dashed line circle) post 
rHuEpo administration compared to baseline, respectively. Values in brackets are number of 
transcripts up- (↑) and down-regulated (↓) compared to baseline. 
  
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 3: Gene Expression Profiles – The Initial Cohort 
 
 
© J Durussel (2014)  77 
 
 
Figure 3.10: Typical blood gene expression profile following rHuEpo. 
Individual changes in gene expression in Aminolevulinic acid synthase 2 (ALAS2) gene, typical 
of dozens of genes differentially expressed following rHuEpo. ALAS2 catalyzes the initial step 
in the haem pathway (Sadlon et al. 1999). Changes are reported in log ratio compared to the 
average baseline values. Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject (n = 18). Each number corresponds 
to the sample time point. 
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3.4 Discussion: 
In the present study, we successfully used gene expression profiling in whole blood to identify 
genes that are differentially regulated following rHuEpo administration in trained male subjects. 
For instance, 133 transcripts were strongly up-regulated during rHuEpo and subsequently down-
regulated up to 4 weeks after administration in all subjects. In addition, 41 transcripts were 
sensitive to rHuEpo injections as they were found to be already differentially expressed 2 days 
after only one single rHuEpo injection. These transcripts are therefore promising candidates to 
detect microdose rHuEpo doping strategies used by athletes (Ashenden et al. 2011; Ashenden et 
al. 2006). By providing the initial blood “molecular signature” of rHuEpo doping, the results of 
the present study suggest that longitudinal changes in the expression of specific biomarker genes 
have the potential to add a new dimension to the ABP to detect rHuEpo doping. However, these 
promising initial results remain to be replicated and validated. This will be considered in 
Chapters 5 and 6. 
 
3.4.1 RNA yield and cRNA 
The increase and subsequent decrease in total RNA yield during and post rHuEpo administration, 
respectively, is likely to be directly related to the changes in reticulocytes. Reticulocytes contain 
RNA which is progressively lost during the differentiation into mature red blood cells (Sysmex 
2010). Of note, this feature enables the measurement of reticulocytes by flow cytometry (Sysmex 
2010; Tanke et al. 1983). However, the changes in RNA yield in the present study did not 
influence downstream analysis as the total RNA input was standardised prior to amplification 
and hybridization (i.e. 500 and 750 ng of RNA and cRNA, respectively). It has been shown that 
a high proportion of globin mRNA reduced the sensitivity of detection of transcripts in a 
microarray experiment and that using globin reduction methods in the preparation of cRNA can 
reduce this negative impact (Liu et al. 2006; Raghavachari et al. 2009; Thach et al. 2005; 
Vartanian et al. 2009). Nevertheless, the effect of removing globin mRNA on the overall 
microarray performance seems to be relatively modest. Firstly, the vast majority of the 
transcripts were commonly detected between methods regardless of whether globin mRNA was 
removed or not (Debey et al. 2006; Liu et al. 2006; Raghavachari et al. 2009; Vartanian et al. 
2009). Secondly, not removing globin mRNA generates highly reproducible data (Vartanian et 
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al. 2009). Thirdly, good housekeeping genes whose expression was consistent throughout the 
study were found (see Chapters 5 and 6). 
 
3.4.2 A first insight into the functions of the genes altered by rHuEpo administration: 
The function of the genes altered by rHuEpo will be discussed in more detail in the following 
chapters. However, in order to give a first insight, it was observed that a large number of these 
genes were unsurprisingly related to the structural or functional properties of haemoglobin or 
erythrocytes. Of note, haemoglobin alpha and beta were not included in the analysis because of 
the overabundance of their mRNA. Aminolevulinic acid synthase 2 (ALAS2) catalyzes the initial 
step in the haem pathway. In order to accommodate the rHuEpo induced increased demand for 
haem molecules which assembled with globin chains form haemoglobin, ALAS2 expression 
increased (Sadlon et al. 1999). A similar explanation of the changes in expression is applicable 
to the following genes and related proteins which are all found in abundance in erythrocytes. 
Haemoglobin delta (HBD) is part of the adult haemoglobin type A2 (α2δ2) which represents 2.5 
to 3.5% of Hbmass (Mosca et al. 2009). Haemoglobin epsilon 1 (HBE1) is part of the embryonic 
haemoglobins Gower 1 and 2 and is then normally supplanted by fetal and adult haemoglobin 
(Manning et al. 2007). The erythrocyte membrane protein band 4.2 (EPB42) is an abundant 
protein component of the erythrocyte membrane and is involved in maintaining the membrane 
organization and structure in erythrocytes (Satchwell et al. 2009). Carbonic anhydrase 1 (CA1) is 
a member of the carbonic anhydrase family which catalyzes the reversible hydration/dehydration 
reaction between carbon dioxide and bicarbonate (Imtaiyaz Hassan et al. 2012). CA1 is the most 
abundant non-haemoglobin protein in erythrocytes (Imtaiyaz Hassan et al. 2012). Solute carrier 
family 4 anion exchanger member 1 (SLC4A1) is the major integral membrane protein of 
erythrocytes and serves to increase the total carbon dioxide carrying capacity of the blood 
(Perrotta et al. 2005). Alpha haemoglobin stabilizing protein (AHSP) is an abundant erythroid 
protein that binds with free alpha haemoglobin and forms a stable complex (Kihm et al. 2002; 
Weiss et al. 2005). 
 
Interestingly, CA1 and HBD, as well as other genes related to erythrocyte functions which were 
differentially expressed during rHuEpo such as 2,3-bisphosphoglycerate mutase (BPGM), 
ferrochelatase (FECH), glycophorin B (GYPB), erythrocyte membrane protein band 4.1 (EPB41) 
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and haemoglobin mu (HBM) were also found to be differentially expressed in sickle cell disease 
patients compared to healthy controls (Raghavachari et al. 2009). BPGM occurs only in the 
erythrocyte and is a multifunctional enzyme which plays a key role in the dissociation of oxygen 
from haemoglobin (Fujita et al. 1998). FECH catalyzes the final steps in the haem pathway 
(Sadlon et al. 1999). GYPB is an erythrocyte membrane protein which bears antigens of blood 
groups (Blumenfeld and Huang 1995). Like EPB42, EPB41 is protein of the erythrocyte 
membrane involved in cytoskeletal connectivity (Satchwell et al. 2009). HBM transcript 
represents approximately 0.1% of the normal adult alpha globin in erythroid tissues (Goh et al. 
2005). 
 
The action of erythropoietin was at first thought to be limited to the regulation of erythropoiesis 
(Jelkmann et al. 2009). However, it has been shown that erythropoietin also has biological 
functions in nonhematopoietic tissues including the brain (Brines and Cerami 2005; Jelkmann et 
al. 2009). Several studies demonstrated and confirmed that erythropoietin is involved in the 
mechanisms of neuroprotection in hypoxic-ishaemic, traumatic, excitotoxic and inflammatory 
injuries, modulation of nitric oxide synthesis and neurotransmitter release, as well as protection 
of the blood-brain barrier against permeability and inflammation induced by vascular endothelial 
growth factor  (Brines and Cerami 2005). In addition, it has been demonstrated that self-reported 
mood, depression, memory, cognitive function and perceived physical condition were improved 
following rHuEpo administration (Miskowiak et al. 2008; Miskowiak et al. 2007; Miskowiak et 
al. 2009, 2010; Miskowiak et al. 2012; Ninot et al. 2006). Furthermore, promising recent results 
showed that erythropoietin therapy, by its neuroprotective and neurogenerative action, can be 
effective against pathophysiological features of schizophrenia and other brain diseases (Charrier 
et al. 2003; Fuchs et al. 2008; Kastner et al. 2012; Sargin et al. 2010; Venda et al. 2010; 
Wustenberg et al. 2011). Although the relation should be considered with caution, several genes 
which were strongly up-regulated during rHuEpo and subsequently down-regulated up to 4 
weeks after administration seemed to be related to the nervous system and/or cognitive function. 
Synuclein alpha (SNCA), which was found to be highly expressed in the brain, is suggested to 
play a role in the regulation of dopamine production and transport as well as in 
neurodegenerative disorders such as Parkinson’s disease (Fuchs et al. 2008; Miller et al. 2004; 
Venda et al. 2010). Although SNCA was initially thought to be “expressed only in nervous 
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system tissue” (Maroteaux et al. 1988), it has recently been demonstrated that SNCA was also 
highly present in the erythrocyte (Bartels et al. 2011; Fauvet et al. 2012; Scherzer et al. 2008). In 
particular, SNCA and haem metabolism genes such as ALAS2 and FECH (see above) were found 
to be co-induced by the transcription factor GATA1 (Scherzer et al. 2008). Based on these 
observations, the authors hypothesized that haem metabolism may be a missing link between 
alpha-synuclein aggregation and iron deposition, which are two common events of some 
neurodegenerative disorders (Scherzer et al. 2008). Dihydropyrimidinase-like 5 (DPYSL5) or 
collapsin response mediator protein 5 (CRMP5) is a member of the CRMP family (Charrier et al. 
2003). CRMPs are strongly expressed in the developing nervous system and are thought to play a 
role in the different events of brain development, myelination and adult neuronal plasticity 
(Charrier et al. 2003). Of note, CRMPs (including CRMP5) protein level was found to be 
increased in hypoxia-ischemia mice brain (Zhou et al. 2008). Polymorphisms in lamin (LMNA), 
which is involved in nuclear processes such as replication and transcription (Goldman et al. 
2002) and near the serpin peptidase inhibitor clade A member 13 (SERPINA13) were found to 
be associated with cognitive function in a British elderly population (Cluett et al. 2010). 
However, this finding was not confirmed in a Chinese group (Yeh et al. 2011). Selenium binding 
protein 1 (SELENBP1) was found to be increased in blood and brain of patients with 
schizophrenia and is potentially associated with growth and remodeling of neuritis (Kanazawa et 
al. 2008). 
 
3.4.3 Conclusion: 
In the present study, we demonstrated that blood gene expression profiles were profoundly and 
significantly altered during rHuEpo administration and for at least 4 weeks after the rHuEpo 
administration leading to the initial “molecular signature” of rHuEpo doping. A large number of 
the identified genes were related to the functional or structural properties of the erythrocyte. 
These very promising initial data suggest that omics technologies such as gene expression have 
the potential to add a new dimension to the ABP for rHuEpo detection. However, these results 
still need to be replicated and validated (see Chapters 5 and 6).  
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Chapter 4 : Replication in Another Cohort (part 1): 
 
Blood Parameters and Running Performance in Kenyan Runners 
Living and Training at Altitude after Recombinant Human 
Erythropoietin Administration 
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4.1 Introduction: 
Administration of rHuEpo increases blood oxygen carrying capacity and endurance performance 
in normoxic environments. It has been shown that 4 to 6 weeks of rHuEpo administration 
increased   O2max by ~8% (Audran et al. 1999; Berglund and Ekblom 1991; Birkeland et al. 
2000; Connes et al. 2003; Durussel et al. 2013a; Parisotto et al. 2000; Russell et al. 2002; 
Wilkerson et al. 2005) as well as submaximal cycling capacity at 80% of   O2max by an 
astonishing ~54% using time to exhaustion (Thomsen et al. 2007) and submaximal running 
performance by ~6% using 3,000 m time trial (Durussel et al. 2013a). While these performance 
studies using rHuEpo are difficult to compare given the variation in exercise protocols and 
rHuEpo administration regimes between studies, a 2 to 6% improvement in middle-distance 
(1,500-5,000 m) running performance is probably a reasonable estimate for the ergogenic effect 
of rHuEpo (Amann et al. 2008; Hopkins et al. 1999). Although caution is required when 
extrapolating these findings to the elite athlete, it should be noted that only a small fraction of 
this improvement would likely be seen as a worthwhile performance enhancement (Hopkins et 
al. 1999). Hence, rHuEpo is, allegedly, frequently subject to abuse by athletes, even though the 
use of rHuEpo is prohibited by WADA and that the ergogenic effects of rHuEpo in top elite 
performance have yet to be scientifically confirmed.  
 
When evaluating the ergogenic effects of rHuEpo during normobaric hypoxia, the relative 
improvement in   O2max induced by rHuEpo administration was greater at a simulated altitude up 
to 3,500 m compared to normoxia, and consequently, the progressive decrease of   O2max due to 
hypoxia was blunted up to this “altitude threshold” (Robach et al. 2008). On the other hand, 
above 3,500 m,   O2max remained unaltered by rHuEpo administration (Lundby and Damsgaard 
2006; Robach et al. 2008). Administration of rHuEpo increased the arterial oxygen content 
regardless of the severity of hypoxia, however, peak oxygen delivery directed to the exercising 
legs was only enhanced during normoxia (Robach et al. 2008). This blood flow redistribution 
may explain why   O2max is increased during normoxia but not during severe hypoxia. However, 
it remains unknown why the relative improvement in   O2max was more than doubled (i.e. 17.5% 
vs. ~8%) at a moderate altitude up to 3,500 m compared to normoxia (Robach et al. 2008). It 
may be noteworthy to mention that non-haematological mechanisms such as augmented buffer 
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capacity, mood improvement and placebo effect have all been proposed to account for the 
observed changes in exercise performance in response to either hypoxia or rHuEpo 
administration (Boning et al. 2008, 2011; Gore et al. 2007; Lundby et al. 2012a; Miskowiak et 
al. 2008; Ninot et al. 2006). Further insights into the interaction between rHuEpo administration, 
hypoxia exposure and exercise performance are needed to better understand the underlying 
mechanisms. 
 
In response to the extraordinary success of the Kenyan and Ethiopian middle- and long-distance 
runners since the 1968 Mexico City Olympics, several factors have been investigated in order to 
explain this east African running supremacy including the fact that most of these runners live and 
train at an altitude of approximately 2,000 to 2,500 m in eastern Africa (Onywera et al. 2006; 
Wilber and Pitsiladis 2012). For instance, the homeland of the Kalenjin tribe, which is known to 
produce the vast majority of the best runners in Kenya, is situated at 1,830 to 2,450 m (Wilber 
and Pitsiladis 2012). Although chronic hypobaric and acute normobaric hypoxia can lead to very 
different physiological responses, it can be speculated that athletes residing at moderate-altitude 
may benefit even more from rHuEpo administration compared to sea-level athletes based on the 
potential enhanced effects of rHuEpo on   O2max in this altitude range (Robach et al. 2008). As 
illustrated by the recent first positive test for rHuEpo in a Kenyan runner who previously won the 
Seoul marathon, Kenya is not spared by doping cases (BBC 2013a). In this part of the world 
where champions are continuously emerging and where being a successful runner is associated 
with substantial socioeconomic rewards, athletes are subjected to an environment with extreme 
pressure to perform (Wilber and Pitsiladis 2012). This specific social, psychological and 
economical situation may increase the likelihood of doping behaviour (Ehrnborg and Rosen 
2009). The ergogenic effect of rHuEpo administration associated with hypoxia has only been 
investigated using acute normobaric hypoxia with volunteers living at or near sea-level (Lundby 
and Damsgaard 2006; Robach et al. 2008). Hence, it remains unknown whether similar effects in 
haematological parameters and exercise performance will be found in athletes exposed 
chronically to moderate altitude. Furthermore, in the anti-doping field, the ABP uses intra-
individual abnormal variability over time of selected haematological parameters in order to 
indirectly detect erythropoiesis-stimulating agents, such as rHuEpo (Callaway 2011; Sottas et al. 
2010). In this context, knowledge of the haematological response following rHuEpo 
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administration in athletes living and training at moderate altitude is required. Therefore, the main 
purpose of the present study was to define the time course of changes in haematological 
parameters,   O2max and running time trial performance following 4 weeks of rHuEpo 
administration in Kenyan endurance runners from the Kalenjin tribe who live and train at 
moderate altitude (~2,150 m) and abstained from official sporting competition for the entire 
duration of the study (Howman 2013; Wagner 2013). These results were compared with 
observations made in the Caucasian cohort living and training at or near sea-level that underwent 
an identical rHuEpo administration regime (Chapter 2) (Durussel et al. 2013a). 
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4.2 Methods: 
4.2.1 Subjects: 
Twenty Kenyan endurance runners from the Kalenjin tribe based at moderate altitude (Eldoret, 
Kenya, 2,150 m, mean ± SD, age: 26.4 ± 4.1 yr, body mass: 56.8 ± 4.7 kg, height: 171.8 ± 6.4 
cm) participated in the study. This cohort (KEN) was compared with a previously published 
cohort (SCO) of nineteen Caucasian endurance trained males based at or near sea-level 
(Glasgow, Scotland, age: 26.0 ± 4.5 yr, body mass: 74.8 ± 7.9 kg, height: 179.8 ± 5.4 cm) that 
underwent an identical rHuEpo regime (Chapter 2) (Durussel et al. 2013a). All subjects 
underwent a medical assessment and provided written informed consent to participate. Subjects 
were requested to maintain their normal training but abstain from official sporting competition 
for the duration of the research study (Howman 2013; Wagner 2013). This study was approved 
by the Ethics Committees of Moi University (Kenya) and University of Glasgow (Scotland, UK) 
and conformed to the Declaration of Helsinki. Diresibachew Haile Wondimu carried out the data 
collection in the Kenyan cohort (see Acknowledgment). 
 
4.2.2 Experimental design: 
Each subject subcutaneously self-injected under supervision 50 IU∙kg-1 body mass of rHuEpo 
(NeoRecormon, Roche, Welwyn Garden City, UK) every second day for 4 weeks. Saline 
injections substituted rHuEpo when the predetermined safety haematocrit limit of 55% was 
reached by one subject in KEN on five occasions (days 14, 16, 18, 20 and 22 after the first 
injection). Thereafter, the subject resumed the standard rHuEpo regimem. Daily oral iron 
supplementation (~ 100 mg of elemental iron, Ferrous Sulphate Tablets, Almus, Barnstaple, UK) 
was given during the 4 weeks of rHuEpo administration. Venous blood samples from an 
antecubital vein were obtained in triplicate at baseline, during rHuEpo administration and for 4 
weeks after rHuEpo administration as previously described (Durussel et al. 2013a). All blood 
samples were taken after 10 min of rest in the supine position (Ahlgrim et al. 2010). Blood 
samples were then measured in triplicate using a Sysmex XT-2000i (Sysmex UK, Milton 
Keynes, UK). The mean value of the triplicate was reported. OFF score was calculated as 
follows: 
haemoglobin concentration  g∙L-1  - 60 reticulocytes  %  (Gore et al. 2003). 
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Resting blood pressure and heart rate were recorded three times on both arms in the supine 
position before blood sampling. Due to practical reasons, the CO-rebreathing method (Schmidt 
and Prommer 2005) could not be set up for this present study and, unlike in SCO, Hbmass was 
unfortunately not measured in KEN. Urine osmolality was measured using a portable osmometer 
(OsmoCheck, Vitech, UK). 
 
4.2.3 Running performance assessment: 
Two 3,000 m time trials separated by at least one day rest were performed on a 400 m outdoor 
athletics track (Chepkoilel Stadium, Eldoret, Kenya) at an altitude of 2,150 m pre, post rHuEpo 
administration and at the end of the study (Figure 4.1). Verbal encouragement was given with 
feedback provided for the split time and remaining laps. The best performance on each occasion 
was used for analysis. The typical error of measurement for time trial performance calculated 
from the two tests on each phase was 1.1% (95% confidence intervals 0.9 to 1.3). Borg’s rating 
of perceived exertion (RPE) (Borg 1970) was recorded at the completion of the time trial. 
Temperature, humidity and wind speed were recorded via portable hygrometer and anemometer. 
In addition to the time trial,   O2max was determined pre, post rHuEpo administration and at the 
end of the study using an incremental test to exhaustion on a motorised treadmill. Subjects were 
familiarized to run on the treadmill at all intensities on the day of the test. After 15 minutes of 
rest, the speed initially set at 9 km∙h-1 for 4 min with an incline of 1% was then increased by 1 
km∙h-1∙min-1 to reach 17 km∙h-1. Thereafter, the speed remained constant and the incline was 
increased by 2.5%∙min-1 until volitional exhaustion. Following a 30 min recovery,   O2max was 
verified using a square-wave protocol to exhaustion at a speed equivalent to the end incline 
attained during the incremental test (Kirkeberg et al. 2011; Pettitt et al. 2013). Gas exchange 
variables were measured breath by breath using an automated metabolic gas analysis system 
(Cosmed K4b2 or FitMate, Cosmed, Rome, Italy). One subject did not perform the exercise 
performance tests at the end of the study because of an injury, while four subjects were unable to 
perform the   O2max tests due to flooding of the laboratory and serious damage to equipment. 
Nineteen and fifteen subjects were therefore included for the statistical analysis of running time 
trial performance and   O2max, respectively. 
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200 m indoor athletics track, Kelvin Hall, Glasgow, Scotland, UK 
 
 
400 m outdoor athletics track, Chepkoilel Stadium, Eldoret, Kenya, at an altitude of 2,150 m. 
 
Figure 4.1: Pictures of the athletics tracks in Scotland (top) and Kenya (bottom) where the 3,000 
m running time trials took place. 
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4.2.4 Statistical analysis: 
The mean was calculated when more than one blood sample was collected per week before 
further analysis. Time trial performance,   O2max and blood parameters data for the key stages of 
the study were analyzed using repeated measures ANOVA with Bonferroni correction for 
multiple comparisons. Relationships between haemoglobin concentration, time trial performance 
and   O2max were assessed using the Pearson’s product moment correlation coefficient. Data are 
described as mean ± SD. When values of the two groups are compared, the results of KEN 
precede SCO. 
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4.3 Results: 
4.3.1 Haematological parameters (Table 4.1, Table 4.2, Figure 2.5, Figure 4.2 and Figure 4.3): 
Table 4.1 illustrates the changes in the main haematological parameters for five key stages of the 
study in both groups. Haematocrit and haemoglobin concentration were significantly higher in 
KEN compared to SCO at baseline (p < 0.001 and p = 0.004, respectively) (Figure 4.3A and 
Figure 4.3B). However, although haematocrit and haemoglobin concentration significantly 
increased in both groups following rHuEpo (p < 0.001), KEN and SCO reached similar 
maximum values approximately one week after the rHuEpo administration (p = 0.638 and p = 
0.958, respectively) (Figure 4.3A and Figure 4.3B). Reticulocyte percentage followed a similar 
pattern in both groups. From similar baseline values (p = 0.146), reticulocyte percentage 
increased rapidly after the first two injections (p < 0.001), and attained higher values in SCO 
compared to KEN during the rHuEpo administration (p = 0.003) (Figure 4.3C). Nadir was 
reached approximately two weeks after the last rHuEpo injection with similar values in both 
groups (p = 0.101), which were significantly lower compared to baseline values (p < 0.001) 
(Figure 4.3C). However, while the reticulocyte percentage remained decreased four weeks after 
the last rHuEpo injection compared to baseline in SCO (p < 0.001), pre-injection levels were 
restored in KEN (p = 0.106) (Figure 4.3C). OFF score significantly decreased during rHuEpo (p 
< 0.001) and then increased post administration (p < 0.001) in both groups (Figure 4.3D). 
However, OFF score in KEN was significantly elevated at baseline and at the middle point of 
rHuEpo administration compared to SCO (p = 0.004 and p = 0.001, respectively) (Figure 4.3D). 
Interestingly, in contrast to the mean group results, one Kenyan subject (white triangle and line 
highlighted in red) had a distinctive haematological response to rHuEpo administration (Figure 
4.2). His haematocrit and haemoglobin concentration remained relatively stable throughout the 
study and the response in reticulocyte percentage was blunted. Table 4.2 illustrates the changes 
in the resting systolic and diastolic blood pressure as well as in resting heart rate for five key 
stages of the study in both groups. KEN had slightly lower baseline resting systolic blood 
pressure (p = 0.005) and heart rate (p = 0.024) compared to SCO but similar diastolic blood 
pressure (p = 0.122). No major changes were observed after rHuEpo administration in resting 
systolic and diastolic blood pressure as well as in resting heart rate. Urine osmolality remained 
relatively constant throughout the study period (378 ± 193 mOsmol∙kgH2O
-1
, p = 1.000). 
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Figure 4.2: Individual changes in haematocrit (A), haemoglobin concentration (B), reticulocytes 
(C) and OFF score (D) in KEN. 
Each line corresponds to one subject (the “non-responder” is highlighted in red) and each symbol 
corresponds to the same subject in all figures (n = 20). Individual mean value was calculated 
when more than one blood sample was collected per week. The bar graphs represent the mean 
values of the 20 subjects (KEN). The grey bars represent the 4 weeks of rHuEpo administration.  
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Figure 4.3: Changes in haematocrit (A), haemoglobin concentration (B), reticulocytes (C) and 
OFF score (D) in SCO (n = 19) and KEN (n = 20). 
Results are mean ± SD. SCO and KEN are represented by the black circle and the white square, 
respectively. The grey zone represent the 4 weeks of rHuEpo administration.   
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Table 4.1. Haematocrit, haemoglobin concentration, reticulocytes and body mass 
before, during and 4 weeks post rHuEpo administration in SCO and KEN 
 
SCO (n = 19) 
 
Baseline 
Week 2 of 
rHuEpo 
End of 
rHuEpo 
Week 2 
post 
rHuEpo 
Week 4 
post 
rHuEpo 
Haematocrit (%) 
41.9 44.7
***
 49.2
***
 47.7
***
 45.1
***
 
 ± 1.8  ± 2.0  ± 2.0  ± 2.2  ± 1.7 
Haemoglobin (g∙dl-1) 
14.4 15.2
***
 16.7
***
 16.1
***
 15.6
***
 
 ± 0.7  ± 0.7  ± 0.9  ± 0.9  ± 0.7 
Reticulocytes (%) 
1.07 2.57
***
 1.46
**
 0.44
***
 0.55
***
 
 ± 0.31  ± 0.44  ± 0.41  ± 0.13  ± 0.15 
OFF score 
83 56
***
 97
**
 122
***
 111
***
 
± 12 ± 10 ± 14 ± 9 ± 10 
Body mass (kg) 
75.1 74.7 75.0 74.6 74.6 
 ± 8.4  ± 7.8  ± 7.9  ± 7.6  ± 7.5 
 
KEN (n = 20) 
Haematocrit (%) 
45.3
†††
 46. 9
**††
 49.6
***
 49.0
***
 47.0
*††
 
 ± 2.6  ± 2.6  ± 2.6  ± 3.5  ± 2.1 
Haemoglobin (g∙dl-1) 
15.2
††
 15.9
***†
 16.7
***
 16.6
**
 16.1
**
 
 ± 0.9  ± 1.0  ± 1.0  ± 1.4  ± 0.9 
Reticulocytes (%) 
0.93 2.07
***††
 1.22
**†
 0.54
***
 0.71 
 ± 0.28  ± 0.50  ± 0.27  ± 0.24  ± 0.37 
OFF score 
97
††
 74
***††
 99 117
***
 111
***
 
± 14 ± 17 ± 12 ± 14 ± 13 
Body mass (kg) 
56.7
†††
 56.7
†††
 56.7
†††
 56.5
†††
 56.5
†††
 
 ± 4.9  ± 4.9  ± 4.6  ± 4.6  ± 4.7 
 
Values are means ± SD.  Data were analyzed using repeated measures ANOVA (SPSS, 
version 19). Significant differences compared to baseline values are indicated by * p < 
0.05, ** p < 0.01 and *** p < 0.001. Significant differences in KEN compared to SCO are 
indicated by † p < 0.05, †† p < 0.01 and ††† p < 0.001. SCO: 19 Caucasian trained men 
living at sea level; KEN: 20 Kenyan runners living at moderate altitude. 
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Table 4.2. Resting blood pressure and heart rate before, during and 4 weeks post 
rHuEpo administration in SCO and KEN 
      
 
SCO (n = 19) 
 
Baseline 
Week 2 of 
rHuEpo 
End of 
rHuEpo 
Week 2 
post 
rHuEpo 
Week 4 
post 
rHuEpo 
Systolic blood pressure 
(mmHg) 
128 ± 9 126 ± 7 126 ± 6 126 ± 7 124 ± 7 
Diastolic blood pressure 
(mmHg) 
70 ± 8 69 ± 8 69 ± 7 70 ± 7 69 ± 8 
Heart rate (beats∙min-1) 62 ± 8 60 ± 7 60 ± 7 59 ± 7 61 ± 8 
  
 
KEN (n = 20) 
Systolic blood pressure 
(mmHg) 
121 ± 6
††
 118 ± 7
**††
 122 ± 8 121 ± 9 119 ± 7
†
 
Diastolic blood pressure 
(mmHg) 
67 ± 5 65 ± 4 67 ± 4 66 ± 7 65 ± 5 
Heart rate (beats∙min-1) 56 ± 7† 54 ± 8† 54 ± 7*†† 56 ± 9 55 ± 7† 
 
Values are means ± SD. Data were analyzed using repeated measures ANOVA (SPSS, 
version 19). Significant differences compared to baseline values are indicated by * p < 0.05, 
** p < 0.01 and *** p < 0.001. Significant differences in KEN compared to SCO are 
indicated by † p < 0.05, †† p < 0.01 and ††† p < 0.001. SCO: 19 Caucasian trained men 
living at sea level; KEN: 20 Kenyan runners living at moderate altitude. 
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4.3.2 Running performance (Table 4.3, Table 4.4, Figure 4.4, Figure 4.5, Figure 4.6 and Figure 
4.7): 
Table 4.3 illustrates the changes in time trial performance and   O2max. Both time trial 
performance and   O2max were significantly better in KEN compared to SCO throughout the 
study (p < 0.001) (Figure 4.4 and Figure 4.6). However, interestingly, the relative improvements 
were similar between the two groups for time trial performance as well as for   O2max post 
administration (~5%, p = 0.188 and ~8%, p = 0.180, respectively) and 4 weeks after rHuEpo 
(~3%, p = 0.938 and ~4%, p = 0.692, respectively) (Table 4.4, Figure 4.5 and Figure 4.7). Unlike 
SCO whose RPE post time trial remained relatively constant throughout the study, RPE in KEN 
increased after rHuEpo administration compared to pre-injections levels (16.1 ± 1.1 vs. 14.6 ± 
1.5, p < 0.001) (Table 4.3). Temperature, humidity and wind records are reported in Table 1. 
 
Time trial performance was significantly correlated with   O2max throughout the study when 
KEN was grouped with SCO (r > 0.78, p < 0.001) but not when KEN alone was analyzed (p > 
0.337) (Figure 4.8). A significant correlation in individual responses compared to baseline 
between parameter was observed for time trial performance and   O2max post rHuEpo 
administration when KEN was analyzed alone and when grouped with SCO (r = 0.86, p < 0.001, 
r = 0.62, p < 0.001, respectively). No significant correlation was found between haemoglobin 
concentration and either time trial performance or   O2max.  
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 SCO (n = 18) KEN (n = 20) 
 
 
 
Figure 4.4: Changes in time trial performance in SCO and KEN. 
The top panels represent individual changes in SCO (top left panel) and KEN (top right panel). 
The bottom panel illustrates the mean ± SD. SCO and KEN are represented by the black circle 
and the white square, respectively.  
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 SCO (n = 18) KEN (n = 20) 
 
 
 
Figure 4.5: Relative changes in time trial performance in SCO and KEN. 
The top panels represent individual relative changes in SCO (top left panel) and KEN (top right 
panel). The bottom panel illustrates the mean ± SD. SCO and KEN are represented by the black 
circle and the white square, respectively.  
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 SCO (n = 18) KEN (n = 16) 
 
 
 
Figure 4.6: Changes in maximal oxygen uptake (  O2max) in SCO and KEN. 
The top panels represent individual changes in SCO (top left panel) and KEN (top right panel). 
The bottom panel illustrates the mean ± SD. SCO and KEN are represented by the black circle 
and the white square, respectively.  
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 SCO (n = 18) KEN (n = 16) 
 
 
 
Figure 4.7: Relative changes in maximal oxygen uptake (  O2max) in SCO and KEN. 
The top panels represent relative individual changes in SCO (top left panel) and KEN (top right 
panel). The bottom panel illustrates the mean ± SD. SCO and KEN are represented by the black 
circle and the white square, respectively. 
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Figure 4.8: Relationship between maximal oxygen uptake (  O2max) and 3,000 m running time 
trial performance in KEN and SCO. 
Relationship between absolute   O2max and 3,000 m running time trial performance in KEN and 
SCO at baseline (white squares and black circles, respectively; solid line) and immediately after 
the rHuEpo administration (light grey triangles and dark grey diamonds, respectively; dotted 
line).  
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Table 4.3. Running 3,000 m time trial performance and maximal oxygen uptake in SCO 
and KEN 
 
SCO 
  Baseline End of rHuEpo End of the study 
3,000 m total time (min:sec) 11:08 ± 1:15 10:30
***
 ± 1:07 10:46
***
 ± 1:13 
First 1 km split time (min:sec) 3:35 ± 0:28 3:23
**
 ± 0:18 3:27
*
 ± 0:22 
Second 1 km split time (min:sec) 3:46 ± 0:28 3:35
***
 ± 0:28 3:40
**
 ± 0:26 
Third 1 km split time (min:sec) 3:49 ± 0:25 3:32
***
 ± 0:22 3:39
**
 ± 0:26 
RPE scale (6-20) 17.8 ± 1.9 18.4 ± 1.2 18.8 ± 1.3 
Temperature (Cº) 19.7 ± 2.5 19.0 ± 1.9 19.5 ± 3.8 
Humidity (%) 48.9 ± 9.5 46.6 ± 8.7 44.6 ± 8.8 
  O2max (l∙min
-1
) 4.2 ± 0.4 4.6
***
 ± 0.5 4.3
*
 ± 0.5 
  O2max (ml∙min
-1∙kg-1) 56.0 ± 6.2 60.7
***
 ± 5.8 58.0
*
 ± 5.6 
 
KEN 
3,000 m total time (min:sec) 9:23
†††
 ± 0:28 8:57
***†††
 ± 0:22 9:04
***†††
 ± 0:20 
First 1 km split time (min:sec) 3:04
†††
 ± 0:10 2:56
**†††
 ± 0:07 2:57
*†††
 ± 0:07 
Second 1 km split time (min:sec) 3:17
††
 ± 0:22 3:02
*†††
 ± 0:08 3:04
†††
 ± 0:08 
Third 1 km split time (min:sec) 3:10
†††
 ± 0:13 3.00
†††
 ± 0.28 3:03
*†††
 ± 0:08 
RPE scale (6-20) 14.6
†††
 ± 1.5 16.1
***†††
 ± 1.1 15.3
†††
 ± 1.2 
Temperature (Cº) 24.0
†††
 ± 2.5 25.4
†††
 ± 2.4 23.3
†
 ± 3.9 
Humidity (%) 55.4 ± 16.1 50.4 ± 9.2 58.5
††
 ± 15.9 
Wind speed (m∙s-1) 1.6 ± 0.8 1.9 ± 0.8 2.8 ± 0.7** 
  O2max (l∙min
-1
) 3.6
†††
 ± 0.4 3.9
**†††
 ± 0.4 3.7
†††
 ± 0.4 
  O2max (ml∙min
-1∙kg-1) 65.3
†††
 ± 5.1 69.2
**†††
 ± 5.9 67.2
†††
 ± 6.0 
 
Values are means ± SD. Data were analyzed using repeated measures ANOVA (SPSS, version 
19). Significant differences compared to baseline values are indicated by * p < 0.05, ** p < 
0.01 and *** p < 0.001. Significant differences in KEN compared to SCO are indicated by † p 
< 0.05, †† p < 0.01 and ††† p < 0.001. SCO: Scottish trained individuals living and training at 
or near sea-level; 18 subjects were included in the analysis of both time trial performance and 
  O2max; KEN: Kenyan runners living and training at moderate altitude; 19 and 15 subjects 
were included in the analysis of time trial performance and   O2max;  O2max: Maximal oxygen 
uptake. 
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Table 4.4. Relative changes in running 3,000 m time trial performance, maximal 
oxygen uptake, haematocrit and haemoglobin concentration in KEN and SCO. 
   
 KEN SCO 
 
End of rHuEpo 
End of the 
study 
End of rHuEpo 
End of the 
study 
3,000 m 
performance 
-4.6 ± 2.4% 
(-5.8 to -3.5) 
-3.3 ± 2.6% 
(-4.6 to -2.1) 
-5.7 ± 2.5% 
(-6.9 to -4.5) 
-3.4 ± 2.6%  
(-4.7 to -2.1) 
Maximal oxygen 
uptake (  O2max) 
6.2 ± 5.4% 
(8.9 to 3.4) 
3.1 ± 5.7% 
(5.9 to 0.4) 
8.7 ± 5.0% 
(11.2 to 6.2) 
3.9 ± 4.9% 
(6.4 to 1.3) 
Haematocrit 
9.7 ± 4.7% 
(11.9 to 7.5)
***
 
4.1 ± 5.0% 
(6.2 to 1.9)
*
 
17.6 ± 4.9% 
(19.8 to 15.3) 
7.8 ± 4.5% 
(10.0 to 5.6) 
Haemoglobin 
concentration  
10.1 ± 5.5% 
(12.5 to 7.6)
**
 
5.9 ± 5.8% 
(8.4 to 3.4) 
16.2 ± 5.2% 
(18.7 to 13.7) 
8.2 ± 5.1% 
(10.7 to 5.7) 
 
Values are means ± SD (95% confidence intervals). Data were analyzed using repeated 
measures ANOVA (SPSS, version 19). Significant differences in KEN compared to 
SCO are indicated by * p < 0.05, ** p < 0.01 and *** p < 0.001. KEN: Kenyan runners 
living and training at moderate altitude; 19 and 15 subjects were included in the 
analysis of time trial performance and   O2max. SCO: Scottish trained individuals living 
and training at or near sea-level; 18 subjects were included in the analysis of both time 
trial performance and   O2max. 
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4.4 Discussion: 
The main aim of this study was to determine whether the effects of rHuEpo administration on 
blood parameters,   O2max and running time trial performance in Kenyan endurance runners 
living and training at moderate altitude (~2,150 m) would be similar to those observed in 
Caucasian trained males living and training at or near sea-level (Chapter 2) (Durussel et al. 
2013a). The main finding of this study was that, although baseline values were markedly 
different between groups and blood parameters did not change as much in KEN as in SCO, the 
relative improvements in running performance post rHuEpo (~5%) and 4 weeks post 
administration (~3%) were not significantly different between both groups. 
 
4.4.1 Haematological parameters: 
On the basis of the limited literature of haematological profiles of the Kenyan distance runners, it 
seems that Kenyan endurance athletes living and training at moderate altitude (2,000-2,500 m) 
may have relatively high haemoglobin concentration and haematocrit but within or close to the 
levels typical of sea-level populations (Moore et al. 2007). The mean haemoglobin concentration 
and haematocrit reported in our study were slightly lower but in accordance with the values 
previously reported in the literature (Ashenden et al. 2003; Moore et al. 2007; Prommer et al. 
2010). This small difference may be due to the posture adopted before blood sampling (Ahlgrim 
et al. 2010) which was not reported in the other studies. Regardless of these minor discrepancies, 
baseline haemoglobin concentration and haematocrit values were as expected higher in KEN 
compared to SCO. The administration of rHuEpo stimulated the bone marrow production in both 
groups as indicated by the significant increase in immature reticulocyte fraction and reticulocyte 
percentage. Subsequently, haemoglobin concentration and haematocrit significantly increased in 
both groups to a similar mean maximum of approximately 17 g∙dl-1 and 50% one week after the 
cessation of rHuEpo. While increasing haematocrit enhances the oxygen carrying capacity of the 
blood, it is also associated with elevated blood viscosity which in turn can limit cardiac work and 
may hamper exercise performance (Boning et al. 2011; Schuler et al. 2010). It has been 
demonstrated in vivo that there is indeed an optimal haematocrit for systemic exercise in mice 
(Schuler et al. 2010). Some authors reported that the optimal haematocrit values for human 
exercise performance should be within the broad range of 43 to 55% (Boning et al. 2011; 
Robertson et al. 1982), while others speculated that it should be close to the measurements 
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reported in a Finnish cross-country skier three times Olympic gold medallist with an autosomal 
dominant mutation in erythropoietin receptor which was associated with remarkable 
haemoglobin concentration and haematocrit above 20 g∙dl-1 and 65%, respectively (Juvonen et 
al. 1991; Schuler et al. 2010). Our results showed that the elevated blood viscosity after rHuEpo 
administration in our study illustrated by the increase in haematocrit and haemoglobin 
concentration which peaked at similar times and levels in both groups did not hinder significant 
improvement in running performance either in SCO or in KEN.  
 
4.4.2 Running performance: 
Although baseline values were markedly different between groups and blood parameters did not 
change as much in KEN as in SCO, the relative improvements in running performance as well as 
in   O2max post rHuEpo and 4 weeks post administration were not significantly greater in SCO 
compared to KEN. It has been well established that, despite slight differences in the frequency of 
injections and in the dosage used, rHuEpo administration for 4 to 6 weeks increases   O2max by 
approximately 8% in normoxia (Audran et al. 1999; Berglund and Ekblom 1991; Birkeland et al. 
2000; Connes et al. 2003; Durussel et al. 2013a; Parisotto et al. 2000; Russell et al. 2002; 
Wilkerson et al. 2005). In the present study, improvements of similar magnitude were observed 
in Kenyan sub-elite endurance runners who live and train at moderate-altitude altitude (2,000-
2,500 m). In addition, the changes in the laboratory based measurements translated into actual 
improvements in running performance in the field. On average, the subjects were 26 s faster 
during the 3,000 m run at an elevation of 2,150 m (corresponding to a ~5% improvement). While 
the blood oxygen content after rHuEpo was not enhanced as much in KEN as in SCO, illustrated 
by the increase in haemoglobin concentration and haematocrit of ~10% in KEN and ~17% in 
SCO, the relative improvements in running performance and   O2max were approximately similar 
(~5 and ~7%, respectively). It has been previously reported that the relative improvement of 
  O2max induced by rHuEpo administration was more than doubled (i.e. 17.5%) at a simulated 
moderate altitude up to 3,500 m compared to normoxia (Robach et al. 2008). Based on these 
results, the similar relative improvement in   O2max associated with a smaller increase in blood 
oxygen content after rHuEpo in KEN compared to SCO may be explained by the fact that the 
experiments were carried out in moderate-altitude hypoxia and normoxia, respectively. 
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These findings question how rHuEpo administration enhances exercise performance, especially 
at moderate-altitude. As no measurable nonhematopoietic ergogenic effect of rHuEpo on 
exercise performance in normoxic conditions was observed in two different studies conducted by 
the same authors, they attributed the ergogenic effects of rHuEpo to the increase in oxygen 
carrying capacity (Lundby et al. 2008b; Rasmussen et al. 2010). The oxygen supply to 
exercising muscle depends on the haemoglobin concentration and cardiac output. However, 
haemoglobin concentration is only weakly related to   O2max whereas the relationship between 
Hbmass and   O2max is much stronger (Kanstrup and Ekblom 1984; Schmidt and Prommer 2010). 
Unlike haemoglobin concentration, Hbmass is not affected by changes in plasma volume and is 
therefore a key complementary parameter to evaluate blood oxygen carrying capacity (Schmidt 
and Prommer 2010). Unfortunately, Hbmass and related blood volumes were not determined in 
KEN. As a result and although the urine osmolality of KEN, which can give some indication of 
the hydration status, did not significantly change throughout the study, it cannot be ruled out that 
the rHuEpo-induced change in Hbmass and related blood volumes were different when comparing 
SCO and KEN. In addition, because the study was designed primarily for other purposes, the 
study was not blinded and did not include a control group. As such, factors unrelated to rHuEpo 
such as altered motivation (placebo, order effect, etc.) may partly explain the reported 
performance effects and reflected in the small but significant rise in RPE after rHuEpo in KEN. 
Nevertheless, it is tempting to speculate that the similar relative improvements in running 
performance and   O2max, despite haemoglobin concentration and haematocrit not changing as 
much in KEN as in SCO, may be due to mechanisms not directly related to the blood oxygen 
carrying capacity such as augmented buffering capacity (Boning et al. 2008, 2011) and mood 
improvement (Miskowiak et al. 2008; Ninot et al. 2006). Other potential explanations involving 
the central nervous system include the anticipatory model which would argue that greater 
recruitment of motor units was allowed during the 3,000 m run post rHuEpo administration 
because the control mechanism of feed-forward and feedback to the brain was modified (Kayser 
2003; Noakes 2008a, b; Noakes et al. 2001). Despite some conjecture, the precise mechanism(s) 
underlying the apparently similar ergogenic effects of rHuEpo at moderate altitude as compared 
to normoxia (i.e. sea-level) remain speculative. 
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4.4.3 Non-responders to rHuEpo administration: 
Based on the blunted response in the haematological parameters and exercise performance, one 
Kenyan subject did not respond to rHuEpo administration. It is well known that there is a marked 
variability in the sensitivity to rHuEpo in anaemic patients as well as in rHuEpo dose 
requirement (Eschbach et al. 1989; Macdougall 1995). Approximately 90% of patients receiving 
rHuEpo respond to rHuEpo therapy by increasing their haemoglobin concentration. The 
remaining 10% of patients show either no response or suboptimal response, i.e. failing to attain 
target haemoglobin concentration levels despite increasing the dose of rHuEpo to very high 
levels (Macdougall 1995). In addition, the sensitivity to hypoxia exposure during altitude 
training in healthy volunteers or athletes is also variable as reflected by significant but not clear-
cut differences in plasma erythropoietin concentrations (Chapman et al. 1998). The athletes who 
responded to altitude training demonstrated higher erythropoietin levels which in turn seemed to 
trigger a sufficient increase in Hbmass and associated improvements in exercise performance 
(Chapman et al. 1998; Robach and Lundby 2012; Wilber et al. 2007). The particular subject in 
KEN who demonstrated a blunted haematological and exercise performance response after 
rHuEpo may therefore be representative of the 10% of the treated patients or of the “non-
responders” to altitude training. Further research is needed to determine the exact causes of this 
variability in responsiveness to rHuEpo administration and altitude training. 
 
4.4.4 rHuEpo and anti-doping at altitude: 
The use of rHuEpo is prohibited by WADA. The direct urinary test to detect rHuEpo was 
developed and published by Lasne et al. in 2000 (Lasne and de Ceaurriz 2000; Lasne et al. 
2002). However, while the effects of rHuEpo administration on haematological parameters and 
exercise performance can last for weeks as shown in the present study, the test has a rather 
limited detection window, i.e. a few hours up to a few days depending on the dose used 
(Ashenden et al. 2006; Breidbach et al. 2003; Lundby et al. 2008a). At the same time as the 
development of the direct test, potential indirect detection of rHuEpo using blood markers of 
altered erythropoiesis is being explored (Cazzola 2000; Parisotto et al. 2000). The ABP was 
introduced as a new tool to indirectly detect blood doping which can lead to disciplinary 
sanctions imposed by a sports organization or its tribunal at the same time as intelligently 
targeting athletes for additional testing (Schumacher et al. 2012; Zorzoli and Rossi 2012). The 
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ABP approach relies on identifying intra-individual abnormal variability over time of selected 
haematological parameters including haemoglobin concentration, reticulocyte percentage and 
OFF score (Callaway 2011; Sottas et al. 2010). In this context, factors such as residence at 
altitude and ethnicity have been shown to significantly influence these haematological 
parameters (Ashenden et al. 2003; Ashenden et al. 2001; Sharpe et al. 2002) and confirmed in 
the present study as the magnitude of change in haemoglobin concentration, reticulocyte 
percentage and OFF score used in the ABP was reduced in KEN as compared with SCO in 
response to the same rHuEpo administration regime. As a result, it may be more difficult to 
detect rHuEpo doping at altitude compared to sea-level using the currently anti-doping methods 
due to the blunted haematological response. There are indeed concerns about the risk of the 
misuse of altitude exposure by some athletes in order to mask blood doping practices such as the 
administration of rHuEpo (Lundby et al. 2012b; Sanchis-Gomar et al. 2009). Interestingly, a 
recent published review concluded that the size of the benefit of rHuEpo administration in top 
elite athletes, which has yet to be scientifically confirmed, is likely to be small or nonexistent 
(Heuberger et al. 2012). The present findings are contrary to this conclusion. Although one still 
has to be cautious in extrapolating findings from sub-elite to truly elite athletes, the significant 
improvement in running performance observed in the present study would almost certainly 
translate into a worthwhile enhancement in elite performance (Hopkins et al. 1999). Moreover, 
in professional cycling stage races, such as the Tour de France, the mountain stages, which peak 
at altitudes ranging from approximately 1,500 m up to above 2,500 m, often separate winners 
from contenders (Jeukendrup et al. 2000). If the ergogenic effects of rHuEpo are indeed 
enhanced at moderate-altitude or can at least significantly reduce the hypoxia-induced 
impairment in exercise performance, rHuEpo administration has the potential to improve further 
the athlete’s chance of winning the stage or the overall classification. However, further research 
is required to confirm these findings and related hypotheses. 
 
In conclusion, this is the first study to demonstrate that 4 weeks of rHuEpo administration 
significantly increased the already relatively high basal haemoglobin concentration and 
haematocrit values of Kenyan endurance runners living and training at moderate-altitude by 
~10%. Although the rHuEpo-induced increase in key haematological parameters in these altitude 
Kenyan endurance runners was not as high compared to Caucasian counterparts living and 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 4: Blood and Performance – Replication 
 
 
© J Durussel (2014)  108 
training at or near sea-level, the relative improvements of ~5% and ~3% in running performance 
immediately after the rHuEpo administration and 4 weeks after the last injection were similar in 
both groups. These findings have important implications for current anti-doping practices. 
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Chapter 5 : Replication in Another Cohort (part 2): 
 
Blood Gene Expression Profiles in Kenyan Runners Living and 
Training at Altitude after Recombinant Human Erythropoietin 
Administration 
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5.1 Introduction and aim: 
Administration of rHuEpo improves endurance capacity and performance not only at sea-level 
(Chapter 2) (Durussel et al. 2013a; Thomsen et al. 2007) but also at moderate altitude (Chapter 
4) (Robach et al. 2008). Hence rHuEpo is frequently subject to abuse by athletes as revealed by 
the declarations of confessed dopers such as Lance Armstrong (Walsh 2012) and Tyler Hamilton 
(Hamilton and Coyle 2012), although the use of rHuEpo is prohibited by WADA. The aim of the 
previous study described in Chapter 3 was to assess the effects of rHuEpo on blood gene 
expression profiles in order to identify a “molecular signature” of rHuEpo doping and hence 
provide a basis for the development of improved testing models to detect rHuEpo doping based 
on gene expression profiles. On the basis of the data generated by the study described in Chapter 
3, blood gene expression profiles were profoundly and significantly altered during rHuEpo 
administration and for at least 4 weeks after the rHuEpo administration leading to the initial 
“molecular signature” of rHuEpo doping. For example, using a 1.5 fold-change threshold, 133 
transcripts were found to be differentially expressed in the same way during (up-regulated) and 
subsequently post (down-regulated) rHuEpo administration. Also, 41 transcripts were found to 
be already up-regulated 2 days after only one single rHuEpo injection. These very promising 
data suggest that omics technologies such as gene expression have the potential to add a new 
dimension to the ABP for rHuEpo detection. However, part of the validation process of 
microarray data, these results need to be replicated (Allison et al. 2006; Chuaqui et al. 2002). 
The haematological and exercise performance results previously described in Chapter 4 
confirmed that the perturbation involving rHuEpo worked effectively in both the Scottish and 
Kenyan groups. Using the same gene microarray molecular methods previously described in 
Chapter 3, the aim of the present study was to assess and compare the effects of rHuEpo on 
blood gene expression profiles discovered in the Scottish sea-level group with another cohort 
composed of Kenyan endurance runners living and training at moderate altitude who underwent 
an identical rHuEpo administration.  
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5.2 Methods: 
5.2.1 Experimental design: 
In order to replicate the findings in the previously described Scottish (SCO) cohort, twenty 
Kenyan endurance runners (KEN, mean ± SD, age: 26.4 ± 4.1 yr, body mass: 56.8 ± 4.7 kg, 
height: 171.8 ± 6.4 cm) based at moderate altitude (Eldoret, Kenya, ~2,150 m) participated in the 
study and underwent an identical rHuEpo administration regime in moderate hypoxic conditions, 
i.e. each subject subcutaneously self-injected 50 IU∙kg-1 body mass of rHuEpo (NeoRecormon, 
Roche, Welwyn Garden City, UK) every second day for 4 weeks. All subjects underwent a 
medical assessment and provided written informed consent to participate. The subjects were 
requested to maintain their normal training but abstain from official sporting competition for the 
duration of the research protocol (Howman 2013; Wagner 2013). This study was approved by 
University of Glasgow Ethics Committee as well as the Moi University Committee and 
conformed to the Declaration of Helsinki. 
 
5.2.2 Blood sampling, RNA extraction and processing for microarrays analysis (Figure 3.1): 
After 10 min of rest in the supine position, 3 ml of whole blood were collected into Tempus 
Blood RNA tubes (Applied Biosystems, Foster City, USA) from an antecubital vein in triplicate 
at baseline, during rHuEpo administration and for 4 weeks after rHuEpo administration (Figure 
2.1). The Tempus tubes were vigorously mixed immediately after collection, incubated at room 
temperature for 3 hours and stored at -20˚C. The frozen tubes were shipped to Glasgow 
(Scotland, UK) on ice and stored at -20˚C before RNA extraction. Eight time points per subjects 
were selected for gene expression analysis, i.e. two baseline samples, then one sample each at 2 
days, 2 weeks and 4 weeks after the first rHuEpo injection and 1 week, 2 weeks and 4 weeks 
after rHuEpo administration. RNA was extracted using the Tempus Spin RNA isolation kit (Life 
Technologies, Paisley, UK) (see Appendix B.2). RNA yield was determined using a NanoDrop 
spectrophotometer (Thermo Fisher Scientific, Wilmington, USA) and the RIN was assessed 
using an Agilent 2100 Bioanalyzer (Agilent technologies, Santa Clara, USA). RNA was stored at 
-80°C until further analysis. RNA was then prepared using the Illumina TotalPrep RNA 
Amplification Kit (Ambion, Austin, USA). The procedure consists in synthesizing cRNA by in 
vitro transcription from the cDNA produced by reverse transcription from 500 ng of RNA. For 
the Illumina microarray, 750 ng of the purified labeled cRNA samples were randomly hybridized 
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to the Illumina HumanHT-12 v4.0 Expression BeadChip Kits following the manufacturers’ 
recommended procedures (Illumina, San Diego, Canada). The Bead arrays were scanned on the 
Illumina BeadArray Reader and raw intensity values were saved in Illumina GenomeStudio 
software. 
 
5.2.3 Microarray data analysis: 
The microarray data analysis used was the same as in Chapter 3. Briefly, data were log2 
transformed after adding a small constant of 51 to avoid negative values as well as to reduce the 
influence of probes with low signal intensities close to the background noise. The regression 
coefficient between the arrays was determined and was used as a scaling factor to remove the 
array effect (Figure 3.2 and Figure 3.3). Rank Products analysis (Breitling et al. 2004) with a 5% 
false discovery rate (Benjamini and Hochberg 1995) was used to identify the differentially 
expressed transcripts during and post rHuEpo administration. An additional 1.5 fold-change 
threshold was applied for a more stringent analysis. Ingenuity Pathway Analysis was used to 
further analyze the data by incorporating biologically valid relationships (in a similar manner to 
Gene Ontologies).  
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5.3 Results: 
5.3.1 RNA yield: 
The average yield of the total RNA was 10.6 ± 6.6 μg in KEN. Although the RNA yield in KEN 
graphically followed a similar pattern to that in SCO (Figure 5.1), no significant difference was 
observed during or post rHuEpo administration compared to baseline in KEN (probably due to a 
lack of power, n = 6). Values between the two groups were similar until 4 weeks post rHuEpo 
administration when the RNA yield in KEN was higher than in SCO (p = 0.028). The average 
RIN value for KEN was 9.1 ± 0.2 (see Appendix B.2). 
 
5.3.2 Transcripts altered by rHuEpo administration (Table 5.1, Table 5.2, Figure 5.2, Figure 
5.3, Figure 5.4, Figure 5.5, Figure 5.6 and Figure 5.7): 
Using the additional 1.5 fold-change threshold, there were 52 (up-regulated) transcripts which 
were already up-regulated two days after only the first rHuEpo injection, and remained so 
throughout administration in KEN (Figure 5.2). Among these transcripts, 30 were in common 
with SCO (Figure 5.2 and Table 5.1). The remaining 11 and 22 transcripts were also up-
regulated in both groups but were not included in the intersection of the Venn diagram due to the 
stringent 1.5 fold-change threshold. Rap1 GTPase-activating protein 1 (RAP1GAP), family with 
sequence similarity 46 member C (FAM46C) and oxysterol-binding protein 2 (OSBP2) were the 
top three genes whose expression were altered by a mean fold change higher than 2 in both 
groups two days after only the first rHuEpo injection (Figure 5.3 and Table 5.1). However, 
unlike the other genes, there was an extremely high variability in the gene expression response in 
RAP1GAP (Figure 5.3). Fewer transcripts were differentially expressed post rHuEpo 
administration in KEN compared to SCO (Figure 5.4 and Table 5.2). However, the 15 transcripts 
which were differentially expressed during (up-regulated) as well as subsequently post (down-
regulated) rHuEpo administration in SCO were also found in KEN (Figure 5.5 and Table 5.2). 
Delta-aminolevulinate synthase 2 (ALAS2), alpha-synuclein (SNCA – 2 transcripts) and ring 
finger protein 213 (RNF213) were the top three genes whose expression were down-regulated by 
a mean fold change higher than 4 in SCO and higher than 2 in KEN (Figure 5.6 and Table 5.2). 
Although the changes in gene expression were of lesser magnitude compared to the genes 
presented above, a few transcripts such as eukaryotic translation elongation factor 1 delta 
(guanine nucleotide exchange protein) (EEF1D), ribosomal protein S29 (RPS29) and parkinson 
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protein 7 (PARK7) were, unlike the majority of the discovered transcripts, down-regulated during 
rHuEpo administration and then up-regulated post administration (Figure 5.7). Using Ingenuity 
Pathway Analysis, the dysregulated genes were found to be mainly related to either the 
functional or structural properties of the erythrocyte or to the cell cycle and its regulation. 
 
5.3.3 Housekeeping genes: 
The top 100 best housekeeping genes in SCO and KEN were compared and one transcript was 
found to be in common. The gene associated with this transcript was MORF4 family-associated 
protein 1 (MRFAP1). MRFAP1 was a relatively abundant transcript with a maximum fold change 
across the samples lower than 1.5 and a low variation over time in both groups (Figure 5.8). 
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Figure 5.1: Changes in total RNA yield extracted from 3 ml of whole blood stabilized in 
Tempus tubes in SCO (n = 18) and KEN (n = 6)
4
. 
Values are means ± SD. Time point 0 represents the first rHuEpo injection. The grey zone 
represents the 4 weeks rHuEpo administration. SCO and KEN are represented by the circle and 
the square, respectively. 
  
                                                          
4
 See Appendix A for KEN (n = 18). 
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 SCO (n = 18)  KEN (n = 6) 
 
 SCO KEN 
 
 
Figure 5.2: Venn diagrams of transcripts differentially expressed during rHuEpo compared to 
baseline in SCO and KEN. 
The 3-way Venn diagrams (top panels) depicts the transcripts differentially expressed (5% false 
discovery rate and 1.5 fold-change threshold) 2 days (yellow, solid line circle), 2 weeks (red, 
dotted line circle) and 4 weeks (brown, dashed line circle) after the first rHuEpo injection 
compared to baseline, respectively. Values in brackets are number of transcripts up- (↑) and 
down-regulated (↓) compared to baseline. SCO (n = 18) and KEN (n = 6) are represented in the 
left and right top panels, respectively. The 2-way Venn diagram (bottom panel) depicts the 
intersection of the 3-way Venn diagrams. 
41 (↑) 52 (↑)
11 30 22
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Figure 5.3A: Individual changes in gene expression in the top three genes whose expression were altered by a mean fold change 
higher than 2 in both groups two days after the first rHuEpo injection. 
Rap1 GTPase-activating protein 1 (RAP1GAP): Changes are reported in normalised intensity (left panels) and log ratio compared to 
the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the rHuEpo 
administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, respectively.  
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Figure 5.3B (continued): Family with sequence similarity 46 member C (FAM46): Changes are reported in normalised intensity (left 
panels) and log ratio compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone 
represents the rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green 
and red, respectively.  
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Figure 5.3C (continued): Oxysterol-binding protein 2 (OSBP2): Changes are reported in normalised intensity (left panels) and log 
ratio compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively. 
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 SCO (n = 18)     KEN (n = 6) 
 
 SCO KEN 
 
 
Figure 5.4: Venn diagrams of transcripts differentially expressed post rHuEpo compared to 
baseline in SCO and KEN. 
The 2-way Venn diagrams in the top panels depict the transcripts differentially expressed (5% 
false discovery rate and 1.5 fold-change threshold) 2 weeks (purple, solid line circle) and 4 
weeks (green, dashed line circle) after the rHuEpo administration compared to baseline, 
respectively. Values in brackets are number of transcripts up- (↑) and down-regulated (↓) 
compared to baseline. SCO (n = 18) and KEN (n = 6) are represented in the left and right top 
panels, respectively. The 2-way Venn diagram in the bottom panel depicts the intersection of the 
2-way Venn diagrams in the top panels.  
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 SCO (n = 18)  KEN (n = 6) 
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Figure 5.5: Venn diagrams of transcripts differentially expressed during and post rHuEpo 
compared to baseline in SCO and KEN. 
The 3-way Venn diagrams (top panels) depicts the transcripts differentially expressed (5% false 
discovery rate and 1.5 fold-change threshold) during the last 2 weeks of rHuEpo (dark red, 
dashed and dotted line circle) as well as 2 weeks (purple, solid line circle) and 4 weeks (green, 
dashed line circle) post rHuEpo administration compared to baseline, respectively. Values in 
brackets are number of transcripts up- (↑) and down-regulated (↓) compared to baseline. SCO (n 
= 18) and KEN (n = 6) are represented in the left and right top panels, respectively. The 2-way 
Venn diagram (bottom panel) depicts the intersection of the 3-way Venn diagrams. 
133 15
118 15 0
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 5: Gene Expression Profiles – Replication 
 
 
© J Durussel (2014)  122 
 
Figure 5.6A: Individual changes in gene expression in top three genes whose expression were down-regulated by a mean fold change 
higher than 4 in SCO and higher than 2 in KEN 2 weeks post rHuEpo administration compared to baseline. 
Delta-aminolevulinate synthase 2 (ALAS2): Changes are reported in normalised intensity (left panels) and log ratio compared to the 
average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the rHuEpo administration. 
Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, respectively.  
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Figure 5.6B (continued): Alpha-synuclein (SNCA – 2 transcripts): Changes are reported in normalised intensity (left panels) and log 
ratio compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively.  
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Figure 5.6C (continued): Ring finger protein 213 (RNF213): Changes are reported in normalised intensity (left panels) and log ratio 
compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively. 
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Figure 5.7A: Individual changes in gene expression in the genes which were down-regulated during rHuEpo and then up-regulated 
after administration. 
Eukaryotic translation elongation factor 1 delta (EEF1D): Changes are reported in normalised intensity (left panels) and log ratio 
compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively. 
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Figure 5.7B (continued): Ribosomal protein S29 (RPS29): Changes are reported in normalised intensity (left panels) and log ratio 
compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively. 
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Figure 5.7C (continued): Parkinson protein 7 (PARK7): Changes are reported in normalised intensity (left panels) and log ratio 
compared to the average baseline values (right panels). Time point 0 represents the first injection. The grey zone represents the 
rHuEpo administration. Each line corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green and red, 
respectively. 
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Figure 5.8: Individual changes in gene expression in the housekeeping gene MORF4 family-associated protein 1 (MRFAP1). 
Changes are reported in normalised intensity (left panels) and log ratio compared to the average baseline values (right panels). Time 
point 0 represents the first injection. The grey zone represents the rHuEpo administration. Each line corresponds to one subject. SCO 
(n = 18) and KEN (n = 6) are represented in green and red, respectively. 
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Table 5.1. Common gene biomarkers in SCO and KEN differentially expressed 
during rHuEpo administration (including 2 days after the first rHuEpo injection). 
Probe  Gene  SCO (n=18)  KEN (n=6)  
ILMN_1776519  RAP1GAP  2.4 ± 1.8 (-1.1 ; 6.8)  2.2 ± 1.9 (1.3 ; 5.2)  
ILMN_1713266  FAM46C  2.3 ± 1.8 (-1.9 ; 7.2)  2.4 ± 1.5 (1.5 ; 4.2)  
ILMN_1781966  OSBP2  2.2 ± 1.5 (1.1 ; 4.1)  2.3 ± 1.9 (1.2 ; 4.9)  
ILMN_1708323  ALAS2  1.9 ± 1.6 (-1.2 ; 4.0)  1.6 ± 2.1 (-1.7 ; 3.9)  
ILMN_1652431  CA1  1.9 ± 1.6 (-1.1 ; 4.5)  2.2 ± 1.9 (-1.2 ; 5.0)  
ILMN_3285762  LOC100131164  1.9 ± 1.6 (1.0 ; 3.7)  1.9 ± 2.0 (-1.3 ; 4.4)  
ILMN_2352921  BPGM  1.8 ± 1.6 (-1.1 ; 4.6)  2.3 ± 1.8 (1.1 ; 6.1)  
ILMN_1766165  SNCA  1.8 ± 1.6 (-1.1 ; 3.4)  1.9 ± 2.0 (-1.4 ; 5.0)  
ILMN_1786328  WDR40A  1.8 ± 1.4 (1.1 ; 3.5)  1.9 ± 1.5 (1.2 ; 3.1)  
ILMN_1683093  GYPB  1.8 ± 1.4 (-1.1 ; 3.1)  2.0 ± 1.7 (1.0 ; 3.7)  
ILMN_1774091  FECH  1.8 ± 1.4 (1.0 ; 3.3)  1.9 ± 1.6 (1.0 ; 3.3)  
ILMN_1654118  BCL2L1  1.7 ± 1.6 (-2.0 ; 3.5)  1.7 ± 1.5 (-1.0 ; 3.2)  
ILMN_1680652  SELENBP1  1.7 ± 1.6 (-1.3 ; 3.7)  1.8 ± 1.9 (-1.3 ; 4.1)  
ILMN_1701933  SNCA  1.7 ± 1.6 (-1.2 ; 4.2)  1.7 ± 1.8 (-1.4 ; 3.1)  
ILMN_1814397  EPB42  1.7 ± 1.5 (-1.3 ; 3.0)  1.8 ± 1.7 (-1.0 ; 4.8)  
ILMN_1678919  YOD1  1.7 ± 1.5 (1.0 ; 3.9)  1.7 ± 1.2 (1.4 ; 2.4)  
ILMN_1735712  KRT1  1.7 ± 1.5 (1.0 ; 3.0)  1.8 ± 1.8 (-1.4 ; 4.8)  
ILMN_1695187  GYPE  1.7 ± 1.4 (-1.2 ; 2.8)  1.9 ± 1.7 (1.0 ; 3.5)  
ILMN_1801313  SIAH2  1.7 ± 1.4 (1.1 ; 3.5)  1.6 ± 1.3 (1.1 ; 2.5)  
ILMN_1784207  C1ORF128  1.7 ± 1.4 (1.0 ; 3.0)  2.0 ± 1.5 (1.3 ; 4.0)  
ILMN_2058782  IFI27  1.6 ± 1.9 (-3.7 ; 6.5)  2.1 ± 1.9 (-1.2 ; 5.0)  
ILMN_1704079  RBM38  1.6 ± 1.5 (-1.4 ; 3.1)  1.6 ± 1.6 (-1.0 ; 3.2)  
ILMN_1815527  HBD  1.6 ± 1.5 (-1.4 ; 3.0)  1.7 ± 1.8 (-1.2 ; 3.3)  
ILMN_1704446  SLC6A10P  1.6 ± 1.5 (-1.4 ; 2.7)  1.5 ± 1.4 (-1.0 ; 2.5)  
ILMN_1729487  GMPR  1.6 ± 1.5 (-1.3 ; 3.0)  1.7 ± 1.8 (-1.1 ; 3.8)  
ILMN_3278170  LOC441455  1.6 ± 1.5 (-1.3 ; 2.9)  1.6 ± 1.7 (-1.4 ; 3.2)  
ILMN_1759117  XK  1.6 ± 1.4 (1.1 ; 2.9)  1.8 ± 1.2 (1.3 ; 2.2)  
ILMN_1708016  C20ORF108  1.5 ± 1.5 (-1.3 ; 2.6)  1.6 ± 1.7 (-1.3 ; 3.9)  
ILMN_1736911  TMOD1  1.5 ± 1.5 (-1.2 ; 2.8)  1.7 ± 1.9 (-1.4 ; 3.9)  
ILMN_2336335  MARCH8  1.5 ± 1.3 (-1.0 ; 2.4)  1.7 ± 1.4 (1.1 ; 3.1)  
 
 
Values are fold-change at 2 days after the first rHuEpo injection compared to baseline. Values 
are means ± SD (minimum ; maximum). 
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Table 5.2. Common gene biomarkers in SCO and KEN differentially expressed 
during and post rHuEpo administration. 
Probe  Gene  SCO (n=18)  KEN (n=6)  
ILMN_2367126 ALAS2 -5.6 ± 1.9 (-18.7 ; -1.5) -2.8 ± 1.3 (-3.6 ; -1.8) 
ILMN_1701933 SNCA -4.4 ± 1.9 (-12.5 ; -1.2) -2.3 ± 1.7 (-5.2 ; -1.1) 
ILMN_1766165 SNCA -4.3 ± 1.9 (-14.1 ; -1.3) -2.2 ± 1.7 (-5.2 ; -1.0) 
ILMN_1749722 RNF213 -4.3 ± 1.9 (-13.9 ; 1.1) -2.3 ± 1.7 (-4.9 ; -1.1) 
ILMN_1651358 HBE1 -3.8 ± 1.8 (-10.6 ; -1.4) -1.7 ± 1.3 (-2.6 ; -1.3) 
ILMN_1701386 STRADB -3.6 ± 1.8 (-9.4 ; -1.2) -2.2 ± 1.4 (-3.5 ; -1.3) 
ILMN_1804938 GPR175 -3.6 ± 1.8 (-8.5 ; 1.1) -2.1 ± 1.5 (-3.8 ; -1.3) 
ILMN_1815527 HBD -3.5 ± 1.6 (-8.1 ; -1.5) -2.0 ± 1.4 (-3.3 ; -1.1) 
ILMN_1714765 LOC389599 -3.1 ± 1.7 (-8.1 ; -1.0) -2.1 ± 1.3 (-2.7 ; -1.5) 
ILMN_1715963 FBXO7 -3.0 ± 1.8 (-9.8 ; 1.2) -1.8 ± 1.7 (-3.7 ; 1.1) 
ILMN_1680652 SELENBP1 -3.0 ± 1.6 (-6.9 ; -1.3) -2.2 ± 1.4 (-3.5 ; -1.4) 
ILMN_2096322 ADIPOR1 -3.0 ± 1.6 (-6.8 ; -1.1) -1.7 ± 1.4 (-2.6 ; -1.1) 
ILMN_1786328 WDR40A -2.9 ± 1.6 (-6.8 ; -1.2) -1.9 ± 1.6 (-3.2 ; 1.1) 
ILMN_1688322 ADIPOR1 -2.9 ± 1.6 (-6.1 ; 1.0) -1.6 ± 1.4 (-2.4 ; -1.1) 
ILMN_1652431 CA1 -2.4 ± 1.5 (-6.5 ; -1.3) -1.8 ± 1.3 (-2.8 ; -1.3) 
 
 
Values are fold-change at 2 weeks after the rHuEpo administration compared to baseline. Values 
are means ± SD (minimum ; maximum). 
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5.4 Discussion: 
The major findings of the present study were that: firstly, that the discovered promising gene 
expression results found in Caucasian well trained males living and training at sea level (SCO) 
were successfully replicated in a cohort composed of Kenyan endurance runners living and 
training at moderate altitude (KEN) who underwent an identical rHuEpo administration regime; 
secondly, that only minimal differences in blood gene expression were found between the two 
groups. 15 transcripts were strongly up-regulated during rHuEpo and subsequently down-
regulated up to 4 weeks after administration in both groups. In addition, 30 transcripts seemed to 
be very sensitive to rHuEpo injections as they were found to be already differentially expressed 2 
days after only one single rHuEpo injection. As such, these latter transcripts are promising 
candidates to detect microdose rHuEpo doping strategies used by athletes (Ashenden et al. 2011; 
Ashenden et al. 2006). These results confirm that omics technologies such as gene expression 
have the potential to add a new dimension to the ABP to detect rHuEpo doping. However, the 
results of the present study still remain to be validated using another quantitative gene 
technology (see Chapter 6). 
 
5.4.1 Transcripts altered by rHuEpo administration: 
The major finding of the current project was that most of the transcripts that were found to be 
significantly altered by rHuEpo in SCO were also revealed in KEN. Thirty transcripts were 
sensitive to rHuEpo injections as they were found to be already differentially expressed 2 days 
after only one single rHuEpo injection. The top three genes were rap1 GTPase-activating protein 
(RAP1GAP), family with sequence similarity 46, member C (FAM46C) and oxysterol binding 
protein 2 (OSBP2). Rap1 is a small G protein of the Ras family involved in cell adhesion, cell 
proliferation and cell junction formation and which is regulated by guanine nucleotide exchange 
factors and GTPase-activating proteins including RAP1GAP (Gloerich and Bos 2011). Rap1 
seems to play an important role in the cardiovasculature, such as platelet aggregation, 
angiogenesis, endothelial permeability, and myocyte growth (Jeyaraj et al. 2011). Unlike the 
other genes, where a similar pattern of changes in expression was observed in all subjects, the 
changes in RAP1GAP expression levels varied considerably between subjects. While RAP1GAP 
expression remained fairly constant throughout the study in four subjects, moderate and strong 
up- and subsequent down-regulation patterns were observed in the remaining subjects. It is, 
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nevertheless, difficult to speculate on the possible reasons for this finding due to the large 
diversity of mechanisms of rap1. The precise function of FAM46C remains unknown, however, 
mutation of FAM46C was found to be associated with multiple myeloma and was suggested to 
play a role in the regulation of translation as an mRNA stability factor (Chapman et al. 2011). 
OSBP2 was found to be mainly expressed in the retina but also in pineal, testis and fetal liver 
and it was suggested that OSBP2 may play a role in macular degeneration, however, despite 19 
different tissues analyzed, whole blood was not included in this study (Moreira et al. 2001). It 
has been shown that expression of OSBP2 was increased in blood samples from patients with 
cholangiocarcinoma, a highly malignant tumor originating from bile duct epithelial cells 
(Loilome et al. 2012). In order to minimise the risk of being caught via current detection 
methods by inducing only minor fluctuations in the ABP blood markers and/or by "normalizing" 
these markers after blood manipulations such as autologous blood transfusion, athletes are now 
using the so-called "micro doses" of rHuEpo which allegedly range from 10 to a maximum of 40 
IU
.
kg
-1
 body mass (Ashenden et al. 2011; Ashenden et al. 2006; Morkeberg et al. 2013). Indeed, 
Ashenden et al. have demonstrated that the ABP did not reveal any suspicious doping activities 
when a rHuEpo microdosing strategy was used (Ashenden et al. 2011). Except RAP1GAP, 
whose expression was highly variable across the subjects, the other genes are very promising 
candidates to detect microdose rHuEpo doping as a result of their high sensitivity to rHuEpo 
administration. 
 
Fifteen transcripts were strongly up-regulated during rHuEpo and subsequently down-regulated 
up to 4 weeks after administration in both groups. The top three genes were delta-
aminolevulinate synthase 2 (ALAS2), alpha-synuclein (SNCA – 2 transcripts) and ring finger 
protein 213 (RNF213). As previously described (Chapter 3), ALAS2 catalyzes the initial step in 
the haem pathway (Sadlon et al. 1999). The increase and subsequent decrease in the ALAS2 
expression was representative of the rHuEpo-induced changes in haemoglobin production 
illustrated by the changes in haematological parameters (Chapters 2 and 4). As previously 
discussed (Chapter 3), SNCA was initially thought to be “expressed only in nervous system 
tissue” (Maroteaux et al. 1988). However, as previously described, SNCA is highly present in 
the erythrocyte and is coexpressed with haem metabolism genes including ALAS2 (Bartels et al. 
2011; Fauvet et al. 2012; Scherzer et al. 2008). RNA genome-wide association study identified 
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RNF213 as the first gene associated to Moyamoya disease in which blood flow to the brain is 
restricted due to arterial stenosis (Kamada et al. 2011). It has been suggested that RNF213 is 
involved in novel signaling pathway in intracranial angiogenesis (Liu et al. 2011). Fewer 
transcripts were found to be significantly differentially expressed post rHuEpo administration 
compared to baseline in KEN relative to SCO. This finding can be explained either by a potential 
lack of power (i.e. 6 KEN were compared to 18 SCO
5
) or by a faster readjustment post rHuEpo 
towards baseline gene expression levels in KEN compared to SCO as illustrated, for instance, by 
the reticulocyte percentage and RNA yield (see Appendix A). 
 
Unlike the majority of the dysregulated transcripts, a few genes such as eukaryotic translation 
elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D), ribosomal protein S29 
(RPS29) and parkinson protein 7 (PARK7) were found to be down-regulated during rHuEpo 
administration and then up-regulated post administration. Of note, PARK7 as well as SNCA are 
involved in Parkinson’s disease. However, the usefulness of these genes and related proteins as 
biomarkers of Parkinson’s disease depends on the tissue investigated such as human 
cerebrospinal fluid compared with plasma (Hong et al. 2010; Shi et al. 2010). In a similar 
manner, the biomarkers of rHuEpo administration discovered in whole blood in this research are 
not necessarily useful in other tissues such as monocytes (Jie et al. 2012) or saliva (see Appendix 
E). The same gene can have different function(s) in different tissue. As such, because the results 
of the present study are only based on whole blood, and although it has been demonstrated that 
rHuEpo had numerous positive effects in preclinical neurodegenerative disease models (Sargin et 
al. 2010), it would be adventurous to discuss in the present thesis the potential link between 
rHuEpo and neurodegenerative diseases such as Parkinson's disease. EEF1D is a subunit of the 
elongation factor 1, which catalyzes the transfer of aminoacyl-tRNA onto ribosomes. Elongation 
factor 1 plays a critical role in regulating gene expression and particularly during the cell cycle 
(Le Sourd et al. 2006; Sasikumar et al. 2012). Using a zebrafish model, it has been demonstrated 
that RPS29 is involved in the development of red blood cells and in the regulation of the cell 
cycle (Taylor et al. 2012). Using cells cultures model, it has been revealed that PARK7 plays an 
important role in protecting red blood cells against oxidative damage (Xu et al. 2010). 
                                                          
5
 As stated in Chapter 7 and Appendix F, 12 more KEN subjects will be analysed to make a balanced microarray 
analysis. 
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5.4.2 Housekeeping genes: 
Only one gene, MORF4 family-associated protein 1 (MRFAP1), was commonly in the top 100 
best housekeeping genes in SCO and KEN. MRFAP1 protein was found to be only detectable in 
a small number of human tissues, in particular testis and brain but blood was not included in the 
analysis (Larance et al. 2012). Regardless of its exact function in whole blood, MRFAP1 was a 
relatively abundant transcript with low inter- and intra-subject variation over time and can 
therefore be used as a consistent housekeeping gene for both SCO and KEN samples. 
 
5.4.3 Non-responders to rHuEpo administration: 
As previously discussed in Chapter 4, based on the blunted response in the haematological 
parameters and exercise performance, one Kenyan subject (white triangle in Figure 4.2, Figure 
4.4 and Figure 4.5) did not respond to rHuEpo administration and may therefore be 
representative of the 10% of the treated patients who are characterized by either no response or a 
suboptimal response to rHuEpo therapy (Macdougall 1995). There are several recognized causes 
of resistance or hyporesponsiveness to rHuEpo treatment such as iron deficiency and 
inflammatory conditions, however, exclusion of all known factors does not eliminate the marked 
variability in the sensitivity to rHuEpo (Kanbay et al. 2010; Macdougall and Cooper 2002). It 
has been shown in a small cohort of 10 patients with myelodysplastic syndromes that there were 
significant differences in gene expression between patients who are responsive or non-responsive 
to rHuEpo (Cortelezzi et al. 2008). Gene expression profile assessment may have the potential to 
provide a diagnostic test to predict the response to rHuEpo of anaemic patients. However, the 
gene response profile of the “non-responder” in our study did not seem to significantly differ 
from the other subjects. Although several genes which were found to be differentially expressed 
between responsive and non-responsive patients after rHuEpo administration were also found to 
be altered by rHuEpo in our study, such as Mitogen-activated protein kinase 3 (MAP2K3) and 
RAP1GAP, it is difficult to interpret the results further due to the difference in study design and 
methodology (Cortelezzi et al. 2008). In particular, RNA was extracted from bone marrow cells 
and response over time was not evaluated (Cortelezzi et al. 2008). Nevertheless, as this doctoral 
research provides valuable data on the “normal” blood gene expression response to rHuEpo in 
healthy volunteers, it would now be of interest, using the same methodology, to longitudinally 
investigate the blood gene expression response in anaemic patients receiving rHuEpo in order to 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 5: Gene Expression Profiles – Replication 
 
 
© J Durussel (2014)  135 
better understand as well as hopefully predict and improve the responsiveness to rHuEpo 
therapy. 
 
5.4.4 Conclusion: 
In conclusion, the blood “molecular signature” of rHuEpo doping discovered in Caucasian well 
trained males living and training at sea level (SCO) was successfully replicated in a cohort 
composed of Kenyan endurance runners living and training at moderate altitude (KEN) who 
underwent an identical rHuEpo administration regime. In addition to suggesting that ethnicity 
and residence at altitude have only minor influence on the effects of rHuEpo on blood gene 
expression profiles, these results confirm that omics technologies such as gene expression have 
the potential to add a new dimension to the ABP to detect rHuEpo doping. However, these 
results should be verified using another quantitative gene platform in order to provide further 
confidence in the validity of the findings (Allison et al. 2006; Chuaqui et al. 2002) (see Chapter 
6).  
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6.1 Introduction and aim: 
In this doctoral research, gene microarray technology was successfully used to discover genes 
that are differentially regulated following rHuEpo administration in Caucasian trained males 
living at or near sea-level (Chapter 3). Thereafter, part of the operational validation process 
(Allison et al. 2006; Chuaqui et al. 2002), the same technology and methodology was 
successfully used to replicate the blood gene expression results in another cohort composed of 
Kenyan runners living at moderate altitude that underwent an identical rHuEpo administration 
regime (Chapter 5). In order to provide further confidence in the validity of the findings, a 
constructive validation which aims to replicate the results using another quantitative gene 
technology was required (Allison et al. 2006; Chuaqui et al. 2002). 
 
The methodology used for the constructive validation varies depending on the research 
hypothesis of the study and is influenced by practical factors such as the quantity of sample 
material and the number of gene targets to be validated (Chuaqui et al. 2002). The QuantiGene 
Plex assay, which combines branched DNA and bead-based multiplexing technology, allows for 
the simultaneous analysis of a large number of target genes per sample (up to 500) and enables 
high-throughput screening (Flagella et al. 2006). In addition to being extremely reproducible, 
specific and sensitive, the QuantiGene Plex assay provides an independent method of 
measurement compared to the other technologies such as quantitative real-time reverse 
transcription polymerase chain reaction (qRT-PCR) and microarray platforms by eliminating the 
need for RNA reverse transcription, labelling and amplification steps (Canales et al. 2006; 
Flagella et al. 2006). The aim of the present project was to validate the microarray-based results 
of a subset of promising target genes whose expression was altered following rHuEpo 
administration using the QuantiGene Plex 2.0 assay.  
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6.2 Methods: 
6.2.1 Samples: 
RNA samples of four subjects in each group of SCO and KEN (i.e. eight subjects in total 
including the “non-responder”), collected at the same 8 time points as previously described for 
the microarray analysis (i.e. two baseline samples, then one sample each at 2 days, 2 weeks and 4 
weeks after the first rHuEpo injection and 1 week, 2 weeks and 4 weeks after rHuEpo 
administration) (Figure 2.1) and stored at -80°C after extraction from the Tempus Blood RNA 
tubes, were used for the QuantiGene Plex analysis (Panomics/Affymetrix, Vignate-Milano, Italy) 
(Figure 3.1). 
 
6.2.2 QuantiGene Plex assay protocol: 
The QuantiGene Plex 2.0 assay combines branched DNA (bDNA) signal amplification and 
xMAP profiling magnetic beads technologies. The bDNA enables target RNA quantification by 
amplifying the reporter signal rather than target sequences and the xMAP fluorescent 
microspheres or “beads” are used as a support to capture specific RNA molecules (Flagella et al. 
2006). The signal amplification mediated by bDNA amplification technology consists of 
sequential hybridizations of preamplifiers, amplifiers and label probes. The RNA of target genes 
is first captured via hybridization using specific probe sets which are composed of capture 
extenders, labels extenders and blockers (Figure 6.1). The capture and label extenders contain 
oligonucleotides that are complementary to the target RNA as well as to the capture probes of the 
microsphere and the bDNA amplifier molecule, respectively, while the blockers contain 
oligonucleotides that are complementary to the target RNA where the two other type of probes 
cannot bind in order to maintain the RNA-DNA structure intact (Flagella et al. 2006) (Figure 
6.1). By adding Strepatvidin-conjugated R-Phycoerythrin (SAPE) that binds to the label probes, 
the resulting fluorescence signal associated with the individual microspheres is read using a flow 
cytometer Luminex instrument. The fluorescence signal measured from each bead is proportional 
to the number of captured transcripts. 
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Step 1: Target transcripts are captured 
to their corresponding magnetic beads 
through the hybridization interactions 
of the capture probes (of the beads) and 
the capture extenders. 
 
 
Step 2: The signal amplification is 
mediated by the bDNA amplifier and 
the label probe molecules that 
hybridize to the tails of the label 
extenders. 
 
 
Step 3: Each amplification unit 
contains multiple hybridization sites for 
biotinalyted label probe that captures 
SAPE. The resulting fluorescence 
signal, which is proportional to the 
number of captured transcripts, is then 
read on a Luminex. 
 
Figure 6.1: Overview of the workflow of the QuantiGene Plex assay adapted from (Flagella et 
al. 2006). 
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Each RNA sample was run in duplicate with two different sample RNA inputs. Sample RNA 
inputs of 500 ng and 50 ng (experiment 1 using 24 samples from 3 subjects) or 200 ng and 100 
ng (experiment 2 using 40 samples from 5 subjects) were used. The fluorescence signal was read 
on the MAGPIX (Luminex, Oosterhout, The Netherlands) and median fluorescence intensity 
(MFI) values were saved using xPonent software. 
 
6.2.3 QuantiGene data analysis: 
Following background subtraction, the ratio of the target genes MFI to the geometric mean of the 
housekeeping genes MFI was calculated. Fold change compared to the average baseline values 
was then calculated and log2 transformed. 
 
6.2.4 Selection of the target and housekeeping genes for QuantiGene Plex analysis: 
Seven target genes were selected based on their fold change, their sensitivity to the first rHuEpo 
injection, their down-regulation post rHuEpo administration and the availability of the transcripts 
in the database of the company (Table 6.1). In addition, the common best housekeeping gene in 
SCO and KEN discovered using microarray (MRFAP1) as well two housekeeping genes from 
the database of the company were selected (Table 6.1). 
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Table 6.1. Selected genes for QuantiGene analysis 
 
N° Genes  Names  Type ILMN_GENE ACCESSION 
1 ACTB Actin, beta 
Housekeeping 
gene 
ILMN_2038777 NM_001101 
2 ALAS2  
Delta-aminolevulinate 
synthase 2  
Target ILMN_1708323 NM_000032 
3 BPGM  
2,3-bisphosphoglycerate 
mutase  
Target ILMN_2352921 NM_001724 
4 CA1  Carbonic anhydrase 1  Target ILMN_1652431 NM_001738 
5 FAM46C  
Family with sequence 
similarity 46, member C  
Target ILMN_1713266 NM_017709 
6 MRFAP1  
MORF4 family-
associated protein 1  
Housekeeping 
gene 
ILMN_2055165 NM_033296 
7 OSBP2  
Oxysterol-binding 
protein 2  
Target ILMN_1781966 NM_030758 
8 PPIB 
Peptidylpropyl 
isomerase B 
(cyclophilin B) 
Housekeeping 
gene 
ILMN_1703622 NM_000942 
9 SELENBP1  
Selenium binding 
protein 1  
Target ILMN_1680652 NM_003944 
10 SNCA  Alpha-synuclein  Target ILMN_1766165 NM_000345 
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6.3 Results: 
6.3.1 Housekeeping genes: 
Beta actin (ACTB) was the most abundant and the most stable of the three housekeeping genes 
(Table 6.2 and Figure 6.2). However, overall, all three housekeeping genes were relatively 
consistently expressed over time in all subjects and at levels relatively similar to the target genes 
(Table 6.2 and Figure 6.2). 
 
6.3.2 Sample RNA input: 
The reproducibility of the results from duplicate samples using different RNA sample input was 
good (Figure 6.3). However, Luminex instruments exhibit saturation over ~20,000 MFI and 
highly abundant genes such as ALAS2 and FAM46C often reached this threshold with RNA 
sample input ≥ 200 ng and even with 100 ng in some cases for ALAS2 (Table 6.2 and Figure 6.3). 
On the other hand, RNA sample input lower than 100 ng may not be sufficient for the low 
expressed transcript such as OSBP2, whose signal may be confounded with the background noise 
(Table 6.2, Figure 6.3). 
 
6.3.3 Target genes: 
The correlation between QuantiGene Plex and microarray data was good and the QuantiGene 
Plex results overall replicated the Illumina microarray results (Figure 6.4 and Figure 6.5). The 
down-regulation in gene expression post rHuEpo administration was slightly more profound 
using the QuantiGene Plex compared to the Illumina microarray analysis (Figure 6.5). The 
relative expression of the target genes varied from very high, such as ALAS2, to very low, such 
as OSBP2 (Table 6.2). Although the relative expression of the latter gene was close to the 
background noise, especially with low RNA sample inputs, the up- and subsequent down-
regulation profile observed during and post rHuEpo administration using the Illumina microarray 
technology was nevertheless replicated (Table 6.2, Figure 6.3 and Figure 6.4E). Log ratios of 
relative expression target to housekeeping genes are presented in Figure 6.6. 
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Figure 6.2: Individual changes in gene expression in the three housekeeping genes using the QuantiGene Plex assay. 
Actin, beta (ACTB), MORF4 family-associated protein 1 (MRFAP1) and peptidylpropyl isomerase B (cyclophilin B) (PPIB): Changes 
are reported in log ratio compared to the average baseline values. Time point 0 represents the first injection. The grey zone represents 
the administration. Each line corresponds to one subject. SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. 
The dashed line corresponds to the “non-responder” (NR). 
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Figure 6.3: Relationship between dilutions of the sample input using QuantiGene Plex assay. 
Results are reported in log ratio compared to the average baseline values. Sample inputs of 500 
and 50 ng as well as 200 and 100 ng were used for the experiments 1 (24 samples from 3 
subjects) and 2 (n = 40 samples from 5 subjects), respectively. 
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Figure 6.4A: Individual changes in gene expression in the seven target genes. 
Delta-aminolevulinate synthase 2 (ALAS2): Results of the QuantiGene Plex assay and the Illumina microarray are presented in the left 
and right panel, respectively. Changes are reported in log ratio compared to the average baseline values. Time point 0 represents the 
first injection. The grey zone represents the administration. Each line corresponds to one subject. SCO (n = 4) and KEN (n = 4) are 
represented in green and red, respectively. The dashed line corresponds to the “non-responder” (NR). 
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Figure 6.4B (continued): 2,3-bisphosphoglycerate mutase (BPGM): Results of the QuantiGene Plex assay and the Illumina 
microarray are presented in the left and right panel, respectively. Changes are reported in log ratio compared to the average baseline 
values. Time point 0 represents the first injection. The grey zone represents the administration. Each line corresponds to one subject. 
SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-responder” 
(NR).
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Figure 6.4C (continued): Carbonic anhydrase 1 (CA1): Results of the QuantiGene Plex assay and the Illumina microarray are 
presented in the left and right panel, respectively. Changes are reported in log ratio compared to the average baseline values. Time 
point 0 represents the first injection. The grey zone represents the administration. Each line corresponds to one subject. SCO (n = 4) 
and KEN (n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-responder” (NR). 
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Figure 6.4D (continued): Family with sequence similarity 46, member C (FAM46C): Results of the QuantiGene Plex assay and the 
Illumina microarray are presented in the left and right panel, respectively. Changes are reported in log ratio compared to the average 
baseline values. Time point 0 represents the first injection. The grey zone represents the administration. Each line corresponds to one 
subject. SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-
responder” (NR). 
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Figure 6.4E (continued): Oxysterol-binding protein 2 (OSBP2): Results of the QuantiGene Plex assay and the Illumina microarray 
are presented in the left and right panel, respectively. Changes are reported in log ratio compared to the average baseline values. Time 
point 0 represents the first injection. The grey zone represents the administration. Each line corresponds to one subject. SCO (n = 4) 
and KEN (n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-responder” (NR). 
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Figure 6.4F (continued): Selenium binding protein 1 (SELENBP1): Results of the QuantiGene Plex assay and the Illumina 
microarray are presented in the left and right panel, respectively. Changes are reported in log ratio compared to the average baseline 
values. Time point 0 represents the first injection. The grey zone represents the administration. Each line corresponds to one subject. 
SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-responder” 
(NR).
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Figure 6.4G (continued): Alpha-synuclein (SNCA): Results of the QuantiGene Plex assay and the Illumina microarray are presented 
in the left and right panel, respectively. Changes are reported in log ratio compared to the average baseline values. Time point 0 
represents the first injection. The grey zone represents the administration. Each line corresponds to one subject. SCO (n = 4) and KEN 
(n = 4) are represented in green and red, respectively. The dashed line corresponds to the “non-responder” (NR). 
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Figure 6.5: Relationship between results from QuantiGene Plex assay and Illumina microarray. 
Results are reported in log ratio compared to the average baseline values. 
  
-5.0 
-2.5 
0.0 
2.5 
5.0 
-5.0 -2.5 0.0 2.5 5.0 
Lo
g 
ra
ti
o
 c
o
m
p
ar
e
d
 t
o
 a
vg
 b
as
e
lin
e
: 
Il
lu
m
in
a
 
Log ratio compared to avg baseline: QuantiGene Plex 
ALAS2 BPGM CA1 FAM46C 
OSBP2 SELENBP1 SNCA x=y 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 6: Gene Expression Profiles – Validation 
 
 
© J Durussel (2014)  153 
 
 
Figure 6.6: Log ratios of relative expression target to housekeeping genes. 
Results are grouped according to the 8 analysed time points i.e. two baseline samples, then one 
sample each at 2 days, 2 weeks and 4 weeks after the first rHuEpo injection and 1 week, 2 weeks 
and 4 weeks after rHuEpo administration. Each line per box represents one subject. Each column 
per box represents one target gene. Relative to extreme values for each target genes, red, yellow 
and blue colours indicate high, medium and low ratio results, respectively.  
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KEN1 1.0 0.6 -6.0 2.6 3.7 3.1 0.1 1.5 1.3 -5.6 3.2 4.8 3.7 1.1 1.2 0.8 -5.6 2.9 4.3 3.5 0.8
KEN4 -1.3 -1.4 -7.1 0.5 2.5 1.2 -1.3 0.5 0.7 -6.2 2.1 4.2 2.5 -0.3 0.1 0.5 -6.6 2.0 4.0 2.3 -0.2
KEN5 0.4 0.9 -6.6 1.7 2.3 2.8 -0.6 1.2 2.3 -5.6 2.6 3.7 3.6 0.5 1.3 2.2 -5.8 2.6 3.8 3.4 0.4
KEN6 1.3 1.1 -5.5 2.2 3.6 3.0 0.0 2.8 3.4 -3.9 3.6 5.2 4.5 1.8 2.5 3.0 -4.7 3.3 5.0 4.1 1.4
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SCO5 -0.4 0.0 -5.7 2.1 3.4 3.3 0.1 -2.9 -2.8 -7.5 -0.1 -0.5 0.6 -3.0 -1.9 -2.0 -7.1 0.4 0.9 1.4 -1.9
SCO7 -1.1 -0.6 -6.2 1.5 2.0 2.8 -0.3 -3.8 -3.4 -7.3 -0.8 -1.2 0.3 -3.2 -2.9 -3.1 -7.3 -0.6 -0.6 0.6 -2.7
SCO12 -1.1 0.2 -6.2 1.8 1.8 3.1 -0.1 -2.9 -2.0 -7.4 0.1 -1.2 0.8 -2.5 -2.2 -1.6 -7.0 0.5 -0.1 1.5 -1.8
SCO18 -2.9 -1.9 -6.9 -0.2 -0.2 1.2 -1.3 -4.3 -3.9 -7.6 -1.6 -2.8 -0.8 -3.4 -3.1 -2.5 -7.1 -1.1 -1.6 0.3 -2.2
KEN1 -2.8 -3.0 -7.7 -0.4 -0.1 0.0 -3.0 -3.1 -3.3 -8.0 -0.8 -0.4 -0.2 -3.2 -2.6 -3.2 -7.9 -0.4 -0.4 0.3 -2.6
KEN4 -0.5 0.2 -6.6 1.6 2.8 2.4 -0.2 -1.1 -0.8 -6.5 1.0 2.2 1.4 -1.1 -0.4 -0.9 -6.4 1.3 3.3 2.1 -0.6
KEN5 -1.2 0.6 -6.9 1.2 0.6 2.2 -0.9 -0.6 0.6 -6.7 1.1 1.3 2.4 -0.9 -0.2 0.2 -6.5 1.0 1.3 2.3 -1.1
KEN6 -0.9 0.3 -6.1 1.2 2.6 2.1 -0.5 -3.0 -1.6 -7.2 -0.2 -0.6 0.6 -2.6 -0.9 -0.8 -6.7 0.3 1.3 1.5 -1.5
Base1 Base2
EPO3 (2 days) EPO4 (2 weeks) EPO5 (4 weeks)
POST6 (1 week) POST7 (2 weeks) POST8 (4 weeks)
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Chapter 6: Gene Expression Profiles – Validation 
 
 
© J Durussel (2014)  154 
 
Table 6.2. Median fluorescence intensity (MFI) signals of the selected genes for the different 
RNA inputs 
 
Genes  Type 
50 ng  
N = 24 (3 x 8) 
100 ng 
N = 40 (5 x 8) 
200 ng 
N = 40 (5 x 8) 
500 ng 
N = 24 (3 x 8) 
   
   
ACTB 
Housekeeping 
gene 
974 ± 375 
(271 ; 1437) 
5855 ± 1501 
(2653 ; 10272) 
10126 ± 2903 
(1315 ; 15951) 
7389 ± 1864 
(3752 ; 10160) 
MRFAP1  
Housekeeping 
gene 
253 ± 94 
(74 ; 382) 
617 ± 102 
(347 ; 870) 
1107 ± 237 
(280 ; 1556) 
2739 ± 505 
(1678 ; 3521) 
PPIB 
Housekeeping 
gene 
217 ± 97 
(46 ; 401) 
531 ± 215 
(122 ; 1268) 
978 ± 407 
(300 ; 2310) 
2330 ± 764 
(1308 ; 4221) 
   
   
ALAS2  Target 
1879 ± 1418 
(221 ; 6206) 
8877 ± 8038 
(229 ; 29659) 
14318 ± 11149 
(363 ; 37083) 
15860 ± 9091 
(2324 ; 29342) 
BPGM  Target 
955 ± 504 
(252 ; 2532) 
3363 ± 2257 
(431 ; 9709) 
6124 ± 3737 
(227 ; 15571) 
10662 ± 4960 
(2887 ; 21479) 
CA1  Target 
315 ± 291 
(39 ; 1429) 
1520 ± 1453 
(73 ; 5576) 
2786 ± 2614 
(116 ; 11670) 
3573 ± 3069 
(526 ; 12621) 
FAM46C  Target 
2293 ± 1258 
(617 ; 6165) 
5985 ± 3591 
(935 ; 13925) 
10669 ± 5717 
(786 ; 21747) 
19268 ± 7277 
(6297 ; 31763) 
OSBP2  Target 
7 ± 2 
(4 ; 11) 
14 ± 6 
(5 ; 36) 
26 ± 12 
(7 ; 68) 
40 ± 18 
(17 ; 87) 
SELENBP1  Target 
271 ± 207 
(32 ; 964) 
1135 ± 995 
(80 ; 3950) 
2106 ± 1828 
(126 ; 7601) 
3261 ± 2529 
(355 ; 8681) 
SNCA  Target 
259 ± 153 
(56 ; 752) 
836 ± 525 
(119 ; 2219) 
1533 ± 963 
(147 ; 3934) 
2602 ± 1559 
(492 ; 6904) 
 
Values are reported as median fluorescence intensity (MFI). Values are means ± SD (minimum ; 
maximum) across the 24 (i.e. 3 subjects x 8 time points; experiment 1 in green) samples analysed 
with RNA input of 50 and 500 ng as well as the 40 (i.e. 5 subjects x 8 time points; experiment 2 in 
red) samples analysed with RNA input of 100 and 200 ng, respectively. 
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6.4 Discussion: 
The main results of the present study were that the microarray-based gene expression profiles of 
a subset of promising target genes whose expression was profoundly altered following rHuEpo 
administration were successfully replicated and validated using QuantiGene Plex 2.0 assay. The 
present results offer the exciting prospect of the possibility of setting up in the near future a new 
diagnostic test which can potentially reveal the blood molecular signal signature of rHuEpo 
doping although thorough validation experiments are required. In addition, while current anti-
doping blood samples have important logistic and cost implications since blood samples must be 
shipped refrigerated (2-12ºC) and analysed within 36 h of collection (Sottas et al. 2010), RNA 
stabilised in Tempus tubes is easy to handle and is stable for 5-7 days at room temperature and 
for months when kept frozen (Matheson et al. 2008; Prezeau et al. 2006; Shou et al. 2005). 
These findings have important implications for current and future anti-doping practices. 
 
6.4.1 Housekeeping genes: 
Beta actin (ACTB), MORF4 family-associated protein 1 (MRFAP1) and peptidylpropyl 
isomerase B (cyclophilin B) (PPIB) were selected as housekeeping genes. All three 
housekeeping genes were relatively consistently expressed over time in all subjects and at levels 
relatively similar to the target genes, although ACTB was the most abundant and seemed to be 
the most stable. The three housekeeping genes were included in the geometric mean, which was 
used to normalise the target gene signals. However, additional experiments that further define 
intra- and inter-individual variability of the housekeeping genes are required in order to establish 
the optimal relative expression normalization method. 
 
6.4.2 Sample RNA input: 
In order to determine the optimal RNA input, 50 and 500 ng were initially used in the first 
experiment (24 samples in duplicate corresponding to 3 subjects x 8 time points) and 100 and 
200 ng were then used in the second experiment (40 samples in duplicate corresponding to 5 
subjects x 8 time points). As Luminex instruments exhibit saturation over ~20,000 MFI and the 
relative abundance of our target genes extends over a wide range, at least duplicates with two 
different RNA inputs will be necessary to ensure valid signal detection, i.e. over background 
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noise and lower than the saturation threshold, in future studies. Further experiments are needed 
to define the optimal RNA inputs but it would probably range from approximately 50 to 200 ng. 
 
6.4.3 Target genes: 
In agreement with previous work which evaluated the performance characteristics of three 
quantitative gene expression technologies including QuantiGene assay and correlated their 
expression measurements to those of commercial microarray platforms including Illumina, our 
results showed a good correlation between QuantiGene Plex and microarray results (Canales et 
al. 2006). Overall, the QuantiGene Plex results replicated and validated the Illumina microarray 
results for the target genes, whose expression was profoundly altered following rHuEpo 
administration. In agreement with previous reports, the down-regulation in gene expression post 
rHuEpo administration was slightly more profound when measured using the QuantiGene Plex 
compared to the Illumina microarray analysis (Canales et al. 2006; Raymond et al. 2010). This 
latter feature may make the blood molecular signature of rHuEpo doping even more defined post 
administration. 
 
Testosterone over epitestosterone (T/E) ratio is used to indirectly detect testosterone doping 
(Aguilera et al. 2001; Sottas et al. 2008b). Following this example, ratios of relative expression 
target to housekeeping genes were determined in order to investigate whether this approach can 
potentially be applied to rHuEpo detection. Based on our initial results from a limited number of 
subjects and target genes, it seems that population-based thresholds, despite being potentially 
informative, are probably not the best anti-doping strategy to detect rHuEpo doping. It has been 
demonstrated that the performance of the population-based T/E limit (i.e. greater than 4) to 
detect testosterone doping is poor while individual longitudinal profile monitoring can be much 
more efficient (Sottas et al. 2007; Sottas et al. 2008b). Further studies are necessary to evaluate 
the intra- and inter- variations of the blood gene expression profiles and their respective gene 
expression ratios. 
  
In conclusion, although further thorough validation experiments are required, particularly in 
order to define the intra- and inter-individual variability of the housekeeping as well as target 
genes, the results of the present study offer the exciting prospect of the possibility of setting up in 
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the near future a new, specific, sensitive, practical and cost-effective diagnostic test which can 
potentially reveal the blood molecular signature of rHuEpo doping and can add another 
dimension to the ABP in terms of robustness and performance to detect rHuEpo doping. 
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7.1 General discussion: 
Through this doctoral thesis, several research investigations have been conducted to assess the 
effects of rHuEpo administration on blood gene expression profiles in endurance trained males 
living at or near sea-level and at moderate altitude (~2,150 m) in order to identify a molecular 
signature of rHuEpo doping and thus provide a basis for the development of novel and robust 
testing models to detect blood doping. First, the time course of changes in Hbmass and related 
blood parameters as well as time trial performance were defined in endurance trained males 
living and training at or near sea-level following four weeks of rHuEpo administration; second, 
the ergogenic effects of rHuEpo were investigated via the assessment of changes in 
haematological parameters and laboratory- and field-based endurance performance tests in 
endurance runners living and training at moderate altitude in Kenya and then compared with the 
sea-level cohort that underwent an identical rHuEpo administration regime; third, the effects of 
rHuEpo administration on blood gene expression profiles were longitudinally evaluated using 
whole transcriptome microarray technology in trained males living and training at or near sea-
level; fourth, the same molecular methodology was applied in order to replicate and compare the 
gene expression profiles in another cohort living and training at moderate-altitude in Kenya who 
underwent an identical rHuEpo administration regime; fifth, the gene microarray based findings 
were validated using a specific and sensitive quantitative gene expression technology. 
 
The main findings described in this doctoral thesis were: first, the improvements in the 
laboratory based measurements after rHuEpo administration in endurance trained males 
translated into improvement in exercise performance in the field. More particularly, 3,000 time 
trial running performance was significantly improved following 4 weeks of rHuEpo 
administration and remained significantly elevated 4 weeks after administration. These 
performance effects coincided with significantly rHuEpo-induced elevated   O2max and Hbmass. 
Second, 4 weeks of rHuEpo administration was able to significantly increase the already 
relatively high haematological parameters as well as   O2max of Kenyan endurance runners living 
and training at moderate altitude (~2,150 m). Third, although the rHuEpo-induced increase in the 
key haematological parameters was not as high in the Kenyan group compared to the Scottish 
group, the relative improvements of approximately 5% and 3% in running performance 
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immediately after the rHuEpo administration and 4 weeks after the last injection were similar 
between both groups. Third, using whole transcriptome microarray technology, blood gene 
expression profiles were found to be profoundly and significantly altered from 2 days after the 
first rHuEpo injection and up to 4 weeks after the rHuEpo administration, leading to an initial 
blood molecular signature of rHuEpo doping. A large number of the identified genes were 
related to the functional or structural properties of the erythrocyte. Fourth, using the same gene 
microarray methodology, the molecular signature of rHuEpo doping discovered in the Scottish 
group was successfully replicated in the Kenyan cohort composed of endurance runners living 
and training at moderate altitude and who underwent an identical rHuEpo administration regime. 
Fifth, the microarray-based gene expression profiles of a subset of the promising genes whose 
expression was profoundly altered following rHuEpo administration were successfully validated 
using a different specific and sensitive quantitative gene expression platform. In addition to 
providing the strongest evidence to date that omics biomarkers such as gene expression have the 
potential to add another dimension to the ABP to detect rHuEpo doping, the main findings 
described in this doctoral thesis offer the exciting prospect of the possibility of setting up in the 
near future a new, specific, sensitive, practical and cost-effective diagnostic test which can 
potentially reveal the blood molecular signature of rHuEpo doping. 
 
7.1.1 Limitations of the research: 
Like all research this doctoral research is not without limitations. As there were only minimal 
data regarding the assessment of the effects of erythropoiesis stimulating drugs using whole 
transcriptome analysis from whole blood, this research can be characterized as an extensive and 
key proof-of-principle study. The main limitation of the design stems from the fact that our study 
was not blinded and there was no control group. Nevertheless, in addition to having established 
adequate molecular methods and molecular workflow to enable valid and optimal assessment of 
blood gene expression for follow-up and future studies (see below), this doctoral research 
provided convincing and very promising findings in the development of a robust test to detect 
rHuEpo doping. Another limitation was that elite competitive athletes could not be recruited for 
such studies for obvious ethical reasons (Howman 2013; Wagner 2013). Factors such as genetic 
traits, training history and training load almost certainly differ from those of the subelite yet 
endurance trained population investigated in this research (Hopkins et al. 1999). In addition, the 
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rHuEpo dose regimen used in this research (i.e. 50 IU∙kg-1 body mass every two days for four 
weeks) did not closely reproduce the strategy of “micro doses” rHuEpo doping allegedly 
currently used by athletes (see below). As such, caution should be taken in the interpretations of 
the applications of the findings and further thorough and careful validation is necessary. For 
instance, it is of paramount importance to evaluate the intra- and inter- variations of the blood 
gene expression profiles in elite competitive athletes including potential confounding effects 
such as intense exercise and altitude training. 
 
7.1.2 Bayesian approach to the interpretation of blood doping gene markers: 
The ABP was introduced as a new tool to indirectly detect blood manipulation, such as rHuEpo 
doping, and which can lead to disciplinary sanctions imposed by a sports organization or its 
tribunal, as well as to intelligently target athletes for additional testing (Schumacher and 
d'Onofrio 2012; Schumacher et al. 2012; Zorzoli and Rossi 2012). The ABP approach relies on 
identifying intra-individual abnormal variability over time of selected haematological parameters 
(Figure 1.2) (Callaway 2011; Sottas et al. 2010). More precisely, the ABP approach uses 
Bayesian networks for the evaluation of the likelihood of doping based on several variables 
and/or factors which can then be used as evidence for disciplinary sanction. Bayesian networks 
are interpretable and flexible models for representing the probabilities of causal relationships 
between multiple interacting variables (Sottas et al. 2008a; Sottas et al. 2010). In the anti-doping 
field, the Bayesian model directly estimates the probability of blood doping based on previous 
individual test history and heterogeneous factors known to influence blood parameters. This 
feature allows the model to remove the variance due to inter-subject differences and 
heterogeneous factors such as gender, ethnicity, altitude exposure, age and sport discipline 
(Sottas et al. 2008a). Based on the promising findings of this doctoral research, blood gene 
biomarkers can potentially be integrated into the ABP in order to further improve its 
performance. Therefore, the inter- and intra-subject variability as well as factors which can affect 
blood gene expression profiles must be precisely determined. The present research demonstrated 
that ethnicity and residence at altitude only minimally influence the blood gene expression 
signature of rHuEpo doping. However, further research is required to measure reference ranges 
and the impact of external factors on blood gene expression profiles.  
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7.2 Future work: 
By identifying the initial blood molecular signature of rHuEpo doping, this doctoral research 
provides a strong and necessary basis for the development of novel and robust testing models to 
detect rHuEpo doping. Given these promising results, it is of paramount importance to precisely 
determine the reference values of the blood molecular signature of rHuEpo doping using 
different dose regimens as well as to thoroughly assess the effects of external factors on blood 
gene expression profiles, such as altitude training including different hypoxic “dose” and 
protocols, sport discipline, level of competition, gender, ethnicity and age. These investigations 
are necessary before potentially including the promising blood gene biomarkers in the ABP. 
 
7.2.1 Microarray and QuantiGene experiments: 
Following the success of the QuantiGene Plex pilot experiment and with the prospect of setting 
up a potential future test which can reveal the molecular signature of rHuEpo doping, our 
research group has recently been granted additional short notice funding (see Appendix F). This 
additional fund will allow us to: 1) finalise the microarray experiment, i.e. 12 more Kenyan 
subjects to be analysed to make a balanced design, although this is unlikely to significantly 
change the overall results and the transcripts of interests (see Appendix A); 2) increase the 
number of target genes to 50 which will allow for a more defined and precise molecular 
signature of rHuEpo doping. Fifty target genes in all subjects (i.e. 39 in total) will be analysed 
using the specific, sensitive, time and cost-effective QuanitiGene Plex technology. This study 
will enable the validation of the molecular signature of rHuEpo doping as well as the 
establishment of the bases for a testing procedure. 
 
7.2.2 Microdose rHuEpo: 
The gene expression results generated by this doctoral research are very promising. For example, 
using a 1.5 fold-change threshold, 30 genes were found to be already up-regulated 2 days after 
only one single rHuEpo injection, such as FAM46C (family with sequence similarity 46 member 
C) gene (Figure 5.3). These data provide the strongest evidence to date that omics technologies 
such as gene expression have the potential to improve the ABP approach for rHuEpo detection. 
However, in order to induce only minor fluctuations in the ABP blood markers and/or to 
"normalize" these markers after blood manipulations such as autologous blood transfusion and 
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by doing so minimising the risk of being caught, athletes are now using "micro doses" of rHuEpo 
which allegedly range from 10 to a maximum of 40 IU∙kg-1 body mass and remained 
undetectable by the ABP (Ashenden et al. 2011; Ashenden et al. 2006). It has been recently 
shown that the so-called MAIIA test has the potential to identify trace amounts of exogenous 
rHuEpo with altered glycosylation in blood and urine samples and can therefore potentially be 
used to detect very small doses of rHuEpo (Ashenden et al. 2012; Lonnberg et al. 2012; 
Morkeberg et al. 2013). The next question is whether the biomarkers of the molecular signature 
of rHuEpo doping discovered in this doctoral research using a fairly high regimen of rHuEpo 
injections of 50 IU∙kg-1 body mass are able to reveal microdose rHuEpo doping as a stand-alone 
test or in combination with new developing methods such as the MAIIA test. Our research group 
successfully applied for a new WADA research grant (12C09YP) to answer this question. Ten 
healthy endurance trained subjects not involved in competition will participate in a randomized, 
double-blind, placebo-controlled crossover microdose rHuEpo regimen (Figure 7.1). This new 
study entitled “A systems biology biomarker based approach to the detection of microdose 
recombinant human erythropoietin doping” will start in September 2013. 
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Figure 7.1: Experimental design of the microdose rHuEpo study. 
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7.2.3 Assessment of the confounding effects of exercise: 
Samples for anti-doping purposes are often collected at sporting or training venues after intense 
exercise (Rupert 2009). However, it has been previously demonstrated that exercise can 
significantly affect gene expression profiles of peripheral blood mononuclear cells and white 
blood cells (Buttner et al. 2007; Connolly et al. 2004). It is therefore essential to define the 
effects of exercise on blood gene expression profiles and particularly on the “molecular 
signature” of rHuEpo doping. To do so, we will use the follow-up project entitled “A systems 
biology biomarker based approach to the detection of microdose recombinant human 
erythropoietin doping” (12C09YP) to address our research question. Briefly, in order to provide 
a set of robust candidate genes that can be used for the detection of rHuEpo doping, blood gene 
expression assessment will be performed during and post intense exercise after microdose 
rHuEpo or placebo in the double-blinded trial (Figure 7.1). The intense exercise will consist of a 
series of 10 s Wingate cycle ergometer bouts to test not only the effects of exercise on blood 
gene profiles but also the effects of rHuEpo on progressive anaerobic fatigue and to assess 
repeated sprint ability. The ability to reproduce maximal performance in subsequent short-
duration sprints separated by brief recoveries is a key fitness requirement in most team and 
racket sports (Girard et al. 2011). Of note, the International Tennis Federation recently adopted 
the ABP program (BBC 2013b), while there are personalities in football, such as the Arsenal 
manager Arsène Wenger, who publicly said that he feared doping was rife in football (The 
Telegraph 2013). The research study outlined above will also be used to provide a basis for the 
development of recommendations on the collection of samples in order to ensure “valid” blood 
gene expression profiles results. In particular, given the potential robustness of specific gene 
expression profiles, it is envisaged that athletes will no longer need to wait for two hours after 
training or competition before a blood sample is taken for the ABP (Operating Guidelines V3.1, 
WADA, 2012). 
 
7.2.4 Assessment of the confounding effects of altitude exposure: 
It is known that natural or simulated altitude training is used by athletes for performance 
enhancement (e.g Millet et al. 2010), although the scientific evidence on the real effects of 
altitude training on elite performance when athletes return to sea level is not clear-cut. Only the 
live high-train low (LHTL) method developed by Levin and Stray-Gundersen (Levine and Stray-
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Gundersen 1997) using natural altitude seems to be consensually accepted to be effective 
(Bonetti and Hopkins 2009; Siebenmann et al. 2012). In addition, it remains unclear to what 
extent these effects on performance are due to the mechanism of erythropoiesis (Bonetti and 
Hopkins 2009). Regardless of these conflicting results, it has been shown that altitude exposure 
has the potential to influence haematological indices of rHuEpo doping (Ashenden et al. 2003; 
Ashenden et al. 2001). As a result, there are concerns not only about the risk of false positives 
but also about the misuse of altitude exposure by some athletes in order to mask blood doping 
practices such the administration of rHuEpo (Lundby et al. 2012b; Sanchis-Gomar et al. 2009). 
There is, therefore, an urgent need for developing specific and robust testing models which can 
differentiate altitude training from blood doping combined (or not) with altitude exposure. Omics 
technologies such as gene expression have the potential to provide a “molecular signature” 
specific to rHuEpo and altitude exposure. The aim of this follow-up project is to compare blood 
gene expression profiles altered by rHuEpo (fairly high and microdose regimens) with altitude 
exposure in order to provide a set of candidate genes that can be used to differentiate rHuEpo 
from altitude training. 
 
7.2.5 Other external factors to be investigated: 
It has been previously demonstrated that other external factors can influence blood profiles. For 
instance, strenuous endurance exercise can induce changes in some blood parameters not only by 
the well-described increase in plasma volume known as the athlete’s pseudoanaemia (Weight et 
al. 1991) but also by exercise-induced haemolysis due to metabolic modifications, oxidative 
stress and especially repeated foot impact (foot strike) (Lombardi et al. 2013; Telford et al. 2003; 
Yusof et al. 2007). The effects of strenuous long distance exercise such as cycling stage race and 
ultra marathons on blood gene expression profiles should consequently be investigated in elite 
endurance athletes. As most blood parameter values differ substantially between males and 
females, the currently used reference ranges in the ABP were determined separately for each sex 
(Sharpe et al. 2002; Sottas et al. 2008a). A similar differentiation approach should be applied to 
blood gene expression profiles in order to evaluate gender differences and similarities. Last but 
not least, injury-related immobility has the potential to affect blood gene profiles, as it has been 
reported that immobility for a period of 4 weeks reduced Hbmass by ~19% in a female athlete 
competing at international level (Schumacher et al. 2008). The knowledge of the influence of 
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these external factors on blood gene expression profiles will lead to higher sensitivity and 
specificity of the ABP. 
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7.3 General conclusion: 
In conclusion, the main findings of the research presented in this thesis are as follows: 
 
 The improvements in the laboratory based measurements of exercise capacity after 
rHuEpo administration in endurance trained males translated into improvement in 
exercise performance in the field. 
 
 rHuEpo administration increased the already relatively high haematological parameters 
as well as   O2max of Kenyan endurance runners living and training at moderate altitude 
(~2,150 m). 
 
 Although the rHuEpo-induced changes in haematological parameters were not as high in 
KEN as in SCO, the improvement in exercise performance was similar. 
 
 Using gene microarray analysis, blood gene expression profiles were profoundly altered 
by rHuEpo administration. 
 
 Living and training at moderate-altitude (~2,150 m) together with ethnicity did not 
significantly influence the blood gene expression response induced by rHuEpo 
administration as the findings were replicated and only minimal differences were found 
between the two groups. 
 
 Further to the gene microarray based analysis, a subset of blood gene biomarkers which 
defines the molecular signature of rHuEpo doping was validated using another sensitive 
and specific quantitative gene technology.  
 
 The results generated by this research provide the strongest evidence to date that blood 
gene expression profiles have the potential to improve and add a new dimension to the 
ABP for rHuEpo detection. 
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Appendix A: Illumina microarray experiments carried out in batches: 
The Illumina microarray experiments were carried out in batches with 3 subjects (April 2011), 6 
subjects (February 2012) and 9 subjects (September 2012) for SCO. Interestingly, increasing the 
number of subjects only marginally changed the findings, i.e. transcripts whose expression was 
significantly altered by rHuEpo administration (Figure VIII.1). 
 
 
 
Figure VIII.1: Venn diagrams of transcripts differentially expressed during rHuEpo compared 
to baseline in the different microarray experiments in SCO. 
The 3-way Venn diagrams depicts the transcripts differentially expressed (5% false discovery 
rate and 1.5 fold-change threshold) during and after rHuEpo administration revealed by 
including subjects 1 to 9 (green, solid line circle), 10 to 18 (blue, dotted line circle) and 1 to 18 
(orange, dashed line circle) in the analysis. 
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Although it will likely not significantly change the overall results and the transcripts of interests, 
12 more KEN subjects will be analysed to make a balanced microarray analysis (i.e. 18 subjects 
in each group).  
Figure VIII.2 depicts the latest results of the changes in total RNA yield for 18 subjects in each 
group. Except slightly higher values during rHuEpo especially due to one subject, no major 
differences were observed compared to Figure 5.1 (KEN = 6). 
 
 
 
Figure VIII.2: Changes in total RNA yield extracted from 3 ml of whole blood stabilized in 
Tempus tubes in SCO (n = 18) and KEN (n = 18). 
Values are means ± SD. Time point 0 represents the first rHuEpo injection. The grey zone 
represents the 4 weeks rHuEpo administration. SCO and KEN are represented by the circle and 
the square, respectively. 
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Appendix B: Molecular laboratory work issues and troubleshooting: 
B.1 Issue with Illumina microarrays in December 2011: 
Due to the constraints of the study protocol (Figure 2.2), a maximum of five subjects could take 
part in the trial at the same time and therefore the collection of samples was carried out over a 
period of two years. During this period, the microarray experiments were performed in batches. 
The initial microarray experiment including three subjects was successfully performed in April 
2011. The second batch including six subjects was performed in December 2011 but surprisingly 
failed. This was completely unexpected since all the intermediate results and quality controls 
were similar between both batches i.e. good quantity and quality of RNA and cRNA assessed by 
the NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, USA) and the Agilent 
2100 Bioanalyzer (Agilent technologies, Santa Clara, USA). After verifying the lab tracking 
form to make sure that no mistake had been made during the laboratory manipulations, the 
microarray results were analysed and discussed (Table VIII.1 and Figure VIII.3). The initial 
conclusion was that the problem came from either a faulty batch of BeadChips or the 
streptavidin-Cy3, although the latter was stored in a frozen state and no problem had been 
reported during previous experiments. A decision was made to perform a troubleshooting 
experiment using an unused BeadChip which was a year past its expiry date, a newly ordered 
batch of streptavidin-Cy3 and six cRNA samples (two cRNA from the successful batch in April 
2011, two cRNA from the failed batch in December 2011 and two newly made cRNA from RNA 
of the December 2011 batch). This troubleshooting experiment was performed in January 2012 
(Table VIII.1 and Figure VIII.3). The conclusions were that the troubleshooting experiment was 
successful but the results were not as good as the April 2011 experiment because of the expired 
BeadChip. The samples were therefore not the problem, and we re-contacted the company and 
provided them with our results and conclusions. Illumina sent new microarray BeadChips free of 
charge. We were relieved when the microarray experiment using the new BeadChips was 
successful and confirmed our initial results obtained in April 2011. 
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A. Successful microarray “April 2011” B. Failed microarray “December 2011”  
 
C. Troubleshooting expired microarray “January 2012” 
 
 
Figure VIII.3: Summary of the microarray experiments results which were successful in April 
2011 (A) but failed in December 2011 (B). The experiment performed in January was a 
troubleshooting experiment using an Illumina BeadChip over a year past its expiry date. 
  
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Appendix B 
 
 
© J Durussel (2014)  CCII 
 
Table VIII.1. Comparison of the control summary microarray experiments results after 
performing the troubleshooting experiment. 
    
 
Successful 
microarray “April 
2011” 
Failed microarray 
“December 2011” 
Troubleshooting 
expired microarray 
“January 2012” 
Gene detected (0.01) ~ 9,000 ~ 700 ~ 5,000 
Gene detected (0.05) ~ 12,000 ~ 2,500 ~ 8,000 
Signal Average 222 38 94 
Signal P95 540 43 142 
Biotin 34,000 90 3,000 
CY3 HYB 15,000 75 2,500 
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B.2 Issue with MagMAX kit in October/November 2012: 
The MagMAX for stabilized blood tubes RNA isolation kit (Ambion, Austin, USA) was used to 
extract RNA from the stored frozen Tempus Blood RNA tubes (Applied Biosystems, Foster 
City, USA) instead of the Tempus Spin RNA isolation kit (Life Technologies, Paisley, UK) 
because, according to the company, the latter removes most of the small RNAs including 
microRNA (miRNA) while the former purifies miRNA with total RNA. In addition to the gene 
expression analysis using messenger RNA, our research group wanted to include miRNA in the 
analysis and the samples were consequently processed accordingly. It has been shown that 
miRNAs, a class of recently discovered small RNA molecules, play a major role in post-
transcriptional regulation, thought to directly regulate thousands of genes (Bartel 2004; 
Filipowicz et al. 2008; Selbach et al. 2008). Interestingly enough, although mature erythrocytes 
(rHuEpo stimulates their production) are generally thought to lack RNA, it has recently been 
demonstrated that they do contain both RNA and especially miRNA, whose presence, however, 
has not yet been explained (Chen et al. 2008; Hamilton 2010). Therefore, the assessment of 
miRNAs, providing an insight into the interaction between messenger RNA and miRNA and 
consequently the impact of gene expression on protein synthesis seemed to be an important 
factor to be included in a gene expression profile approach to detect rHuEpo. 
The MagMAX for stabilized blood tubes RNA isolation kit worked well for all the SCO samples 
with a good quantity and quality of RNA assessed by the NanoDrop spectrophotometer (Thermo 
Fisher Scientific, Wilmington, USA) and the Agilent 2100 Bioanalyzer (Agilent technologies, 
Santa Clara, USA). After processing more than 150 samples from 18 different subjects (SCO), 
the average RNA yield was 10.9 ± 6.0 with an average RIN value of 8.3 ± 1.1 and the lowest 
RIN value was 7.0. However, KEN samples were processed in October 2012 using a new 
MagMAX for stabilized blood tubes RNA isolation kit and despite an expected good yield, the 
quality was poor. The RNA was highly degraded with RIN values below 5.0 (Figure VIII.4A). 
In order to determine whether the problem came from the KEN samples, two samples which had 
not been extracted yet from SCO, as well as two new samples freshly collected were processed. 
In addition to these four samples, two other freshly collected samples with an old Tempus Spin 
RNA isolation kit were also processed. The results were clear (Figure VIII.4). Regardless of the 
origin of the samples, the quality was poor with the MagMAX for stabilized blood tubes RNA 
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isolation kit and good with the Tempus Spin RNA isolation kit, respectively. As a result, the 
problem did not come from the samples but from the extraction kit. The company wanted to 
replace our MagMAX for stabilized blood tubes RNA isolation kit free of charge, however, they 
were out of stock at that time, which in turn would had significantly delayed the KEN microarray 
experiment. Meanwhile, the samples used for miRNA analysis were not whole blood anymore 
(i.e. Tempus Blood RNA tubes) but plasma. In addition, we realized that more samples can be 
processed in less time with a better quality using the Tempus Spin RNA isolation kit compared 
to the MagMAX for stabilized blood tubes RNA isolation kit. As a result, due to these practical 
reasons, the Tempus Blood RNA tubes from KEN were extracted using the Tempus Spin RNA 
isolation kit. The average RIN value for KEN was 9.1 ± 0.2 and the lowest RIN value was 8.5. 
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Electropherogram of a RNA sample extracted using the faulty MagMAX kit 
 
 
 
A. Electropherogram of a duplicate of the above sample extracted using the Tempus Spin kit 
 
 
 
Figure VIII.4: Typical electropherograms (Agilent 2100 Bioanalyzer, Agilent Technologies, 
Santa Clara, USA) observed during the troubleshooting RNA quality experiments in 
October/November 2012.  
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Appendix C: Lists of genes from Venn diagrams: 
 
 
Figure 3.7: 
41 transcripts:   
ALAS2 
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C16ORF35 
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E2F2 
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FECH 
GLRX5 
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OSBP2 
PIP5K2A 
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RBM38 
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SIAH2 
SLC4A1 
SLC6A10P 
SNCA 
SNCA 
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TRIM58 
WDR40A 
XK 
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351 transcripts: 
ABCC13 
ACPT 
ACTRT1 
ADIPOR1 
ADIPOR1 
ADORA1 
ADRA2C 
AHSP 
ALAS2 
ALDH5A1 
AMAC1L3 
ANKRD9 
AP2A1 
AP2A1 
AP2M1 
AP2M1 
ARL4A 
ARL4A 
ARTN 
ASCC2 
ATP6AP1L 
ATP6V0C 
ATP6V0C 
ATXN10 
BAT3 
BBC3 
BCL2L1 
BCR 
BDNF 
BLVRB 
BMP2K 
BNIP3L 
BSG 
C14ORF45 
C16ORF35 
C18ORF10 
C18ORF10 
C19ORF22 
C19ORF62 
C19ORF62 
C20ORF132 
C22ORF13 
C22ORF25 
C22ORF30 
C2ORF24 
C9ORF62 
C9ORF78 
CAMK1G 
CARM1 
CCDC23 
CCDC52 
CDC34 
CES3 
CFHR2 
CHD8 
CHPT1 
CHPT1 
CISD2 
CLK2 
CMTM3 
COL8A2 
CREG1 
CSDA 
CTNNAL1 
CTSB 
DARC 
DCAF6 
DDR1 
DNA2 
DNAJA4 
DNAJB2 
DPM2 
DPM2 
DPYSL5 
DSCAM 
EIF1B 
EIF2AK1 
EIF2C2 
ELOF1 
EPB41 
EPB41 
EPB49 
EPHA8 
FAM104A 
FAM116B 
FAM117A 
FAM134A 
FAM83F 
FBXO7 
FBXO7 
FBXO9 
FCGR3A 
FGF23 
FHL2 
FIS1 
FKBP8 
FLJ20489 
FOXO3 
FOXO3 
FOXO4 
FRMPD2L1 
FURIN 
FXR2 
FZD7 
G6PC 
GDF1 
GJC2 
GLUL 
GMPPB 
GNA12 
GPR109B 
GPR146 
GPR175 
GPX1 
GRINA 
GRINA 
GSPT1 
GUK1 
GYPC 
GYPC 
HAGH 
HAGH 
HBE1 
HBM 
HBQ1 
HDAC6 
HDAC7A 
HDGF 
HEBP1 
HEMGN 
HEMGN 
HIVEP3 
HMBS 
HMBS 
HOXD3 
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HPS1 
HPS1 
HS.105618 
HS.149244 
HS.187290 
HS.291319 
HS.412918 
HS.537603 
HS.539888 
HS.544069 
HS.544245 
HS.564949 
HS.569831 
HS.57079 
HS.571622 
IFIT1L 
IGF2BP2 
IGFBP1 
IRX1 
ISCA1L 
ITLN1 
KAT2B 
KCNJ10 
KDM2B 
KIAA1539 
KLC3 
KLF1 
LGALS3 
LMNA 
LOC100130332 
LOC100130623 
LOC100130905 
LOC100131391 
LOC100131726 
LOC100132266 
LOC148430 
LOC284422 
LOC387686 
LOC388588 
LOC389599 
LOC440313 
LOC440359 
LOC441081 
LOC441481 
LOC642377 
LOC642469 
LOC643665 
LOC643933 
LOC644039 
LOC644852 
LOC645173 
LOC645284 
LOC646463 
LOC646508 
LOC647742 
LOC648003 
LOC648390 
LOC648526 
LOC648796 
LOC650832 
LOC652045 
LOC652140 
LOC652968 
LOC653073 
LOC653498 
LOC653635 
LOC653778 
LOC653907 
LOC654103 
LOC654155 
LOC729870 
LOC730226 
LYL1 
LYPD3 
MAF1 
MAGEL2 
MAP2K3 
MAP2K3 
MAP2K3 
MAP2K3 
MAP4K4 
MARCH2 
MARCH2 
MARCH8 
MARCH8 
MBNL3 
MBNL3 
MCOLN1 
MED1 
MED22 
MEGF10 
MGC13057 
MICAL2 
MICALCL 
MIR1976 
MIR877 
MKRN1 
MPP1 
MUC6 
MXI1 
MXI1 
MXI1 
MYL4 
NFE2 
NFIX 
NINJ2 
NOC4L 
NOXO1 
NR1D1 
NTAN1 
OPTN 
OR2A42 
OR2W3 
PDZK1IP1 
PHLDB1 
PHOSPHO1 
PINK1 
PIP4K2A 
PLEK2 
PNPLA2 
POLR1D 
PPM1A 
PPP2R5B 
PRDM9 
PRDX2 
PRDX2 
PRR5 
PRR5 
PSME4 
PSMF1 
PTMS 
PTPN6 
RAB2B 
RAB3IL1 
RAD23A 
RANBP10 
RGS10 
RIOK3 
RIOK3 
RNF11 
RNF213 
RNF40 
RNU6-1 
ROPN1B 
RP11-529I10.4 
RPIA 
RTF1 
RUNDC3A 
SEMA6B 
SENP7 
SERPINA13 
SESN3 
SIPA1L3 
SLC14A1 
SLC1A5 
SLC25A23 
SLC25A37 
SLC25A39 
SLC25A45 
SLC30A3 
SLC38A5 
SLC6A8 
SLC6A9 
SLC7A5 
SLITRK1 
SMOX 
SMOX 
SNORD8 
SNX3 
SPRYD3 
SPTB 
SRRD 
SRXN1 
ST6GALNAC4 
ST6GALNAC4 
STOM 
STRADB 
TBC1D10B 
TESC 
TFDP1 
TFDP1 
TGM2 
TGM2 
TMCC2 
TMEM111 
TMEM63B 
TMEM86B 
TNS1 
TRAK2 
TRIM10 
TRIM10 
TSPAN5 
TSTA3 
TTC25 
TUBB2A 
TYW1 
UBE2F 
UBE2H 
UBE2O 
UBE2W 
UBXN6 
VTI1B 
VWCE 
WASF2 
WDR26 
WDR45 
WDR89 
WNK1 
WNK1 
WWP2 
XPO7 
YBX1 
YIPF6 
YPEL3 
ZNF653 
ZRANB1 
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Figure 3.9: 
133 transcripts: 
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Appendix D: Electropherograms of cRNA from two subjects as typical examples: 
 
Subject A: as a first typical example 
 
 
Figure VIII.5A: Representative electropherograms (Agilent 2100 Bioanalyzer) of cRNA. 
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Subject B: as a second typical example 
 
 
 
Figure VIII.5B: (continued) 
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Appendix E: Transcriptomic analysis from saliva samples: 
A minimally invasive source of potential biomarkers with advantages in collection convenience 
which may improve athlete compliance with anti-doping tests is saliva. Saliva samples were 
collected at similar time points as blood samples during the study (Figure 2.1) using two 
different methods, i.e. Oragene RNA collection kit (DNA Gentok Inc., Ottawa, Canada) and 
indicating FTA mini cards (Whatman, GE Healthcare, Little Chalfont, UK) according to their 
respective manufacturers’ instructions. Saliva samples initially stored in the Oragene RNA 
containers at -20°C were then incubated at 50°C for 1 hour and aliquoted into 8 x 500 µl. Four 
aliquots were kept at -80°C and the remaining at -20°C. The FTA mini cards were stored at 
-20°C. RNA was extracted following the Oragene RNA purification protocol using the Qiagen 
RNeasy micro kit (Qiagen, Crawley, UK) and using the MagMAX viral RNA isolation kit 
(Ambion, Austin, USA) for the Oragene and FTA mini cards saliva samples, respectively 
 
The RNA yields were inconsistent in terms of quantity and quality. Although further analyses are 
necessary, there was very high inter- and high intra-individual variability 1) in the RNA yield 
possibly due to the differences in the levels of oral bacterial RNA across individual donors 
(Figure VIII.6) (Patel et al. 2011) and 2) in the quality of the RNA samples (Figure VIII.7), 
respectively. Nevertheless, the degradation of the RNA extracted from the Oragene saliva 
samples was much lower compared to a previously published study which used microarray 
analysis and concluded that “the quality of the majority of the microarrays was acceptable” 
despite the poor quality of the saliva RNA samples (Kupfer et al. 2010). 
 
Four Oragen saliva RNA samples were analysed alongside the blood RNA samples during the 
QuantiGene validation experiment. Samples collected at baseline and at the end of the rHuEpo 
administration in two subjects were selected. Not surprisingly, the genes were either not 
expressed in saliva or the results were not consistent (Figure VIII.8). The results confirmed that 
the biomarkers of rHuEpo administration discovered in whole blood in this research are not 
necessarily useful in other tissues such as saliva. Whole transcriptome analysis for each tissue of 
interest is required for biomarker discovery.  
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Figure VIII.6: Total RNA yield of Oragene RNA samples. 
RNA yield concentration extracted from 500 µl of saliva stabilized in Oragene RNA collection 
kit in 6 subjects of our research study (top panel) and in a published study (bottom panel) (Patel 
et al. 2011). Bottom figure taken from Patel et al. (2011).  
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Subject B of Figure VIII.6: Typical examples 
   
 
Subject C of Figure VIII.6: Typical examples 
  
 
Subject D of Figure VIII.6: Typical examples 
   
 
Figure VIII.7: Representative electropherograms (Agilent 2100 Bioanalyzer) of Oragene RNA 
saliva samples. 
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Figure VIII.8: Median fluorescence intensity (MFI) signals of four Oragene saliva RNA 
samples with the two different RNA inputs 
Samples collected at baseline and at the end of the rHuEpo administration in two subjects were 
selected. Of note, RNA from whole blood produced MFI signals > 1,000 for most of the target 
and housekeeping genes (see Table 6.2). 
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Appendix F: Approved proposal for emergency funding: 
A New Dimension to the Detection of Recombinant Human Erythropoietin Doping Using 
Blood Gene Expression Profiles: Development of Direct Anti-Doping Applications 
 
INTRODUCTION: 
The main purpose of the research project funded by the World Anti-Doping Agency 
(WADA) in 2008 entitled “A gene-microarray based approach to the detection of recombinant 
human erythropoietin (rHuEpo) doping in endurance athletes” (08C19YP) was to develop new 
improved methods based on gene expression profiles. This research project has generated most 
promising results which have the potential to add a new dimension to the current detection 
methods such as the Athlete Biological Passport (ABP). However, further works are required 
before establishing a robust diagnostic test. Please see below a summary of the research project 
in lay language as well as more technical information. 
 
SUMMARY (lay language): 
The use of rHuEpo is prohibited by WADA. Omics technologies can be used to reveal 
the specific molecular signature of a particular stimulus (rHuEpo doping for instance). Therefore, 
molecular markers, such as gene markers, characteristic of rHuEpo doping have the potential to 
improve further the discriminatory power of current detection methods such the ABP (Reichel 
2011a). The aim of the study was to assess the effects of rHuEpo on blood gene expression 
profiles in endurance trained males in order to identify a molecular signature of rHuEpo doping 
and hence provide a basis for the development of novel testing models to detect doping.  
39 endurance trained males, 19 based at sea-level (Glasgow, Scotland) and 20 based at 
moderate altitude (Eldoret, Kenya, 2100-2800m a.s.l), received rHuEpo for 4 weeks. Blood was 
obtained 2 weeks before, during and 4 weeks after administration (Figure 1). Blood gene 
expression profiles were profoundly altered during rHuEpo and for at least 4 weeks after 
administration leading to a “molecular signature” of rHuEpo doping. Importantly, as illustrated 
in the genes selected as typical example in Figure 3, the same pattern was observed in all 
subjects. These most promising data provide the strongest evidence to date that gene biomarkers 
will add a new dimension to the ABP in terms of sensitivity and specificity. 
In order to set up a potential future test which can reveal the molecular signature of 
rHuEpo doping, a pilot study using a subset of subjects (n=8) and promising target genes (n=7) 
was carried out using a specific, sensitive, time and cost-effective technology (QuantiGene Plex 
assay, Panomics/Affymetrix, Italy). Following the success of this pilot study, we would like to 
increase the number of target genes to 50 which will allow a more defined and precise molecular 
signature of rHuEpo doping and we would like to analyse these 50 target genes in all subjects 
(i.e. 39 in total). This study will enable 1) the validation of the molecular signature of rHuEpo 
doping and 2) the development of the establishment of the testing procedure. 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Appendix F 
 
 
© J Durussel (2014)  CCXVI 
FURTHER TECHNICAL INFORMATION: 
Methods: 39 endurance trained males, 19 based at sea-level (Glasgow, Scotland - SCO) 
and 20 based at moderate altitude (Eldoret, Kenya, 2100-2800m a.s.l. - KEN), received rHuEpo 
injections of 50 IU∙kg-1 body mass every two days for 4 weeks. Blood was obtained 2 weeks 
before, during and 4 weeks after administration (Figure 1). Eight time points per subjects (SCO: 
n = 18, KEN: n = 6) were selected for gene expression analysis, i.e. two baseline samples, then 
one sample each at 2 days, 2 weeks and 4 weeks after the first rHuEpo injection and 1 week, 2 
weeks and 4 weeks after rHuEpo administration (Figure 1). RNA was extracted from blood 
stabilized in Tempus RNA tubes and stored at -80°C. 
Illumina experiment: RNA of 18 and 6 subjects in SCO and KEN, respectively, was 
amplified, labelled and hybridized to Illumina HumanHT-12v4 Expression BeadChips. 
Expression data was analysed using RankProducts (Breitling et al. 2004) with a 5% false 
discovery rate and an additional 1.5 fold-change threshold. 
QuantiGene Plex pilot experiment: RNA of four subjects in SCO and KEN (i.e. 8 
subjects in total) was hybridized, amplified and labelled using branched DNA and xMAP 
magnetic beads technologies. The signal was read using the Luminex MAGPIX. Following 
background subtraction, the ratio of the target genes signal to the geometric mean of the 
housekeeping gene signal was calculated. 
More information on QuantiGene Plex assay: The QuantiGene Plex assay, which 
combines branched DNA and bead-based multiplexing technology, allows the simultaneous 
analysis of a large number of target genes per sample and enables high-throughput screening 
(Flagella et al. 2006). In addition to being extremely reproducible, specific and sensitive, the 
QuantiGene assay provides an independent method of measurement compared to the other 
technologies such as quantitative real-time reverse transcription polymerase chain reaction (RT-
PCR) and microarray platforms by eliminating the need for RNA reverse transcription, labelling 
and amplification steps (Canales et al. 2006; Flagella et al. 2006). 
(http://www.panomics.com/products/gene-expression/plex-2.0-assay/how-it-works) 
 
 
 
 
 
Figure 1: Experimental design  
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Results of the Illumina experiment (summary): 
Using the additional stringent >1.5 FC threshold, hundreds of genes were found to be 
differentially expressed following rHuEpo administration in both groups (Figure 2). Among 
these genes, 30 were already strongly up-regulated 2 days after only one single injection in 
common in both groups (Figure 2). 15 genes were strongly up-regulated during the last 2 weeks 
of rHuEpo and subsequently down-regulated at 2 and 4 weeks after administration (Figure 2). 
Importantly, as illustrated in the genes selected as a typical example in Figure 3, the same pattern 
was observed in all subjects. 
 
 
 
 
 
Figure 2: Venn diagrams of genes differentially expressed during (top panels) and post (bottom 
panels) rHuEpo compared to baseline in SCO (left panels) and KEN (right panels). Values in 
brackets are number of transcripts up- (↑) and down-regulated (↓) compared to baseline. The 
Venn diagram in the middle depicts the intersection of Venn diagrams in SCO and KEN. 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Appendix F 
 
 
© J Durussel (2014)  CCXVIII 
 
 
 
Figure 3: Individual changes in gene expression in four genes selected as typical example. 
Changes are reported in log ratio compared to the average baseline values. Time point 0 
represents the first injection. The grey zone represents the administration. Each line 
corresponds to one subject. SCO (n = 18) and KEN (n = 6) are represented in green, 
respectively.
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Results of the QuantiGene Plex pilot experiment (summary): 
The three housekeeping genes were found to be fairly stable over time in all subjects (Figure 4). The QuantiGene Plex results 
successfully replicated the Illumina microarray results as illustrated in the two genes selected as typical example in Figure 5. 
 
 
 
 
Figure 4: Individual changes in gene expression in the three housekeeping genes using the QuantiGene Plex assay. Actin, beta (ACTB), 
MORF4 family-associated protein 1 (MRFAP1) and Peptidylpropyl isomerase B (cyclophilin B) (PPIB): Changes are reported in log ratio 
compared to the average baseline values. Time point 0 represents the first injection. The grey zone represents the administration. Each line 
corresponds to one subject. SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. 
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 QuantiGene Plex Illumina Microarray 
 
 
 
Figure 5: Individual changes in gene expression in two genes selected as a typical example: 
Delta-aminolevulinate synthase 2 (ALAS2) (top panels) and Family with sequence similarity 
46, member C (FAM46C) (bottom panels). Results of the QuantiGene Plex assay and the 
Illumina microarray are presented in the left and right panels, respectively. Changes are 
reported in log ratio compared to the average baseline values. Time point 0 represents the first 
injection. The grey zone represents the administration. Each line corresponds to one subject. 
SCO (n = 4) and KEN (n = 4) are represented in green and red, respectively. 
-4 
-2 
0 
2 
4 
-28 -14 0 14 28 42 56 
Lo
g 
R
at
io
 
Days 
ALAS2 
SCO5 SCO7 SCO12 SCO18 
KEN1 KEN4 (NR) KEN5 KEN6 
-3.0 
-1.5 
0.0 
1.5 
3.0 
-28 -14 0 14 28 42 56 
Lo
g 
R
at
io
 
Days 
FAM46C 
SCO5 SCO7 SCO12 SCO18 
KEN1 KEN4 (NR) KEN5 KEN6 
A Doctoral Thesis: A Transcriptomic Approach to Detect rHuEpo Doping Appendix F 
 
 
© J Durussel (2014)  CCXXI 
Discussion: In this project, we successfully used gene expression profiling in whole blood 
to identify genes that are differentially regulated following rHuEpo administration in Caucasian 
trained males and Kenyan runners living at sea-level and altitude, respectively, leading to the 
discovery of a “molecular signature” of rHuEpo doping. These results provide the strongest 
evidence to date that omics technologies such as gene expression have the potential to add a new 
dimension to the ABP in terms of specificity and sensitivity for rHuEpo detection. 
 
Following the success of the QuantiGene Plex pilot experiment and at the prospect of 
setting up a potential future test which can reveal the molecular signature of rHuEpo doping, we 
would like 1) to finalise the microarray experiment, i.e. 12 more KEN subjects to be analysed to 
make a balanced design and 2) to increase the number of target genes to 50 which will allow a 
more defined and precise molecular signature of rHuEpo doping and we would like to analyse 
these 50 target genes in all subjects (i.e. 39 in total) using the specific, sensitive, time and cost-
effective QuanitiGene Plex technology. This study will enable the validation of the molecular 
signature of rHuEpo doping as well as the establishment of the testing procedure. 
 
 
BUDGET – Illumina microarray and QuantiGene Plex experiments: 
 Exchange rate = 0.65 
Illumina microarray   
Extraction and amplification kits £ 6,350.00 $ 9,769.23 
Illumina BeadChip £ 12,170.00 $ 18,723.08 
   
QuantiGene Plex   
Assay kit £ 3,098.00 $ 4,766.15 
Blood Sample Processing Kit  £ 678.00 $ 1,043.08 
Quantigene Plex Probeset £ 42,248.00 $ 64,996.92 
Discount 20% QuantiGene Plex -£ 9,204.80 -$ 14,161.23 
TOTAL £55,339.20 $ 85,137.23 
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TIME LINE: 
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Appendix G: One page summary to include in WADA’s website: 
The use of recombinant human erythropoietin (rHuEpo) is prohibited by the World Anti-Doping 
Agency. An omics-based longitudinal screening approach has the potential to improve further 
the performance of current detection methods such as the Athlete Biological Passport. For this 
project, we successfully used gene expression profiling in whole blood to identify genes that are 
differentially regulated following rHuEpo administration in Caucasian trained males and Kenyan 
endurance runners living at sea-level and moderate altitude (~2150 m), respectively. Relative to 
baseline, the expression of hundreds of genes were found to be altered by rHuEpo. In particular, 
15 transcripts were profoundly up-regulated during the 4 weeks of rHuEpo administration and 
subsequently down-regulated up to 4 weeks post administration in both groups. Importantly, the 
same pattern was observed in all subjects. Furthermore, 30 transcripts were already differentially 
expressed two days after the first injection and are therefore promising candidate genes to detect 
microdose rHuEpo doping. The functions of the discovered genes were mainly related to either 
the functional or structural properties of the erythrocyte or to the cell cycle and its regulation. In 
summary, this research project successfully identified the blood “molecular signature” of 
rHuEpo administration and provided a set of candidate genes with potential to be robust 
biomarkers of rHuEpo doping. These preliminary results provide the strongest evidence to date 
that omics technologies such as gene expression have the potential to substantially improve and 
add a new dimension to the current anti-doping methods such the Athlete Biological Passport for 
rHuEpo detection. 
